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General introduction
Non-small cell lung cancer
Lung cancer is a leading cause of cancer related death [1]. In the Netherlands, every year 
more than 12.000 patients are diagnosed with lung cancer. In 85% of cases this concerns 
non-small cell lung cancer (NSCLC). Treatment options in NSCLC patients depend on 
tumor node metastasis (TNM) stage. Approximately 20% of patients are potentially curable 
with surgery (stage I – resectable stage IIIA), but about half of those die due to recurrent 
disease. Irresectable stage III NSCLC can be treated with concurrent or sequential 
chemoradiation. Despite this intensive therapy, prognosis remains poor with 5-year 
survival of 36% for stage IIIA, 26% for stage IIIB, and only 13% for stage IIIC, 10% for stage 
IVA and 0% for stage IVB (TNM 8th edition) [2]. Immunotherapy after chemoradiation is an 
important new asset in the therapeutic armamentarium of irresectable stage III NSCLC, 
improving 2-year overall survival [3,4]. However, locoregional progression and certainly 
the occurrence of distant metastases remain a major issue [5]. Therefore, further intensi-
fication of treatment is required. The reprogrammed tumor metabolism as a hallmark of 
cancer might be such an approach [6].
Physiology of cell metabolism
Cells need an energy source for the regulation of several cellular processes, such as DNA 
damage repair, and transcription of DNA and translation of mRNA required for protein 
synthesis. Most non-proliferating, differentiated cells depend on adenosine triphosphate 
(ATP) (energy) production through oxidative phosphorylation to maintain their integrity. 
As a result, such cells predominantly use glucose as an energy source, which is converted 
to pyruvate and 2 moles of ATP through glycolysis. Subsequently, pyruvate is metabolized 
within the mitochondria by the tricaboxylic acid (TCA) cycle (also known as Krebs cycle) 
and oxidative phosphorylation, resulting in CO2 and large amounts of energy (36 ATP) [7].
 However, for cellular proliferation, other ingredients apart from energy are needed. 
To proliferate, a cell needs to replicate all of its cellular contents including DNA and organelles, 
and the cell has to sustain its redox status [8]. This requires, besides ATP, reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) and glutathione, and the biosynthesis of macro - 
molecules essential for constructing a new cell, such as amino acids, lipids and nucleotides 
[9,10]. Lipids are important components of the cell membrane and mitochondria, and 
amino acids are needed for the production of proteins. Proteins have several cellular 
functions, including growth signal transduction within the cell, transport of molecules 
into and out of the cell, maintenance of the structure of the cytoskeleton, catalyzing 
chemical reactions and the formation of organelles (ribosomes). Nucleotides are required 
for DNA replication and therefore proliferation. NAD(P)H and glutathione are involved in 
the maintenance of cellular redox status. Furthermore, NADPH is an important cofactor for 
the biosynthesis of nucleotides, amino acids and in particular lipids [8,10]. 
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To fulfill these biosynthetic demands, a proliferating cell (and thus a cancer cell) will 
demonstrate a different metabolism compared to a non-proliferating cell [11]. Proliferating 
cells have a higher nutrient uptake and reprogram their glycolytic and mitochondrial 
metabolism to meet the challenges of macromolecular synthesis [9]. Within a normal cell, 
proliferation and the anabolic requirements are carefully regulated by growth factors 
amongst others. However, oncogenic mutations in cancer cells and the tumor microenvi-
ronment (hypoxia amongst others) activate several signaling pathways that stimulate cell 
proliferation, cell survival and tumor metabolism independent of extracellular growth 
factors. In this way, the tight regulation by growth factors is lost, resulting in uncontrolled 
proliferation [7,12].         
Glucose and glutamine metabolism in cancer
Tumor cells metabolize the glycolytic product pyruvate to a lesser extent within the mito - 
chondria. Pyruvate is predominantly (about 85%) converted into lactate by the enzyme 
lactate dehydrogenase A (LDH-A), which is exported out of the cell by monocarboxylate 
transporter 4 (MCT4) (Figure 1) [7]. In normal cells, lactate is only produced under anaerobic 
or hypoxic circumstances. Hypoxia, an important feature of the microenvironment of 
many solid tumors, is caused by an aberrant and less functional tumor microvasculature, 
increased consumption of oxygen, and by tumor-associated anemia. This hypoxic tumor 
microenvironment results in anaerobic glycolysis [13]. However, tumor cells also produce 
lactate in the presence of oxygen, a process called aerobic glycolysis or Warburg effect 
(Figure 1) [6,7]. Already in 1956, Otto Warburg observed the phenomenon that proliferating 
tumor cells are highly glycolytic, i.e. converting the majority of their glucose carbons into 
lactate, even in oxygen-rich conditions [14]. ATP production through glycolysis is much 
faster compared to ATP production by oxidative phosphorylation, but is less efficient 
(2 ATP versus 36 ATP) [9]. Despite the high glycolytic rate in cancer cells, malignant cells 
still derive a significant fraction of their ATP through oxidative phosphorylation, as this is 
a very efficient method for energy production. Glycolysis contributes to about 20% of 
the cellular ATP, with the rest provided by the mitochondria [10]. Oxygen is not limiting for 
electron transport until levels are extremely low (pO2 <0.5 mm Hg, which equals <0.07% 
oxygen) [11,13]. The electron transport chain can function optimally at oxygen levels as 
low as 0.5% [15,16].
 The increase in ATP requirement to support proliferation is small relative to the 
amount of ATP needed to maintain homeostasis in the absence of cell proliferation, 
arguing that much of the increased glucose uptake in proliferating cancer cells is used for 
other purposes [10]. Indeed, glycolysis serves biosynthetic pathways in malignancies, as it 
stimulates the pentose phosphate shunt and biosynthesis of amino acids and lipids 
(Figure 1). After glucose has entered the cytosol through glucose transporters (GLUTs), it is 
converted into glucose-6-phosphate by hexokinase. This intermediate can consequently 
be catabolized within glycolysis or the pentose phosphate shunt. This shunt produces 
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Figure 1   Reprogrammed tumor glucose and glutamine metabolism stimulates 
proliferation
Glucose metabolism in malignancies is mainly by glycolysis and the pentose phosphate shunt and 
to a lesser extent through the Krebs cycle. On the other hand, glutamine is metabolized within the 
mitochondrion of a tumor cell. This reprogrammed metabolism synthesizes macromolecules required 
for proliferation.
The mitochondrion is shown in light orange. Enzymes and transporters are shown in green. The red 
line represents the inhibitory function of pyruvate dehydrogenase kinase 1.
Abbreviations: 3PG, 3-phosphoglycerate; 6PG, 6-phosphogluconolactone; 6PGT, 6-phosphogluconate; 
α-KG, α-ketoglutarate; CAIX, carbonic anhydrase IX; E4P, erythrose-4-phosphate; F6P, fructose- 6-
phosphate; G3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; G6PD, glucose-6-phosphate 
dehydrogenase; GLUT1, glucose transporter 1; HK, hexokinase; LDH-A, lactate dehydrogenase A; MCT4, 
monocarboxylate transporter 4; NHE1, sodium-hydrogen exchanger 1; PDH, pyruvate dehydrogenase; 
PDK1, pyruvate dehydrogenase kinase 1; PEP, phosphoenolpyruvate; PKM2, pyruvate kinase M2 
isoenzyme; PPP, pentose phosphate pathway; R5P, ribose-5-phosphate; SLC1A5, glutamine transporter; 
TKTL1, transketolase like protein 1.
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erythrose-4-phosphate and ribose-5-phosphate, which are the building blocks for 
synthesis of amino acids and nucleotides respectively. Furthermore, NADPH, which is 
required to sustain cellular redox status and for the biosynthesis of lipid biomass, is an 
important product of the pentose phosphate shunt (Figure 1). Glyceraldehyde-3-phos-
phate, a product of both glycolysis and the pentose phosphate shunt, is involved in the 
biosynthesis of lipids. Glyceraldehyde-3-phosphate can also be converted into the 
glycolytic intermediate 3-phosphoglycerate, which can be utilized for the production of 
sphingolipids (important membrane component) and the amino acids serine and glycine 
(Figure 1) [7,11]. So, the most important function of aerobic glycolysis in proliferating 
cancer cells is maintaining constant and sufficient amounts of glycolytic intermediates, as 
these are needed as macromolecular precursors for the production of the required 
ingredients for proliferation: lipids, amino acids, nucleotides and NADPH [9]. The increased 
glucose uptake and glycolytic rate to support biosynthetic pathways is accomplished by 
the upregulation of GLUTs on the cell membrane (Figure 1) [10,11]. For this reason, the 
Warburg effect is the basis of the diagnostic value of 18F-fluorodeoxyglucose positron 
emission tomography (18F-FDG PET) in oncology [8]. 
 The M2 isoform of pyruvate kinase dimer (PKM2), which is almost universally expressed 
in proliferating cells, facilitates this anabolic metabolism. PKM2 dimer has intrinsically 
lower enzymatic activity than PKM1, the predominant isoform in most non-proliferating 
differentiated tissues. With less rapid conversion of phosphoenolpyruvate (PEP) to pyruvate 
(Figure 1), the accumulation of upstream glycolytic intermediates and subsequent shunting of 
these intermediates into anabolic pathways branching off glycolysis can result [7,8,12,17,18]. 
PKM2 can also switch to a tetramer with high enzymatic activity, which redirects pyruvate 
into the TCA cycle. Switching between low and high activity allows PKM2 to act as a 
gatekeeper that dictates the flow of carbons into biosynthetic pathways versus complete 
catabolism for ATP production [7,18]. Also lactate generation serves this macromolecular 
biosynthetic metabolism. Conversion of pyruvate to lactate via LDH-A regenerates NAD+ 
(Figure 1) [11]. NAD+ regeneration is necessary for continued flux through glycolysis, as 
NAD+ is required for the conversion of glyceraldehyde-3-phosphate [11].
 Besides glucose, tumors frequently use the amino acid glutamine for bioenergetics 
and macromolecular synthesis [7,9,11]. After being converted to glutamate by glutaminase 
and subsequently α-ketoglutarate, glutamine can be metabolized in the Krebs cycle to 
oxaloacetate, a process called glutaminolysis. In this way, intermediates of the TCA cycle 
are replenished (anaplerosis) and citrate and oxaloacetate are produced, which are 
required for the biosynthesis of lipids and amino acids respectively (Figure 1) [7-9,11]. 
An alternative to glutaminolysis is the reductive carboxylation pathway where glutamine- 
derived α-ketoglutarate is carboxylated through isocitrate dehydrogenase (IDH) operating 
in the reverse direction of the TCA cycle to generate isocitrate and subsequently citrate 
(Figure 1). Glutamine becomes a source of carbon for lipogenesis through reductive 
carboxylation when cells are proliferating under low-oxygen conditions (Figure 1) [10,15]. 
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In A549 lung carcinoma cells, glutamine dependence and reductive carboxylation flux 
increase under hypoxia, such that glutamine-derived α-ketoglutarate accounts for 
approximately 80% of the carbon used for de novo lipogenesis [19]. Glutamate can also be 
converted into glutathione, a very important redox buffer of all cellular compartments [8]. 
Moreover, glutaminolysis is an important source of NADPH by the conversion of glutamine 
into pyruvate, either through the conversion of citrate into malate and then pyruvate by 
malic enzyme 1 or through the conversion of aspartate  (Figure 1) [11,20,21]. Furthermore, 
under limited availability of glucose, glutamine-derived oxaloacetate can be converted 
into the glycolytic intermediate PEP via the activity of mitochondrial PEP-carboxykinase 
(PCK2) (Figure 1). Glutamine-derived PEP is used to fuel biosynthetic pathways normally 
sustained by glucose through gluconeogenesis (i.e. the opposite direction of glycolysis), 
thereby replenishing the other glycolytic intermediates [22,23]. Also uptake of lactate may 
serve as a gluconeogenic precursor and macromolecular building block through PCK2 
activity [22]. In this way, PCK2 activity helps to adapt to low-glucose conditions and 
enables glucose-independent cell proliferation. PCK2 expression is elevated in NSCLC 
[22,23]. In contrast to non-proliferating cells, the oxidative phosphorylation-dependent 
production of ATP appears secondary to the use of mitochondrial enzymes in the 
synthesis of anabolic precursors. Proliferative metabolism is heavily dependent on the 
reprogramming of mitochondria to serve a synthetic rather than degradative role [12]. 
Regulation of cancer metabolism
This reprogrammed glycolytic and mitochondrial metabolism is the result of complex 
interactions between a dynamic tumor microenvironment where glucose, glutamine 
and oxygen are spatially and temporally heterogeneous, cellular signaling pathways and 
oncogenic mutations. Activation of the hypoxia-inducible factor 1 (HIF-1) pathway [8,9,24,25] 
and the epidermal growth factor receptor/phosphatidylinositol-3-kinase/protein kinase B/
mammalian target of rapamycin (EGFR/PI3K/AKT/mTOR) signaling pathway [7,8,11,12,26], 
activation of the proto-oncogenes c-MYC and RAS [11,27], and inactivation of the tumor 
suppressor p53 [8,11,12] are involved in the regulation of tumor glucose and glutamine 
metabolism amongst others. PI3K signaling through AKT is a major driver of aerobic 
glycolysis in cancer cells. PI3K signaling can increase uptake of glucose by increasing 
expression of GLUT1 on the cell membrane. AKT activation enhances flux through 
glycolysis in part by activating hexokinase (HK) and maintaining HK associated with 
mitochondria, and stimulating phosphofructokinase activity [7,8,11,12,28]. AKT facilitates 
the conversion of mitochondrial-derived citrate into acetyl CoA by phosphorylating and 
activating ATP-citrate lyase, thereby stimulating biosynthesis of lipids (Figure 1) [12]. 
Furthermore PI3K signaling is an important way to increase HIF-1 transcription in cancer. 
HIF-1 is also stabilized under hypoxia and by the glycolytic metabolites pyruvate and 
lactate [11]. Once stabilized, HIF-1 amplifies the transcription of genes encoding glucose 
transporters and most glycolytic enzymes, thereby increasing the capacity of the cell to 
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carry out glycolysis. In addition, HIF-1 activates pyruvate dehydrogenase kinase 1 (PDK1), 
which inactivates pyruvate dehydrogenase (PDH), thereby reducing the flow of glucose- 
derived pyruvate into the Krebs cycle (Figure 1) [8,11,12]. The switch to reductive glutamine 
metabolism under hypoxia and extracellular acidification/chronic acidosis is dependent 
on HIF-2α, upregulating glutamine transporter SLC1A5 and glutaminase isoform GLS1 
[19,29]. Extracellular lactate taken up by cells through monocarboxylate transporter 1 
(MCT1) stabilizes HIF-2α, which subsequently activates c-MYC. This lactate-induced c-MYC 
activation triggers the expression of SLC1A5 and GLS1 and glutaminolysis in oxidative 
cells, thereby connecting glycolysis and glutamine metabolism [30]. Furthermore, HIF-1 
and HIF-2 regulate PCK2 expression under glucose limitation [23]. The oncogene RAS 
promotes glucose metabolism by enhancing glucose uptake through upregulation of 
GLUT1 expression [11,12]. Furthermore, glutamine is the major carbon source for the 
tricarboxylic acid cycle when RAS is activated [31]. The glutamine transporter SLC1A5 is 
upregulated through KRAS signaling in colorectal cancer [32], and the conversion of 
glutamine to glutamate by GLS is modulated by RAS [31]. Moreover, reprogramming of 
glutamine metabolism mediated by oncogenic KRAS in pancreatic ductal adenocarcinoma 
cells results in the conversion of glutamine-derived aspartate into pyruvate with the 
production of NADPH (Figure 1) [20,21]. KRAS activates the RAF/MEK/ERK pathway, leading 
to upregulation of the MYC transcription factor [33]. c-MYC stimulates glycolysis by 
regulating glucose metabolism genes such as GLUT1, HK and LDH-A. c-MYC promotes 
preferential expression of PKM2 over PKM1 by modulating exon splicing. Also, c-MYC plays 
an important role in mitochondrial biogenesis and it increases mitochondrial function. 
Glutamine uptake and catabolism are regulated by c-MYC through increased expression of 
glutamine transporters and glutamine catabolic enzymes such as glutaminase [8,11,12,27,34]. 
The countless combinations of genetic alterations that are found in carcinomas mean that 
there is not a single rigid metabolic program that is characteristic of all transformed cells [19].
Redox status in cancer
As described above, tumor metabolism is involved in the regulation of oxidative stress. 
Oxidative stress is caused by reactive oxygen species (ROS), which are oxygen-containing 
reactive chemical species. There are two types of ROS: free radicals, which contain one or 
more unpaired electron(s) in their outer molecular orbitals, and non-radical ROS, which do 
not have unpaired electron(s) but are chemically reactive and can be converted to radical 
ROS. Examples of radical ROS are superoxide (O2•-) and hydroxyl radicals (OH•). Non-radical 
ROS include hydrogen peroxide (H2O2) [35]. 
 The major site of ROS generation inside cells is the mitochondrial electron transport 
chain where electron leakage generates superoxide, which can be converted to hydrogen 
peroxide and the highly reactive hydroxyl radical [36-38]. In addition to mitochondria, ROS 
are also formed in the cytoplasm by various enzymes, such as nitric oxide synthase [36,37]. 
Besides endogenous sources, environmental stresses, such as ultraviolet radiation, ionizing 
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radiation and hypoxia, also induce cellular ROS production [37]. In the case of ionizing 
radiation, water molecules are subjected to radiolysis, generating highly reactive 
molecules [35,37,38]. 
 Basal ROS levels are higher in cancer cells compared to their normal counterparts [39]. 
The elevated ROS levels in cancer cells are mainly attributed to the following sources: (i) 
Increased metabolic activity and high mitochondrial energetics. (ii) Impairments in 
electron transport chain. ROS induce gene mutations, especially in the mitochondrial 
DNA (mtDNA). Several protein components of the mitochondrial electron transport chain are 
encoded by mtDNA. In this way, mutated mtDNA causes impairments in electron transfer, 
leading to leakage of electrons and generation of superoxide. (iii) Hypoxia, a common 
microenvironmental feature of solid tumors, leads to an increase in mitochondrial ROS 
produced from complex III of the electron transport chain. The exact mechanism by 
which hypoxia contributes to complex III ROS production is currently unknown. ROS can 
subsequently stabilize HIF-1α through the inhibition of prolyl hydroxylases. 
 The higher than normal ROS level in (pre-)cancer cells is associated with initiation and 
progression of cancer by inducing DNA mutations and activating pro-oncogenic pathways 
that regulate cellular proliferation, survival, epithelial to mesenchymal transition, 
angiogenesis and metastasis (e.g. by activating HIF pathway, PI3K/AKT/mTOR signaling 
through inhibition of PTEN and through activation of RAF/MEK/ERK cascade) [36-38]. 
Excessive amounts of ROS can cause irreversible oxidative damage to lipids, proteins and 
DNA resulting in cell cycle arrest and cell death [35,38,39]. Therefore, tight regulation of 
ROS homeostasis is required for (cancer) cell survival.
 Under persistent oxidative stress, cancer cells become well-adapted to this increase in 
ROS by enhancing the endogenous antioxidant capacity that scavenges ROS. This permits 
high ROS levels to activate pro-tumorigenic signaling pathways without building up 
excessively high ROS that could induce cell death or senescence [39]. The antioxidant 
system consists of cytosolic and mitochondrial superoxide dismutase, catalase, glutathione 
system, NAD(P)H, and thioredoxin system. Reduced glutathione (GSH) and NAD(P)H are 
the major nonenzymatic components of intracellular antioxidant defenses [36,37,39]. GSH 
is one of the most abundant antioxidants in mammalian cells and is vital to controlling the 
redox state of all subcellular compartments [8]. GSH (electron donator) can be oxidized to 
form glutathione disulfide (GSSG), which can be reduced back to GSH by glutathione 
reductase using NADPH [37]. Glutamine is the precursor of glutamate, which is required 
for GSH synthesis and therefore antioxidant response [39]. The major sources of intracellular 
NADPH are the pentose phosphate pathway, mitochondrial metabolism and metabolism 
of glutamine through malic enzyme (Figure 1) [11,36]. Therefore, tumor glucose and 
glutamine metabolism and cellular redox status are closely related. Redox adaptation 
through the elevation of endogenous antioxidants confers an increased capacity to 
tolerate oxidative stress [35]. 
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Imaging of tumor glucose metabolism using 18F-FDG PET
Non-invasive characterization of glucose tumor metabolism is possible by means of static 
and dynamic 18F-FDG PET. 18F-FDG consists of a tracer (2-deoxy-D-glucose) radiolabelled 
with a positron emitting radionuclide (18F), which can be visualized with PET. Deoxyglucose, 
like glucose, is taken up by cells using GLUTs, followed by phosphorylation to deoxy-
glucose-6-phosphate by hexokinase (Figure 1 and 2). As the selective phosphoglucose 
isomerase enzyme has no affinity for deoxyglucose-6-phosphate, unlike glucose-6- 
phosphate, this metabolite cannot be further metabolized. Once phosphorylated, deoxy-
glucose-6-phosphate cannot escape the cell and accumulates in the cytosol. In short, 
18F-FDG accumulation reflects cellular glucose needs.
The amount of pretreatment 18F-FDG uptake provides prognostic information: NSCLC 
patients with low 18F-FDG uptake in their primary tumor have a significant longer 
progression- free and overall survival than patients with high 18F-FDG uptake [40]. Apart 
from the prognostic value of pre-radiotherapy 18F-FDG uptake, metabolic changes on 
18F-FDG PET during and after radiotherapy are predictive for outcome and survival of 
NSCLC patients [41-44]. In 55 stage I-III NSCLC patients treated with radical radiotherapy 
alone or with sequential chemoradiation, pre-radiotherapy 18F-FDG PET was compared 
with 18F-FDG PET acquired approximately three months post radiation (Figure 3). Patients 
with residual metabolic activity post radiotherapy have a worse overall survival than 
individuals with a complete metabolic response (hazard ratio for death: 2.94). Maximum 
18F-FDG uptake pre-radiotherapy is significantly higher for patients with residual areas 
compared to patients with a complete metabolic response (maximum standardized 
Figure 2   GLUT1 expression and 18F-FDG uptake in a squamous cell non-small cell lung 
carcinoma
Figure A is an immunofluorescent image of GLUT1 expression in a poorly differentiated squamous 
cell carcinoma. Red, GLUT1; green, vessels. Magnification 100x. Scale bar represents 100 μm. This 
poorly differentiatied squamous cell carcinoma with high GLUT1 expression shows high 18F-FDG 
uptake on static 18F-FDG PET/CT (maximum standardized uptake value 10.7) (B).
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uptake value (SUVmax) 9.6 versus SUVmax 7.1). Areas with high 18F-FDG uptake pre-radio-
therapy largely correspond with residual metabolic-active areas post radiotherapy [41,44]. 
NSCLC patients treated with chemoradiation with a decrease in SUVmean of less than 30% 
in the second week of treatment have a 2-year survival of 43% versus 90% for patients with 
a decrease in SUVmean >30% [42]. Also the change in total lesion glycolysis in the second 
week of concurrent chemoradiotherapy is predictive for progression-free survival in 
irresectable stage III NSCLC [43]. These findings suggest a link between a high rate of 
tumor glucose metabolism, aggressive tumor behavior and resistance to (chemo)
radiotherapy in NSCLC. Metabolic changes on 18F-FDG PET early during treatment might 
guide adaptive radiotherapy, i.e. radiotherapy dose intensification for poor responders.
Figure 3  18F-FDG uptake before and after radiotherapy in NSCLC
A. Example of a stage IIIA non-small cell lung carcinoma in the right upper lobe with persistent 
metabolic activity of the primary tumor three months after treatment.
B. Stage IIIB non-small cell lung carcinoma in the left upper lobe with almost complete metabolic 
response three months after radiotherapy.
A
B
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Chapter 1
 Outline of the thesis
In this thesis, tumor metabolism of the major NSCLC histological subtypes (adenocarcinomas 
and squamous cell carcinomas) and the prognostic potential of metabolism-related 
markers and 18F-FDG PET are investigated. Furthermore, therapies targeting tumor 
metabolism to improve radiotherapy efficacy in NSCLC are examined in an in vitro study 
and in a dosis escalation radiotherapy planning study.
Part I of this thesis, chapters 2-3, describes tumor glucose metabolism in the major 
NSCLC histological subtypes (adenocarcinomas versus squamous cell carcinomas) 
according to expression of several metabolism-related markers on the mRNA and protein 
level, and static 18F-FDG PET. Furthermore, the prognostic potential of metabolism-related 
markers and 18F-FDG PET is explored. Chapter 4 gives further insight in tumor metabolism 
of subclassifications of adenocarcinomas (lepidic, acinar, papillary, micropapillary and 
solid) according to the WHO 2015 classification and the relation of the expression of 
 metabolism-related markers with several oncogenic mutations. Chapter 5 assesses 
whether dynamic 18F-FDG PET has added value over static 18F-FDG PET for tumor delineation 
in NSCLC radiotherapy planning using pathology volumes as reference standard, and 
compares pharmacokinetic rate constants of 18F-FDG metabolism (dynamic 18F-FDG PET), 
including their regional variation, between NSCLC histological subtypes.
In Part II of this thesis, tumor metabolism is exploited in treatment strategies for NSCLC. 
Chapter 6 describes a general overview about the advantages of tumor metabolism for 
tumor cell survival and the relation of glycolytic cancer cell metabolism with aggressive 
tumor behavior. Furthermore, the interaction between the HIF-1 pathway, tumor glucose 
metabolism, cellular redox status and radioresistance is discussed. Finally, several agents 
targeting tumor metabolism to overcome radioresistance are reviewed. In Chapter 7, 
the effect of treatment with lonidamine (glycolysis inhibitor) and/or 968 (glutaminase 
inhibitor) on metabolism, tumor cell growth, cytotoxicity and radiosensitivity is investigated in 
6 NSCLC cell lines (3 adeno- and 3 squamous cell carcinoma) in vitro. Chapter 8 compares 
the maximum achievable dose escalation for locally advanced NSCLC treated with 
concurrent chemoradiation by using a stereotactic boost directed to radioresistant 
subvolumes of the primary tumor as determined by an 18F-FDG PET/CT before start of 
chemoradiation and an early response monitoring 18F-FDG PET/CT.
Chapter 9 provides a general discussion including directions for future research and 
treatment of NSCLC patients. This thesis concludes with a summary of the findings 
(Chapter 10).
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Chapter 2
Abstract
Background Hypoxia leads to changes in tumor cell metabolism such as increased 
glycolysis. In this study, we examined the spatial distribution of the glycolysis and hypoxia 
related markers glucose transporter 1 (GLUT1) and monocarboxylate transporter 4 (MCT4) 
in relation to the vasculature in stage I, II and resectable stage IIIA NSCLC. Furthermore, 
associations of these markers with disease recurrence were investigated. 
Methods GLUT1 and MCT4 expression were determined in 90 NSCLC fresh frozen biopsies 
using immunohistochemical techniques and a computerized image analysis system. 
Markers were analyzed for adenocarcinomas (n=45) and squamous cell carcinomas (n=36) 
separately. Eighty-four patients were retrospectively evaluated for relapse (n=41 for 
adeno carcinomas and n=34 for squamous cell carcinomas). 
Results Squamous cell carcinomas demonstrated higher GLUT1 expression, relative to 
adeno carcinomas (p≤0.001). Also, in squamous cell carcinomas, GLUT1 and MCT4 expression 
increased significantly with increasing distance from the vasculature. This chronic hypoxia 
pattern of metabolic marker expression was not found in adenocarcinomas, in which 
GLUT1 and MCT4 were equally expressed at different distances for the vessels. In adeno-
carcinomas, high GLUT1 expression correlated with a poor differentiation grade (r(s)=0.55, 
p≤0.001) and positive lymph nodes at diagnosis (r(s)=0.45, p=0.003). High GLUT1 
expression was associated with a poor disease-free survival in only adenocarcinomas 
(p=0.044). 
Conclusion Analysis of GLUT1 and MCT4 expression on the histological level suggested a 
different metabolism for adenocarcinomas and squamous cell carcinomas. Likely, adeno-
carcinomas rely mainly on aerobic glycolysis, whereas the behavior of squamous cell 
carcinomas seems to be more physiologically, i.e. anaerobic glycolysis under hypoxic 
conditions. High GLUT1 expression indicated an aggressive tumor behavior in only adeno-
carcinomas. This subgroup of tumors may benefit from new treatment approaches 
targeting metabolism. Since this study has an exploratory character, our results warrant 
further investigation and need independent validation.
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Introduction 
Non-small cell lung cancer (NSCLC) is an important cause of cancer related death [1]. 
Surgery is possible in patients with stage I, II and limited stage III. Despite resectability of 
the tumor, approximately 50% of these patients will suffer relapse [2,3].
 The tumor-node-metastasis (TNM) classification is an important tool to estimate 
prognosis and for decision-making regarding treatment. However, since this classification 
does not provide information about biological behavior of tumors, differences in relapse 
occur within stage groups [4]. Tumor metabolism influences response to therapy [5], and 
could be exploited to predict outcome [6]. Therefore, interest in differences in metabolism 
between subgroups of tumors and metabolic markers to predict prognosis in NSCLC is 
growing. These markers could be used to select patients who may benefit from new, 
biology-based treatment approaches [5,7].
 A difference between normal and tumor cells, is their metabolic route of energy 
production. Tumor cells predominantly rely on glycolysis with production of lactate instead 
of mitochondrial oxidation, even in the presence of oxygen (Warburg effect or ‘aerobic 
glycolysis’) [8-10]. To support the necessary high rate of glycolysis, tumor cells need an 
increased transport of glucose into cells. This is facilitated by upregulation of glucose 
transporters (GLUTs). Glucose transporter 1 (GLUT1) overexpression has been documented 
in most malignancies [11]. hypoxia-inducible factor 1 (HIF-1), which is stabilized under hypoxic 
conditions, is responsible for GLUT1 upregulation [9,12]. The increased level of lactate and 
acid produced by enhanced glycolysis will decrease intracellular pH, which is potentially 
cytotoxic. To counteract this cytoplasmic acidification, cells can upregulate monocarbox-
ylate transporter 4 (MCT4), which transports lactate/H+ out of the cell [9,10]. MCT4 is also 
upregulated in response to hypoxia through HIF-1-mediated gene transcription [13].
 Tumor hypoxia predicts poor prognosis in various tumors independent of treatment 
modality [12,14]. The Warburg effect increases the malignant potential of tumor cells [15]. 
Lactate accumulation in malignancies predicts for metastasis formation during follow-up 
[16]. So, hypoxia and glycolysis related markers, such as GLUT1 and MCT4, which may 
indicate lactate accumulation, could have an additional value as prognosticators next to 
the TNM classification in NSCLC.
 The aim of this study was to examine the spatial distribution of GLUT1 and MCT4 
expression in relation to the vasculature in curatively resected stage I, II and limited stage 
III NSCLC to unravel differences in metabolism between histological subtypes. Furthermore, 
associations of these markers with treatment outcome were investigated to determine 
the prognostic value of these markers.
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Materials and methods
Patients 
One-hundred twenty-seven patients who underwent a curative resection for stage I, II 
and resectable stage IIIA, cN0-1 NSCLC between January 2002 and December 2008 at the 
Radboud University Nijmegen Medical Centre, of whom 129 fresh frozen biopsies were 
available, were included in this study. The study was performed according to institutional 
ethical rules and regulations.
 Of these 127 patients, 5 underwent experimental neo-adjuvant chemotherapy and 
were excluded. Furthermore, 27 biopsies were not suitable for evaluation due to sampling 
error (absence of tumor tissue, inflammatory tissue or necrosis), and 7 biopsies were not 
available. This resulted in 90 tumor biopsies from 88 patients for metabolic marker analysis 
(n=45 for adenocarcinomas and n=36 for squamous cell carcinomas). 
 In three patients, stage IIIB or IV was established during surgery. These patients were 
excluded from outcome analysis. Further, one patient was lost to follow-up. Also, two 
patients had two synchronous primary NSCLC. For follow-up analysis, the most advanced 
tumors were evaluated. Finally, a cohort of 84 tumors of 84 patients was available in which 
the prognostic potential of GLUT1 and MCT4 was investigated (n=41 for adenocarcinomas 
and n=34 for squamous cell carcinomas). Patient characteristics are listed in Table 1. 
Seventy patients underwent a (bi)lobectomy, 11 patients a pneumectomy and 3 patients 
were treated with a wedge resection due to co-morbidity. Twenty patients received 
adjuvant treatment, either chemotherapy (11 patients) or radiotherapy (9 patients).  
Immunohistochemical staining
Biopsies taken from NSCLC resections were frozen in liquid nitrogen and stored at -80°C. 
Sections of 5 µm, mounted on poly-L-lysine coated slides were stored at -80°C until 
staining for GLUT1, MCT4 and blood vessels.
 Before starting the immunohistochemical staining, sections were fixed for 10 minutes 
in acetone (4°C) and rehydrated in phosphate buffered saline (PBS) 0.1 mol/L (pH 7.4) 
(Klinipath, Duiven, The Netherlands). Subsequently, sections were pre-incubated in 
primary antibody diluent (PAD; GeneTex Inc., San Antonio, USA) for 5 minutes at room 
temperature. Between all consecutive steps of the staining procedure, slides were rinsed 
thrice in PBS. 
 Simultaneous staining for GLUT1 plus vessels or MCT4 plus vessels was performed on 
two consecutive tumor sections by incubating the sections with rabbit anti-GLUT1 
(Neomarkers; Fremont, CA, USA) and rabbit anti-MCT4 (Santa Cruz Biotechnology; Santa 
Cruz, CA, USA) respectively, diluted 1:100 in PAD, overnight at 4°C. The second incubation 
took 30 minutes at 37°C with goat anti-rabbitCy3 (Jackson Immuno Research Laboratories 
Inc.; West Grove, PA, USA), diluted 1:600 in PBS, for both GLUT1 and MCT4 sections. 
Afterwards, GLUT1 and MCT4 sections were stained for vessels by incubation with mouse 
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Table 1   Correlation of the clinicopathological status with GLUT1 and MCT4 expression 
and vascular density in 84 NSCLC patients
Characteristics Overall 
(n (%))
GLUT1 
(n (%))
MCT4
(n (%))
Vascular density 
(n (%))
Low High Low High Low High 
Age (years)
< 65
≥ 65
42 (50)
42 (50)
19 (45)
23 (55)
23 (55)
19 (45)
20 (48)
22 (52)
22 (52)
20 (48)
21 (50)
21 (50)
21 (50)
21 (50)
Sex
Male
Female
51 (61)
33 (39)
28 (55)
14 (42)
23 (45)
19 (58)
26 (51)
16 (49)
25 (49)
17 (51)
24 (47)
18 (55)
27 (53)
15 (45)
Histology 
Large cell carcinoma
Adenocarcinoma 
Squamous cell carcinoma 
Other
4 (5)
41 (49)
34 (40)
5 (6)
0 (0)
33 (81)
5 (15)
4 (80)
4 (100) *
8 (19)
29 (85)
1 (20)
1 (25)
21 (51)
17 (50)
3 (60)
3 (75)
20 (49)
17 (50)
2 (40)
3 (75)
9 (22)
27 (79)
3 (60)
1 (25) *
32 (78)
7 (21)
2 (40)
Tumor size (mm) 
< 30
≥ 30
42 (50)
42 (50)
24 (57)
18 (43)
18 (43)
24 (57)
23 (55)
19 (45)
19 (45)
23 (55)
18 (43)
24 (57)
24 (57)
18 (43)
Differentiation 
Well
Moderate
Poor
9 (11)
38 (45)
37 (44)
8 (89)
20 (53)
14 (38)
1 (11) *
18 (47)
23 (62)
5 (56)
16 (42)
21 (57)
4 (44)
22 (58)
16 (43)
3 (33)
18 (47)
21 (57)
6 (67)
20 (53)
16 (43)
pT 
T1
T2
T3
T4
29 (35)
42 (50)
8 (9)
5 (6)
17 (59)
17 (40)
5 (63) 
3 (60)
12 (41)
25 (60)
3 (37)
2 (40)
19 (66)
19 (45)
3 (37)
1 (20)
10 (34) *
23 (55)
5 (63)
4 (80)
12 (41)
25 (60)
2 (25)
3 (60)
17 (59)
17 (40)
6 (75)
2 (40)
pN #
N0
N1
N2
53 (64)
21 (26)
8 (10)
27 (51)
10 (48)
4 (50)
26 (49)
11 (52)
4 (50)
29 (55)
8 (38)
4 (50)
24 (45)
13 (62)
4 (50)
24 (45)
10 (48)
7 (88)
29 (55)
11 (52)
1 (12)
pTNM 7th edition 
Stage I
Stage II
Stage IIIA
46 (55)
24 (28)
14 (17)
25 (54)
9 (37)
8 (57)
21 (46)
15 (63)
6 (43)
28 (61)
9 (37)
5 (36)
18 (39) *
15 (63)
9 (64)
20 (43)
12 (50)
10 (71)
26 (57)
12 (50)
4 (29)
Surgical margins #
Free
Not free
73 (89)
9 (11)
36 (49)
5 (56)
37 (51)
4 (44)
37 (51)
4 (44)
36 (49)
5 (56)
37 (51)
4 (44)
36 (49)
5 (56)
Abbreviations:
GLUT1=glucose transporter 1, MCT4=monocarboxylate transporter 4, NSCLC=non-small cell lung cancer
In this table, the study population is dichotomized by low and high marker expression with cut-off set at median 
value of the whole group of NSCLC (13.6%).
# Analysis performed for 82 patients. Two cases were excluded from the analysis since an incomplete mediastinal 
staging was performed due to the following reasons: 
· Only a wedge resection was performed based on comorbidity
· According to the TNM 6th edition, stage IV was diagnosed as a result of a tumor nodule in a different ipsilaterale 
lobe. According to the TNM 7th edition however, this patient was classified as stage IIIA. 
* p-value significant at the 0.05 level
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antibody to endothelial PAL-E (Euro Diagnostica; Arnhem, The Netherlands) (diluted 1:10 in 
PAD) for 45 minutes at 37°C. This was followed by adding the secondary antibody chicken 
anti-mouseAlexa647 (diluted 1:100 in PBS) (Molecular Probes; Leiden, The Netherlands) 
for 45 minutes at 37°C. After the staining procedure, sections were mounted in fluorostab 
(ProGen Biotechnik GmbH, Heidelberg, Germany).
 To allow optimal discrimination between tumor and non-tumor tissue, a third 
consecutive section was stained by haematoxyline and eosin (H&E). 
Image acquisition
Slides were scanned using a high-resolution 12-bit CCD camera (Coolsnap HQ, Roper 
Scientific Inc., Trenton, NJ, USA) on a fluorescence microscope (Axioskop, Zeiss, Göttingen, 
Germany). Each slide was scanned for two signals (GLUT1 plus vessels or MCT4 plus vessels) 
at 100x magnification. Image processing was performed using IPLab software (Scanalytics 
Inc., Fairfax, VA, USA) on a Macintosh computer as described before [17]. This resulted in 
grey scale images, which were converted to binary images for further analysis. For 
segmentation, thresholds for the fluorescence signals were interactively set at intensities 
where the steepest gradient occurred between background and foreground intensity 
levels [18-21]. 
 
Image analysis
A pathologist specialized in pulmonary pathology indicated the tumor area on the H&E 
stained sections. Guided by these sections, the tumor area was marked on the GLUT1 and 
MCT4 stained sections. With this procedure, non-tumor tissue, necrotic areas and artifacts 
were excluded from the analysis. 
 Marker fractions were defined as the tumor area positive for the marker, divided by 
the total tumor area and were calculated by a computerized automated method [17]. 
To examine the relationship between vessels and GLUT1 and MCT4 expression, a domain 
was constructed around each vascular structure. The boundaries of these domains were 
defined in such a way that they were at equal distance from adjacent vessels [18]. Next, 
each domain was subdivided in arbitrary zones at a distance of 0-50 µm, 51-100 µm, 
101-150 µm and 151-200 µm from the nearest vessel. Subsequently, marker fractions were 
calculated in each of these zones. Tumors without GLUT1 (n=6) or MCT4 expression (n=3) 
were excluded from this zone analysis. 
 Vascular density was calculated as the number of vascular structures per square millimeter. 
Clinical follow-up
Patients were retrospectively evaluated for disease-free survival (DFS). This endpoint was 
calculated from the date of surgery to the date of NSCLC related relapse. For all patients, 
median follow-up time was 47 months (range 1-123). In one case (squamous cell 
carcinoma), follow-up was censored, due to uncertainty about NSCLC related relapse. 
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Follow-up was also censored at the time of diagnosis of a second metachronous primary 
lung carcinoma (n=6). 
Statistical analysis
Statistical analyses were done using SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, 
USA). The Pearson Chi-Square test and Spearman correlation were used to determine 
associations between the metabolic markers on a dichotomous scale and clinicopatho-
logical parameters. The correlation coefficient (r) between the markers on a continuous 
scale and clinicopathological parameters was calculated using the Pearson’s and 
Spearman’s Rank test where appropriate. As the level of GLUT1 and MCT4 expression in 
different regions within a tumor are related, they are considered as dependent. Therefore, 
comparison of multiple groups for heterogeneity analysis in the zone analysis was 
performed by Friedman’s ANOVA, followed by Dunn’s post-hoc analysis. Survival curves 
were generated using the Kaplan-Meier method. A log-rank test with linear trend for 
factor levels was performed to test for statistically significant differences between the 
survival curves. The number of events precluded multivariate analyses. A p<0.05 was 
considered statistically significant. 
Results
Metabolic marker expression and clinicopathology
GLUT1 and MCT4 staining were confined to the cell membrane. Examples of tumors with 
expression of metabolic markers and vascular density are shown in Figure 1 and quantitative 
data of marker fractions in Table 2. 
 For quantitative and survival analyses, the study population was dichotomized by 
low and high marker expression with cut-off set at median values, except for GLUT1 in 
adenocarcinomas. In this subgroup, an optimal cut-off value of 0.26% was applied (median 
1.8%). This resulted in 15 adenocarcinomas with low versus 26 adenocarcinomas with high 
GLUT1 expression. 
GLUT1 expression and clinicopathology
GLUT1 expression correlated significantly with histological subtype, being higher in 
squamous cell carcinomas (p≤0.001) (Table 1-2, Figure 2A).
 In adenocarcinomas, median GLUT1 fraction varied from 0.1% in tumors with a good 
differentiation grade to 2.5% and 13.3% in moderate and poorly differentiated carcinomas 
respectively (r(s)=0.55, p≤0.001) (Figure 2B). Furthermore, GLUT1 fraction was significantly 
higher in adenocarcinomas with lymph node metastases at diagnosis, compared to node 
negative tumors (r(s)=0.45, p=0.003) (Figure 2C). These correlations were not found in 
squamous cell carcinomas (Figure 2B-C). 
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MCT4 expression and clinicopathology 
High MCT4 expression correlated with pT-status (p=0.022) and pTNM-stage (p=0.033) 
(Table 1). This significance was lost when pT-status and pTNM-stage were compared with 
MCT4 expression on a continuous scale. 
Figure 1   Immunofluorescent images of NSCLC showing expression of GLUT1 and MCT4, 
and vascular density 
A. Squamous cell carcinoma with high GLUT1 expression. Vascular density is low.
B. Adenocarcinoma with high MCT4 expression and high vascular density.
Red, GLUT1 or MCT4; green, vessels; magnification 100x; scale bars represent 100 µm.
Table 2   Fractions of GLUT1 and MCT4 and vascular density within all NSCLC and 
histological subtypes
Carcinoma GLUT1 (%) MCT4 (%) Vascular density
All NSCLC 13.6 (0.00-62.0) 16.6 (0.0-62.5) 102.1 (23.5-323.6)
Adenocarcinomas 1.8 (0.0-44.5) 16.3 (0.4-53.7) 145.3 (30.2-323.6)
Squamous cell 
carcinomas
24.1 (5.5-62.0) 17.4 (0.0-61.2) 74.8 (23.5-164.3)
Abbreviations: 
GLUT1=glucose transporter 1, MCT4=monocarboxylate transporter 4, NSCLC=non-small cell lung cancer
Values expressed as median (range).
GLUT1 and MCT4 expression as percentage of total tumor surface. Vascular density expressed as the number of 
vascular structures per square millimeter.
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Vascular density and clinicopathology
Vascular density was significantly higher in adenocarcinomas compared to squamous cell 
carcinomas (p≤0.001) (Table 1-2).
GLUT1 and MCT4 expression and vascular distance
The zone analysis showed an increase in GLUT1 and MCT4 expression with increasing 
distance from the nearest vessel. This diffusion-limited or chronic hypoxia pattern of 
expression [12,22] was more clearly observed in squamous cell carcinomas, in which 
median GLUT1 fractions increased 4-4.5 fold and median MCT4 fractions 3-3.5 fold at >100 
µm from the vessels (Figure 3B-D-F). The observed higher heterogeneity of GLUT1 and 
MCT4 expression in squamous cell carcinomas is supported by the higher Friedman 
statistics in this histology (squamous cell carcinomas: GLUT1: 88.93, p<0.0001 and MCT4: 
Figure 2  GLUT1 expression and the clinicopathological status
A. GLUT1 expression in squamous cell carcinomas compared to adenocarcinomas.
# Mann-Whitney U test
B-C. Correlation of GLUT1 expression with differentiation grade (B) and pN-status (C), according to 
histological subtype.
Boxes represent lower quartile, median value and upper quartile, and whiskers represent minimum 
and maximum value.
A
B C
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Figure 3   GLUT1 and MCT4 expression at increasing distances from the vasculature in 
adenocarcinomas and squamous cell carcinomas
A-B.  Boxplots showing GLUT1 and MCT4 expression at various distances from the blood vessels in 
adenocarcinomas (A) and squamous cell carcinomas (B). See text for details.
Boxes represent lower quartile, median value and upper quartile, and whiskers represent minimum 
and maximum value. 
C-F. Immunofluorescent images showing the pattern of distribution of GLUT1 and MCT4 expression 
within an adenocarcinoma and a squamous cell carcinoma. 
A B
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55.04, p<0.001; adenocarcinomas: GLUT1: 23.90, p<0.0001 and MCT4: 14.02, p=0.0029). In 
squamous cell carcinomas, expression of GLUT1 and MCT4 increased significantly from 
zone 0-50 µm to zone 51-100 µm, and from zone 51-100 µm to zone 101-150 µm (Figure 
3B-D-F), while in adenocarcinomas no significant increase in GLUT1 and MCT4 expression 
was observed between these specific zones (Figure 3A-C-E).
 From Figure 3, the ratio of median GLUT1 fraction:median MCT4 fraction was 
calculated within the different zones around the vessels. Within each of the zones, this 
ratio differed in adenocarcinomas and squamous cell carcinomas, being <1 in adeno-
carcinomas and >1 in squamous cell carcinomas.
Metabolic marker expression and outcome
Disease-free survival and clinicopathology
During follow-up, 23 of 84 patients encountered NSCLC related relapse. Thirteen of 
41 patients with an adenocarcinoma (32%) (n=13 for distant metastases and n=6 for 
locoregional recurrence), while only 4 of 34 patients with a squamous cell carcinoma (12%) 
had recurrence of disease (n=4 for distant metastases and n=3 for locoregional recurrence). 
This trend towards a higher metastatic potential in adeno- versus squamous cell carcinomas 
(p=0.067) could not be explained by a more advanced pTNM stage in adeno- compared 
to squamous cell NSCLCs.
 Of the clinicopathological variables, positive lymph nodes (p=0.001), a more advanced 
pathological stage at diagnosis (p=0.011), and positive surgical margins (p=0.002) were 
significantly associated with a poor DFS. 
Prognostic value of GLUT1 and MCT4
GLUT1 expression did not reveal an association with DFS in all NSCLC. However, in adeno-
carcinomas, high GLUT1 expression demonstrated a significantly worse DFS (p=0.044) 
(Figure 4A). Eleven out of 26 patients with high GLUT1 expression had recurrence of 
disease, leading to a 5-year DFS of 55%, versus only 2 patients of the group with low GLUT1 
expression (n=15), resulting in a 5-year DFS of 85%.
 High MCT4 expression showed a trend towards a worse DFS in adenocarcinomas 
(p=0.151) (Figure 4B). Combination of high GLUT1 expression with high MCT4 expression 
did not further improve the prognostic potential of the metabolic markers in this 
Figure E shows higher MCT4 expression compared to GLUT1 expression (C) at closer distance from 
the vessels in an adenocarcinoma. In a squamous cell carcinoma, GLUT1 (D) and MCT4 (F) are 
increasingly expressed at larger distance from the vessels, i.e. in a chronic hypoxia pattern.
Red, GLUT1 or MCT4; green, vessels. Magnification 400x. Scale bars represent 100 μm. The red artifacts 
within the vessels were excluded from the analysis.
Abbreviations: AC: adenocarcinoma; GLUT1: glucose transporter 1; MCT4: monocarboxylate transporter 4; 
SCC: squamous cell carcinoma
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histological subtype. Five-year DFS for patients with high GLUT1 and high MCT4 expression 
was 50% versus a 5-year DFS of 78% for patients with low expression of one or both 
markers (p=0.04) (Figure 4C). 
Figure 4   Disease-free survival according to GLUT1 and/or MCT4 expression in adeno-
carcinomas
Cut-off value of GLUT1 is set just below the median at 0.26% (median 1.8%), the cut-off value of 
MCT4 is 16.3% (median level).
A
C
B
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Discussion
We investigated the spatial distribution and prognostic impact of GLUT1 and MCT4 in 
NSCLC. The observed differences in marker expression in adeno- and squamous cell 
carcinomas suggest a different metabolism between these histological subtypes.
GLUT1 expression and clinicopathology 
GLUT1 was found to be extensively expressed in squamous cell carcinomas relative to 
adenocarcinomas. In adenocarcinomas, higher GLUT1 expression correlated with a poor 
differentiation grade, as well as with lymph node metastases at diagnosis. These observations 
are in line with other studies [4,23-28].
GLUT1 and MCT4 expression and vascular distance 
The diffusion-limited or chronic hypoxia pattern [12,22] of GLUT1 and MCT4 expression 
was more clearly observed in squamous cell carcinomas compared to adenocarcinomas. 
In adenocarcinomas, no significant increase in GLUT1 and MCT4 expression was observed 
at different distances from the vasculature. Therefore, GLUT1 and MCT4 upregulation 
seems to be stronger related to hypoxia in squamous cell carcinomas. Besides the hypoxia- 
dependent activation of the HIF-1 pathway, HIF-1 can be activated in a hypoxia- 
independent way through the PI3K/AKT/mTOR pathway amongst others, leading to 
aerobic glycolysis [10,12,29]. In adenocarcinomas, GLUT1 and MCT4 may be induced in this 
way under normoxic conditions.
Metabolism of adenocarcinomas and squamous cell carcinomas
Glycolysis generates 2 mol of ATP and 2 mol of lactate per mol of glucose consumed [30]. 
This suggests that glycolytic tumor cells need a lower amount of glucose importers 
relative to lactate exporters. However, mitochondrial oxidation converts 2 mol of pyruvate into 
36 mol of ATP without production of lactate [30]. So, tumor cells that use oxidative phos-
phorylation need a higher amount of glucose transporters relative to lactate transporters. 
 The observed differences in marker expression suggest a different metabolism 
between adeno- and squamous cell NSCLC. Given the observation that GLUT1 and MCT4 
expression seem to be less related to hypoxia in adenocarcinomas, and the ratio of 
GLUT1:MCT4 is <1, this suggests that adenocarcinomas rely mainly on aerobic glycolysis. In 
contrast, squamous cell carcinomas are probably more hypoxic as a result of low vascular 
density, exhibit GLUT1 and MCT4 expression in a ratio >1 and the pattern of expression is 
diffusion-limited. This suggests that squamous cell carcinomas utilize mitochondrial 
oxidation as an energy source under normoxic conditions with anaerobic glycolysis under 
hypoxic conditions. 
 It remains unclear how adenocarcinomas are able to produce enough ATP and 
macromolecules with those low amounts of GLUT1, since glycolysis is a less efficient 
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energy pathway. Other transporters are possibly involved in glucose uptake, for example 
GLUT3 [29]. It was demonstrated that the combination of both GLUT1 and GLUT3 
expression and a poor differentiation grade determined the extent of fluorodeoxyglucose 
(FDG) accumulation in NSCLC [4]. However, GLUT3 expression by itself does not correlate 
with the amount of FDG uptake [4,31,32], and GLUT3 mRNA is lower than GLU1 mRNA 
expression in adenocarcinomas [33]. The utilization of lactate for energetic purposes 
could be another explanation. Aerobic tumor cells express monocarboxylate transporter 
1 (MCT1) on the cell membranes, which allows tumor cells to take up lactate, and use it as 
a substrate for mitochondrial oxidation, with the production of 36 mol of ATP per 2 mol of 
lactate consumed [34]. Also other nutrients like glutamine and fatty acids might be a 
source for ATP and macromolecule synthesis in adenocarcinomas [35-37]. Furthermore, 
proliferation rate is lower in adeno- than squamous cell NSCLCs [38]. So it is likely that 
 adenocarcinomas require fewer nutrients to fulfill the biosynthetic demands.
 A limitation of this exploratory study is the question whether the transporter 
expression level gives sufficient information on the functional activation status of 
transporters. It was demonstrated that GLUT1 expression and FDG accumulation in NSCLC 
correlate significantly [25,32,39], reflecting functionally active glucose transporters. Also, 
MCT4 expression correlated with lactate concentration in lung cancer cell lines in vitro [40]. 
The affinity of MCT4 for lactate is variable and can be increased by exposure to low pH 
values [41]. However, lactate production in vitro does not reflect lactate concentration in 
vivo and tumor glucose concentrations do not correlate with GLUT1 expression in tumor 
xenografts derived from head and neck squamous cell carcinoma lines [16]. Therefore, the 
functional metabolic consequences of differences in transporter expression between 
adeno- and squamous cell NSCLC warrant further investigation of for instance direct 
lactate concentration [42,43]. 
 
Prognostic value of GLUT1 and MCT4 
Previous studies investigating the prognostic potential of GLUT1 in NSCLC have found 
contradicting results [3,23,28]. For adenocarcinomas, high GLUT1 expression has been 
correlated with a poor survival [7,23]. This is in line with our study population showing a 
worse DFS for adenocarcinomas with high GLUT1 expression. The prognostic potential of 
this metabolic markers might be explained by the following mechanism. Glycolysis results 
in the acid end product CO2 and lactate, which are transported out of the cell by MCT4. 
This leads to extracellular acidification and a high extracellular lactate level. Acid and 
lactate can upregulate matrix-degrading metalloproteinases in stromal fibroblasts and 
tumor cells, which are involved in invasion, intravasation and metastasis [9,10,44]. High 
lactate levels have been correlated with a poor prognosis in breast, lung and liver 
carcinomas [10]. Lactate accumulation in malignancies correlates with radioresistance 
[16,42]. Furthermore, the Warburg effect increases the malignant potential of tumor cells 
[15]. MCT4 inhibition may decrease tumor cell invasion and extracellular matrix breakdown 
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[15,41,45,46]. So, the aerobic glycolytic metabolism in adenocarcinomas might promote 
the development of distant metastases. This is in agreement with our finding that adeno-
carcinomas have a higher potential to metastasize.
Conclusion 
We attempted to unravel differences in metabolism between adeno- and squamous cell 
NSCLC. Adenocarcinomas may use aerobic glycolysis as an energy source, whereas the 
metabolism of squamous cell carcinomas seems to rely on anaerobic glycolysis under 
hypoxic conditions. Our findings suggest that an aerobic glycolytic metabolism is an 
additive responsible factor for aggressive behavior in adeno NSCLC. This subgroup of 
tumors may benefit from new treatment approaches targeting metabolism. Since this is 
an exploratory study, our results warrant further investigation and need independent 
validation. 
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Abstract
Introduction Biological features of non-small cell lung carcinomas (NSCLCs) are important 
determinants for prognosis. In this study, differences in glucose metabolism between 
adeno- and squamous cell NSCLCs were quantified using the hypoxia and glycolysis-related 
markers GLUT1, CAIX, MCT1, MCT4, vasculature and 18F-FDG uptake. Relevance of these 
markers for disease-free survival (DFS) was analyzed.
Methods Patients with curatively resected stage I-II and resectable stage IIIA, cN0-1 
adeno- or squamous cell NSCLC, of whom fresh frozen lung resection biopsies and pre- 
treatment 18F-FDG PET-scans were available, were included in this study (n=108). 18F-FDG 
uptake was quantified by calculating total lesion glycolysis (TLG). Metabolic marker 
expression was measured by immunofluorescent staining (protein) and qPCR (mRNA). 
Patients were retrospectively evaluated for DFS.
Results mRNA and protein expression of metabolic markers, with the exception of MCT4, 
and TLG were significantly higher in squamous cell carcinomas than in adenocarcinomas, 
whereas adenocarcinomas were better vascularized (p<0.001). Adenocarcinomas had a 
worse DFS compared to squamous cell carcinomas (p=0.027), based on the potential to 
metastasize. High TLG was associated with a worse DFS only in adenocarcinomas (p=0.008). 
Conclusion Our findings suggest that adenocarcinomas exhibit glycolysis under normoxic 
conditions, whereas squamous cell carcinomas are exposed to diffusion-limited hypoxia 
resulting in a very high anaerobic glycolytic rate. Although squamous cell carcinomas 
have a higher 18F-FDG uptake, regarded as a poor prognostic factor, adenocarcinomas have 
a higher metastatic potential and a worse DFS. These findings show that 18F-FDG PET should 
be interpreted in relation to histology. This may improve the prognostic potential of 18F-FDG 
PET and may aid in exploiting 18F-FDG PET in treatment strategies allied to histology. 
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Introduction
Biological behavior of cancer cells is not only determined by the tumor cells’ genotype, 
but is also modified by the tumor microenvironment. For example, hypoxia, which is the 
result of an insufficient tumor microvasculature, plays a major role in cancer biology. 
Hypoxia is associated with more aggressive tumor behavior, impaired response to radio- 
therapy and chemotherapy, and worse clinical outcome [1]. Metabolism of carcinomas is 
affected by hypoxia, as tumor cells switch to anaerobic glycolysis with production of 
lactate under hypoxic conditions (Pasteur effect). However, in cancer cells, a high glycolytic 
rate is also observed in the presence of oxygen (Warburg effect). This glycolytic tumor 
metabolism is associated with selective growth advantage, tumor cell survival and 
treatment resistance [2-4]. The higher rate of glucose consumption is one of the reasons 
why 18-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET) is useful as 
an imaging tool in solid tumors [2,5,6].
 The hypoxia-inducible factor-1 (HIF-1) pathway plays a pivotal role in cellular adaptation 
mechanisms to hypoxic conditions. The HIF-1 pathway controls expression of many 
endogenous hypoxia- and glycolysis-related transporters and enzymes, such as glucose 
transporter 1 (GLUT1), responsible for cellular glucose uptake, carbonic anhydrase IX 
(CAIX), which prevents intracellular acidification, and monocarboxylate transporters (MCT) 
for the regulation of intracellular lactate level [1,7,8]. Apart from hypoxia, several cancer- 
associated mutations and cell signaling pathways are able to alter tumor metabolism, 
thereby inducing aerobic glycolysis [5,8].
 Several histological subtypes are categorzied within the same disease entity ‘non- 
small cell lung cancer’ (NSCLC). However, biological behavior and treatment-related 
outcome differ between histological subgroups of NSCLC [9,10]. Former analysis of GLUT1 
and MCT4 protein expression suggested differences in glucose metabolism between 
adeno- and squamous cell carcinomas [11]. This finding may have an important impact on 
the interpretation of 18F-FDG PET scans of these two NSCLC histologies.
 In the present study, we analyzed the tumor microenvironment and glucose metabolism 
of adeno- versus squamous cell lung carcinomas by analyzing mRNA and protein levels of 
GLUT1, CAIX, MCT1 and MCT4, vasculature as well as 18F-FDG uptake in curatively resected 
NSCLC patients. Moreover, we determined the consequences of differences in tumor 
glucose metabolism for survival.
532953-L-sub01-bw-Meijer
Processed on: 20-8-2019 PDF page: 48
48
Chapter 3
Materials and methods
Patients
Patients who underwent a curative resection for stage I, II and resectable stage IIIA, cN0-1 
NSCLC at the Radboud University Medical Center between January 2002 and December 
2008, who had fresh frozen lung resection biopsies and pre-treatment 18F-FDG PET scans 
done, were included in this study. The study was performed according to institutional 
ethical rules and regulations.
 One-hundred twenty-nine NSCLCs in 127 patients were identified [11]. Patients who 
received neo-adjuvant treatment were excluded (n=5). In 5 patients both the PET-scan 
and fresh frozen tissue were not available. In 11 tumors, other histologies than adeno- or 
squamous cell carcinoma were found. These tumors were not evaluated. As shown in 
figure 1, 108 NSCLCs in 106 patients remained. In 103 patients with 105 NSCLCs, a pre- 
treatment diagnostic 18F-FDG PET was available for analysis. 18F-FDG uptake of these carcinomas 
was correlated with clinicopathological parameters.
 In the group of 108 NSCLCs, 25 fresh frozen samples were not suitable for evaluation 
due to sampling error (absence of tumor tissue, presence of inflammatory tissue or necrosis) 
and two biopsies could not be retrieved. This resulted in 81 tumors of 79 patients available 
for immunofluorescent staining and qPCR analysis (Figure 1). In this cohort of 81 tumors, 
immunofluorescent staining of GLUT1, CAIX, MCT1 and MCT4, and qPCR analysis of these 
markers were correlated with clinicopathological characteristics. 
 For treatment outcome analysis, three patients with incomplete anatomical resections 
based on unexpected stage IIIB/IV (TNM 7th edition) were excluded and one patient was 
lost to follow-up. Of the two patients with two synchronous primary NSCLCs only the 
most advanced tumors were considered for survival analysis. Figure 1 summarizes numbers 
of available patients for follow-up analyses. Table 1 shows the clinicopathological charac-
teristics of adeno- versus squamous cell carcinomas that were available for ‘histology’ 
follow-up analysis. 
Immunofluorescent staining for GLUT1, CAIX, MCT1, MCT4 and vessels
Biopsies taken from lung cancer resection specimens were snap frozen in liquid nitrogen 
and stored at -80°C until further processing. Sections of 5 µm, mounted on poly-L-lysine 
coated slides, were stored at -80°C until immunofluorescent staining. Immunofluorescent 
staining of GLUT1, CAIX, MCT1, MCT4 and vasculature were performed as described before 
[11,12]. One section per tumor was analyzed for every staining (region of interest). 
The evaluation of the GLUT1 and MCT4 immunofluorescent staining is based on the same 
patients as described in Meijer et al [11].
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Fluorescence microscope image acquisition and analysis
Immunofluorescent image acquisition and analysis was described before [11]. In short, 
slides were scanned at 100x magnification using a high-resolution 12-bit CCD camera 
(Coolsnap HQ, Roper Scientific Inc., Trenton, NJ, USA) on a fluorescence microscope 
(Axioskop, Zeiss, Göttingen, Germany). This resulted in gray scale images, which were 
converted to binary images for further analysis. The tumor area was marked on the stained 
sections. Marker fractions were defined as the tumor area positive for the marker (binary 
images), divided by the total tumor area.
Figure 1   Flowchart of in- and exlusion criteria for correlation and follow-up analyses
Abbreviations: IHC, immunohistochemistry; NSCLC, non-small cell lung carcinoma; PET, positron 
emission tomography; qPCR, quantitative polymerase chain reaction.
MCT1 qPCR analysis failed in one tumor.
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Table 1   Clinicopathological characteristics of adeno- versus squamous cell lung 
carcinomas available for follow-up analysis
Characteristics Adenocarcinomas
(n (%))
n=55
Squamous  
cell carcinomas
(n (%))
n=47
p-value 
adenocarcinomas 
versus squamous 
cell carcinomas
Age (years)
≤ 65
> 65
26 (57%)
29 (52%)
20 (43%)
27 (48%)
NS
Sex
Male
Female
29 (47%)
26 (65%)
33 (53%)
14 (35%)
p = 0.05
Smoking status *
Current smoker
Former smoker (>1 year)
Never
23 (51%)
29 (57%)
3 (100%)
22 (49%)
22 (43%)
0 (0%)
NS
Surgery
Lobectomy
Bilobectomy
Pneumectomy
Wedge resection
48 (59%)
3 (75%)
3 (23%)
1 (33%)
34 (41%)
1 (25%)
10 (77%)
2 (67%)
NS
Tumor size (mm) 
< 30
≥ 30
35 (67%)
20 (40%)
17 (33%)
30 (60%)
p = 0.005
Differentiation $
Well
Moderate
Poor
8 (89%)
23 (51%)
22 (48%)
1 (11%)
22 (49%)
24 (52%)
NS
pT 
T1
T2
T3
T4
23 (64%)
24 (46%)
6 (67%)
2 (40%)
13 (36%)
28 (54%)
3 (33%)
3 (60%)
NS
pN 
N0
N1
N2
Nx #
38 (59%)
13 (48%)
3 (37%)
1 (50%)
27 (41%)
14 (52%)
5 (63%)
1 (50%)
NS
pTNM 7th edition 
Stage I
Stage II
Stage IIIA
35 (63%)
13 (42%)
7 (47%)
21 (37%)
18 (58%)
8 (53%)
p = 0.08
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RT-PCR
Total RNA was isolated with the Norgen’s Total RNA purification kit (Norgen Biotek Corp., 
Thorold, Ontario, Canada), and reversed transcribed using Gibco SuperScript II Reverse 
Transcriptase (Life technologies, Carlsbad, CA, USA). qPCR was performed with specific 
primers for GLUT1 (FW: 5’-GAGCATCATCTTCATCCC-3’, RV: 5’-TCTTTAGCACACTCTTGG-3’), 
CAIX (FW: 5’-GAGGCCTGGCCGTGTTG-3’), RV: 5’-CTGAGCCTTCCTCAGCGATT-3’), MCT1 (FW: 
5’-TCTGTGTCTATGCGGGATTCTT-3’, RV: 5’-TTGAGCCGACCTAAAAGTGGT-3’) and MCT4 (FW: 
5’-GTTGGGTTTGGCACTCAACT-3’, RV: 5’-GAAGACAGGGCTACCTGC-3’) on a CFX96 real-time 
PCR detection system (Bio-Rad Laboratories Inc, Richmond, CA) using SYBR Green. Levels 
are expressed as ratios of HPRT [13].
18F-FDG PET
Prior to 18F-FDG injection, patients fasted for ≥six hours. PET-scans were performed 60 
minutes after intravenous injection of ~250 MBq 18F-FDG (Covidien, Petten, The Netherlands) 
and 10 mg furosemide. PET-scans were acquired on an ECAT-EXACT full ring PET-scanner 
(Siemens/CTI, Knoxville, TN) until September 2005, using three-dimensional emission of 
10 min/bed position and germanium-68 2 min/bed position trasmission scans for 
attenuation correction. PET scans were iteratively reconstructed using two iterations and 
eight subsets. From September 2005 onwards, PET scans were acquired on a PET/CT 
scanner (Biograph Duo, Siemens Medical Solutions USA, Inc.) using three-dimensional 
Table 1   Continued
Characteristics Adenocarcinomas
(n (%))
n=55
Squamous  
cell carcinomas
(n (%))
n=47
p-value 
adenocarcinomas 
versus squamous 
cell carcinomas
Surgical margins 
Free
Not free
Rx #
48 (52%)
6 (75%)
1 (50%)
44 (48%)
2 (25%)
1 (50%)
NS
Adjuvant therapy
Chemotherapy
Radiotherapy
No
9 (60%)
3 (37%)
43 (54%)
6 (40%)
5 (63%)
36 (46%)
NS
* Smoking status is unknown in 3 patients with a squamous cell carcinoma
$ Differentiation is unknown in 2 adenocarcinomas
# An incomplete mediastinal staging was performed due to the following reasons: 
· Only a wedge resection was performed based on comorbidity
· According to the TNM 6th edition, stage IV was diagnosed as a result of a tumor nodule in a different ipsilaterale 
lobe. According to the TNM 7th edition however, this patient was classified as stage IIIA.
532953-L-sub01-bw-Meijer
Processed on: 20-8-2019 PDF page: 52
52
Chapter 3
emissions of 4 min/bed position. A low-dose CT scan for localization and attenuation- 
correction purposes was acquired. Scanning parameters included 40 mA·s (50 mA·s 
for patient weight >100 kg and 60 mA·s for >120 kg), 130 kV, 5 mm slice collimation, 
0.8 s rotation time, and pitch of 1.5, reconstructed to 3 mm slices for smooth coronal 
representation. Both PET-scanners were cross calibrated with the dose calibrator in which 
the administered activity was measured. 
 A hollow, cylindrical phantom of 6283 mL was filled with approximately 50 MBq of an 
aqueous solution of FDG. PET images of this phantom were reconstructed with the same 
settings as used for the patient scans, that is, the number of iterations and subsets, 
attenuation and scatter correction, and post reconstruction Gaussian smoothing. The 
activity concentration in the phantom as measured in the PET image for a set of central 
slices was compared to the known activity concentration. In case the deviation was more 
than 5%, the overall calibration factor was adapted. This procedure was carried out at least 
three times per year. Furthermore, in case of repair or software upgrades of either the 
dose calibrator or the PET scanner, the cross-calibration was repeated. Finally, our daily QC of 
the PET scanner included a scan of a solid Ge-68/Ga-68 phantom. When deviations of 
more than 3% of the measured activity and the theoretical phantom activity (decay 
corrected) occurred, the calibration factor was adjusted as well. 
 Volumes of interest were drawn using a 40% fixed threshold isocontour value [14,15]. 
Subsequently, metabolic tumor volumes and the mean standardized uptake value 
(SUVmean) were calculated. Total lesion glycolysis (TLG) was calculated by multiplying 
tumor volume (cm3) and SUVmean. 
Clinical follow-up
Patients were retrospectively evaluated for disease-free survival (DFS) in November 2013, 
which was calculated from the date of surgery to the date of lung cancer related relapse. 
Follow-up was according to national guidelines and consisted of clinical and radiological 
(at least chest X-ray) routine follow-up every 3 months in the first year and every 6 months 
from the second year or earlier if patients were symptomatic. Follow-up was censored 
at the time of diagnosis of a second metachronous primary lung cancer and death not 
related to NSCLC. 
Statistical analysis
Statistical analyses were performed using SPSS 18.0 statistical software (SPSS Inc., Chicago, 
IL, USA). The Pearson Chi-Square test and Spearman correlation were used to determine 
associations between histology and the other clinicopathological parameters. Differences 
between histological subtypes were measured by means of the Mann-Whitney U test or 
the Independent-Samples T Test where appropriate. Survival analyses were done with the 
Cox Regression and Kaplan-Meier method. DFS analyses were performed for adeno- and 
squamous cell carcinomas separately. For the various variables (marker fraction, mRNA 
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level, TLG), the study population was dichotomized into low and high based on median 
values. Due to the small number of events and consequently low statistical power, 
no further subgroup analysis was performed within the squamous cell carcinomas. 
The number of events precluded multivariate analyses [16]. A p<0.05 was considered 
statistically significant. 
Results
Metabolic marker expression in NSCLC
GLUT1, CAIX, MCT1 and MCT4 protein expression was confined to the cell membrane. 
Examples of tumors after immunofluorescent staining for these markers and vasculature 
are shown in Figure 2. mRNA results of GLUT1, CAIX, MCT1 and MCT4 are shown in Table 2.
 In the total cohort of 81 samples available for tissue correlation analysis (Figure 1), 
GLUT1, CAIX, MCT1 and MCT4 protein expression correlated significantly with mRNA data 
(r (s)=0.51, 0.73, 0.43 and 0.49 respectively; p≤0.001). 
Figure 2   Immunofluorescent images of squamous cell NSCLCs showing GLUT1 (A), CAIX 
(B), MCT1 (C) and MCT4 (D) protein expression
GLUT1, CAIX and MCT4 expression show a diffusion-limited pattern, whereas MCT1 is upregulated at 
the proximity of vessels.
Red, GLUT1, CAIX, MCT1 or MCT4; green, vessels; magnification 100x; scale bars represent 100 µm.
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Tumor microenvironment and glucose metabolism in relation to histology
Protein and mRNA expression of GLUT1, CAIX and MCT1 were significantly higher in 
squamous cell carcinomas relative to adenocarcinomas (Figure 3A-C and Table 2). CAIX protein 
expression was present in 83% of the squamous cell carcinomas, whereas only 47% of the 
adenocarcinomas expressed CAIX (p=0.001). MCT1 protein expression was detectable in 
42% of squamous cell carcinomas compared to only 7% of adenocarcinomas (p<0.001). 
MCT4 expression did not differ between adeno- and squamous cell NSCLC (Figure 3D).
Other prominent differences were a significantly higher vascular density in adeno-
carcinomas (p<0.001) (Figure 3E), larger tumor size in squamous cell carcinomas (Table 1), 
and a significant higher TLG (p=0.002) in squamous cell carcinomas (Figure 3F-H).
Disease-free survival in adeno- versus squamous cell carcinomas 
Adeno- versus squamous cell carcinomas
In our cohort of NSCLC patients, DFS was worse for patients with adenocarcinomas relative 
to squamous cell carcinomas based on the potential of adenocarcinomas to metastasize 
(HR=2.53, 95% CI 1.1-5.1, p=0.027) (Figure 4A). Of the adenocarcinomas, 36% developed 
distant metastases during follow-up, whereas 15% of squamous cell carcinomas encountered 
distant metastases. This resulted in a 5-year DFS of 60% for adenocarcinomas versus 
82% for squamous cell carcinomas. Clinicopathological variables were equally distributed 
among these histologies, with the exception of tumor size and sex (Table 1).
Disease-free survival according to glucose metabolism
High TLG in adenocarcinomas identified patients with a significant worse DFS in this 
histology (cut-off value set at median (11.1); HR 3.36, 95% CI 1.28-8.80, p=0.008) (Figure 4B). 
Table 2   Expression of GLUT1, CAIX, MCT1 and MCT4 mRNA within adeno- versus 
squamous cell NSCLC
Metabolic marker Adenocarcinomas
n=45
Squamous  
cell carcinomas
n=36
p-value
Adenocarcinoma versus
squamous cell 
carcinoma
GLUT1 : HPRT 2.13 (0.00-99.73) 4.60 (0.57-49.52) p = 0.003
CAIX : HPRT 0.03 (0.00-1.34) 0.11 (0.00-1.59) p = 0.017
MCT1 : HPRT 0.07 (0.00-0.56) 0.23 (0.07-2.27) * p < 0.001
MCT4 : HPRT 0.13 (0.01-1.87) 0.08 (0.02-0.71) NS
Abbreviations: GLUT1, glucose transporter 1; CAIX, carbonic anhydrase IX; MCT, monocarboxylate transporter; 
NSCLC, non-small cell lung carcinoma.
mRNA levels are expressed as ratios of HPRT. Values represent median (range).
* qPCR failed in one case
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Figure 3   Tumor microenvironment and tumor glucose metabolism of adeno- versus 
squamous cell carcinomas
A-D: Squamous cell carcinomas demonstrate higher expression of the hypoxia- and glycolysis 
related markers on both protein and mRNA level, with the exception of MCT4, compared to adeno-
carcinomas. 
E: Vascular density (number of vessels/mm2) is significantly higher in adenocarcinomas.
F-H: Squamous cell carcinomas are better visualized on 18F-FDG PET as measured by TLG (SUVmean 
x metabolic tumor volume [cm3]) (F). Figure G demonstrates a pT1aN0M0 adenocarcinoma with a 
tumor size of 2 cm. TLG is 8.6. Figure H shows a pT2aN0M0 squamous cell carcinoma. Tumor size is 
4.5 cm and TLG is 263.6.
mRNA levels are expressed as ratios of HPRT. Boxes represent lower quartile, median value and 
upper quartile, and whiskers represent minimum and maximum value.
A
C
E
B
D
F
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Adenocarcinomas with low TLG have a 5-year DFS of 78% versus 40% for adenocarcino-
mas with high TLG. TLG in adenocarcinomas correlated with tumor size (r(s)=0.81, p<0.01), 
pT stage (r(s)=0.58, p<0.01) and positive lymph nodes at diagnosis (r(s)=0.43, p<0.01).
 Despite the fact that squamous cell carcinomas have a high 18F-FDG uptake (Figure 
3F-H), regarded as a poor prognostic factor, this histology had a better DFS than adeno-
carcinomas. Furthermore, the subset of adenocarcinomas with high TLG had a worse DFS 
compared to all squamous cell carcinomas, which have comparable TLG values and 
clinico pathological characteristics as this subset of adenocarcinomas with high TLG (HR 
4.05, 95% CI 1.9-12.04, p<0.001). DFS of all squamous cell carcinomas versus adenocarcinomas 
with low TLG did not differ (Figure 4B). 
Figure 4   Disease-free survival according to histological subtype (A) and TLG in adeno-
carcinomas (B)
Cut-off value of TLG is set at median (11.1).
B
A
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Discussion
In this study, we analyzed the tumor microenvironment and tumor glucose metabolism of 
adeno- versus squamous cell lung carcinomas using the expression of hypoxia and glycol-
ysis-related markers, vascular density and 18F-FDG uptake in curatively resected stage I-IIIA 
NSCLC. Despite the fact that adeno- and squamous cell carcinomas are categorized within 
the same disease entity of ‘NSCLC’, we found remarkable differences between these 
histological types.  
Tumor microenvironment and glucose metabolism of adeno- versus 
squamous cell lung carcinomas
Expression of the hypoxia- and glycolysis-related markers GLUT1, CAIX and MCT1 on both 
mRNA and protein level, and 18F-FDG uptake were stronger in squamous cell carcinomas 
compared to adenocarcinomas. Other studies also showed a higher expression of GLUT1 
and CAIX protein, and higher 18F-FDG uptake in squamous cell carcinomas [17-24]. The 
lower vascular density in squamous cell carcinomas suggests that tumor blood perfusion 
is less optimal in these tumors, which could lead to areas of diffusion-limited hypoxia and 
subsequent upregulation of the metabolic markers. Earlier we demonstrated the diffusion- 
limited pattern of GLUT1 and MCT4 protein expression in squamous cell NSCLCs [11]. 
Hypoxia is an important cause of tumor necrosis, which is a known feature of squamous 
cell carcinomas [25,26]. Fan et al. also showed that the microvessel density is higher in 
adenocarcinomas [27]. Furthermore, flow extraction product on dynamic contrast- 
enhanced computed tomography (DCE-CT), which represents both blood flow and 
vascular permeability, is significantly higher in adenocarcinomas than in squamous cell 
carcinomas, which was however not confirmed by others [23,28]. 
 Intermediates of glycolysis can be utilized in the pentose phosphate pathway to 
synthetize precursors of nucleotides and amino acids, which are macromolecules required 
for tumor cell growth and proliferation [29,30]. Proliferation rate, as assessed by Ki67 and 
MCM7 expression, is higher in NSCLCs with higher SUVmax [24,28], in CAIX-positive areas 
of NSCLCs [21], and in squamous cell lung carcinomas [24,31].
 In summary, regarding the tumor microenvironment and glucose metabolism of 
NSCLCs, our results indicate that squamous cell carcinomas might be exposed to diffusion- 
limited hypoxia, resulting in an anaerobic glycolytic tumor metabolism. This metabolism 
may contribute to a high proliferation rate through the pentose phosphate pathway. 
In adenocarcinomas, expression of the hypoxia- and glycolysis related markers and 
18F-FDG uptake was lower, accompanied by high vascular density. This suggests that 
adeno carcinomas produce pyruvate and lactate under normoxic conditions [11]. 
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Survival of adeno- versus squamous cell NSCLCs with respect to glucose 
metabolism
A retrospective multivariate analysis of prognostic factors analyzed 12.428 stage I-IV 
NSCLC patients. In this multivariate analysis, squamous cell carcinoma histology was 
identified as an independent favorable prognostic factor, which is in agreement with our 
results [32].
 Within the adenocarcinoma subgroup of our cohort, high glucose dependency, 
measured by high TLG, correlated with positive lymph nodes and more advanced stage at 
diagnosis, and a significant worse DFS in this histology. The prognostic significance of 
18F-FDG PET has been shown in NSCLC patients treated with surgery, chemo- or radiotherapy 
[33,34]. However, despite the fact that the squamous cell carcinomas have a high TLG, 
regarded as a poor prognostic factor, this histology had a significant better prognosis 
in our cohort than a subset of adenocarcinomas with comparable high TLG. DFS did not 
differ between squamous cell carcinomas and adenocarcinomas with low TLG. Therefore, 
our results indicate that the meaning of 18F-FDG accumulation differs among NSCLC 
histologies with respect to understanding tumor glucose metabolism and estimation of 
prognosis. 
 The question remains why squamous cell carcinomas with their high rate of glucose 
metabolism have a more favourable prognosis compared to adenocarcinomas. Adeno-
carcinomas are known to have a high metastatic potential, whereas progressive localized 
disease is more often found for squamous cell histology [25]. Several cellular processes, 
such as epithelial-mesenchymal transition (EMT), cell motility and invasion, are required 
for the formation of distant metastases. Adenocarcinomas may use their energy 
metabolism to support these processes. Expression of both FoxQ1, which has a key role in 
regulating EMT, and vimentin, a mesenchymal marker, were significantly higher in adeno-
carcinomas than in squamous cell carcinomas, which was however not confirmed by 
others [35-37]. Signalling through the MET pathway promotes EMT and the development 
of an invasive phenotype. c-MET and phospho-MET proteins are higher expressed in 
adeno carcinomas than in squamous cell carcinomas [38]. Future studies are warranted to 
explore the metastatic potential of adeno- versus squamous cell NSCLCs and its relation to 
tumor metabolism.
Exploiting differences in biological behavior between adeno- and 
squamous cell NSCLCs in treatment strategies
NSCLC histology is predictive for treatment efficacy and clinical outcome [9]. For example, 
a consistent link between histology and treatment outcome was established for epidermal 
growth factor receptor tyrosine kinase inhibitors and pemetrexed [9,39]. Differences in 
metabolism between histologies may also be exploited in treatment strategies. For 
example, apart from hypoxia, high rate of glucose metabolism is involved in resistance to 
radiotherapy [4]. Therefore, glycolysis inhibitors in combination with chemoradiotherapy, 
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or a radiation boost directed towards regions with high 18F-FDG uptake may be used to 
enhance radiotherapy efficacy [11,40,41]. 
 Locoregional control and survival remain poor in irresectable stage III NSCLC, despite 
the use of concurrent instead of sequential chemoradiation [42]. The subset of adeno-
carcinomas with a high glucose consumption and a worse survival based on the potential 
to metastasize may benefit from glycolysis targeting to prevent the development of 
distant metastases. As squamous cell carcinomas have a very high glycolytic rate and a 
higher frequency of local recurrences, irresectable stage III squamous cell carcinomas 
might benefit from glycolysis targeting in combination with chemoradiation to improve 
loco - regional control. To exploit metabolism in these combined treatment modalities, 
it has to be examined whether our results, i.e. the difference in metabolic behavior 
between resectable stage I-IIIA adenocarcinomas and squamous cell carcinomas, can be 
translated to irresectable stage III NSCLC. Furthermore, to assess treatment-by-histology 
interactions large studies are needed, which may aid in maximizing survival in NSCLC 
patients by refinement of therapy allied to histology. 
Conclusion
In the present study, we analyzed differences in the tumor microenvironment and glucose 
metabolism of adeno- versus squamous cell NSCLCs, and the consequences of these 
differences for prognosis. Squamous cell carcinomas have a higher glycotic rate on both 
the mRNA and protein level, are better visualized on 18F-FDG PET, and have a worse vascu-
larization compared to adenocarcinomas. This suggests that squamous cell carcinomas 
demonstrate glycolysis mainly under hypoxic conditions. Despite the fact that adeno-
carcinomas have a lower 18F-FDG uptake, generally believed to be a favorable prognostic 
factor, relative to squamous cell carcinomas, adenocarcinomas have a higher metastatic 
potential and a worse DFS. These findings show that 18F-FDG PET should be interpreted 
in relation to histology. This may improve the prognostic potential of 18F-FDG PET and 
may aid in exploiting 18F-FDG PET in treatment strategies allied to histology. 
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Abstract
Purpose Both hypoxia and oncogenic mutations rewire tumor metabolism causing 
resistance to radiotherapy. In this study, glucose and glutamine metabolism-related 
markers were examined in stage I-resectable stage IIIA non-small cell lung cancer (NSCLC). 
Furthermore, expression of metabolism-related markers was correlated with mutational 
status to examine mutations that are associated with rewired tumor metabolism.
Methods Mutation analysis was performed for 97 tumors. Glucose and glutamine meta-
bolism-related marker expression was measured by immunofluorescent staining (protein) 
and qPCR (mRNA) (n=81).
Results Glutamine metabolism-related markers were significantly higher in adeno- than 
squamous cell NSCLCs. Glucose transporter 1 (GLUT1) protein expression was higher in 
solid compared to lepidic adenocarcinomas (p<0.01). In adenocarcinomas, mRNA 
expression of glutamine transporter SLC1A5 correlated with tumor size (r(p)=0.41, p=0.005). 
Furthermore, SLC1A5 protein expression was significantly higher in adenocarcinomas 
with worse pTNM stage (r(s)=0.39, p=0.009). EGFR mutated tumors showed lower GLUT1 
protein (p=0.017), higher glutaminase 2 (GLS2) protein (p=0.025) and higher GLS2 mRNA 
expression (p=0.004), compared to EGFR wildtype tumors. GLS mRNA expression was 
higher in KRAS mutated tumors (p=0.019). TP53 mutated tumors showed higher GLUT1 
expression (p=0.009).
Conclusions NSCLC is a heterogeneous disease, with differences in mutational status and 
metabolism-related marker expression between adeno- and squamous cell NSCLCs, and 
also within adenocarcinoma subtypes. GLUT1 and SLC1A5 expression correlate with 
aggressive tumor behavior in adenocarcinomas but not in squamous cell NSCLCs. So, 
these markers could steer treatment modification for subgroups of adenocarcinoma 
patients. TP53, EGFR and KRAS mutations are associated with expression of glucose and 
glutamine metabolism-related markers in NSCLC.
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Introduction
Non-small cell lung cancer (NSCLC) is a heterogeneous disease regarding clinical, patho -
logical, and molecular aspects [1,2]. In 2015, an update of the World Health Organization 
(WHO) classification was introduced, describing the major subtypes of adenocarcinomas 
demonstrating a predominantly lepidic, acinar, papillary, micropapillary, or solid growth 
pattern [3]. This classification system for lung adenocarcinoma is an independent predictor 
of survival [4]. Predominantly micropapillary and solid adenocarcinomas often have a 
more advanced TNM-stage at diagnosis, a higher recurrence rate, and a worse survival 
relative to predominantly lepidic, acinar and papillary subtypes [4]. So, predominantly 
micropapillary and solid adenocarciomas have more aggressive behavior with early 
distant metastasis. 
 Reprogrammed tumor metabolism is one of the hallmarks of cancer, and may 
influence radiotherapy sensitivity [5,6]. To proliferate, a cell needs to replicate all of its 
cellular contents including DNA and organelles, and the cell has to sustain its redox status [7]. 
This requires, besides ATP, reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
and glutathione, and the biosynthesis of macromolecules essential for constructing a new 
cell [8]. The main nutrients required for bioenergetics and macromolecular synthesis and 
thus tumor cell proliferation are glucose and glutamine. Increased glucose uptake by 
tumors to support enhanced glycolysis is accomplished by upregulation of glucose 
transporters (GLUTs) [9]. The higher glycolytic rate results in the production of lactate and 
acid, which are transported out of the cell by monocarboxylate transporters (MCTs) and 
carbonic anhydrase IX (CAIX) [6]. Important transporters and enzymes for glutamine 
uptake and metabolism are solute-linked carrier family A1 member 5 (SLC1A5) and 
mitochondrial glutaminase (GLS) respectively [10,11]. GLS is the key enzyme in the 
conversion of glutamine to glutamate. GLS has two isoforms: GLS1 (kidney glutaminase) 
and GLS2 (liver glutaminase). GLS1 has two splice variants: kidney-type glutaminase (KGA) 
and glutaminase C (GAC) [12]. This metabolic transformation is the result of complex 
interactions between a hypoxic tumor microenvironment and oncogenic mutations, such 
as epidermal growth factor receptor (EGFR), TP53 and Kirsten rat sarcoma viral oncogene 
(KRAS) [9,13-16]. Higher glucose utilization correlates with aggressive tumor behavior and 
treatment resistance including radiotherapy [6]. So, tumor metabolism might be exploited 
in future treatment strategies.
 Our previous analyses showed differences in GLUT1, CAIX, and MCT1 expression, 
vascular density and 18-fluoro-2-deoxyglucose (18F-FDG) uptake between adeno- and 
squamous cell NSCLCs, supporting differences in tumor glucose metabolism among 
NSCLC histological subtypes [17-19]. In view of the association between glucose 
metabolism and aggressive tumor behavior, and the worse prognosis in predominantly 
micropapillary and solid adenocarcinomas, we further explored glucose and glutamine 
metabolism-related markers between adeno- and squamous cell NSCLC and within sub-
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classifications of adenocarcinomas in this study. Furthermore, expression of metabolism- 
related markers was correlated with mutational status to examine oncogenic mutations 
that are associated with reprogrammed tumor metabolism in NSCLC.
Materials and methods
Patients
Patients who underwent a curative resection for stage I, II, and resectable stage IIIA, cN0-1 
adeno- or squamous cell NSCLC at the Radboud University Medical Center between 
January 2002 and December 2008 were included in this study as described before [18]. 
Of these 108 NSCLCs, fresh-frozen lung resection biopsies for metabolism-related marker 
analysis were available for 81 NSCLCs. Formalin-embedded lung resection material for 
mutation analysis was available for 97 NSCLCs (Figure 1).
Pathology 
After surgery, the involved lung-lobe was fixed in formaldehyde by inflating formaldehyde 
into the lobar/main bronchus and lobar/main artery. Fixated tumors were cut into 
transversal slices. Here, maximum macroscopic transversal tumor dimension (mm) was 
measured. In case of a maximum tumor dimension in craniocaudal length, maximum 
tumor size (mm) was calculated by: slice thickness*(number of tumor positive slices minus 1). 
By subtracting 1, we took into account that the flanking slices mostly did not show full 
thickness tumor infiltration. Lung resection specimens were revised by a pathologist (ML) 
and typified on H&E stained slides according to the WHO 2015 classification. 
Immunofluorescent staining
Biopsies taken from fresh lung cancer resection specimens were snap frozen in liquid 
nitrogen and stored at -80°C until further processing. Sections of 5 µm, mounted on 
poly-L-lysine coated slides, were stored at -80°C until staining. Immunofluorescent staining 
of GLUT1, CAIX, MCT1, MCT4 and vascular density was described before [17]. 
 Staining for SLC1A5 and GLS2 was performed on two consecutive tumor sections by 
incubating the sections with rabbit anti-SLC1A5 (Abcam, Cambridge, UK) and rabbit 
anti-GLS2 (ThermoFischer Scientific, Waltham, Massachusets, USA) respectively, diluted 
1:150 in PAD (Bio-Rad Laboratories Inc, Richmond, CA, USA), overnight at 4°C for SLC1A5 
and 45 minutes at 37°C for GLS2. For SLC1A5, the second and third incubation took 30 
minutes at 37°C with goat anti-rabbitCy3 (Jackson Immuno Research Laboratories Inc.; 
West Grove, PA, USA) and donkey anti-goatCy3 (Jackson) respectively, diluted 1:600 in PAD. 
For GLS2, the second incubation took 45 minutes at 37°C with goat anti-rabbit Cy3, diluted 
1:300 in PAD. After staining, sections were mounted in Fluoromount (SERVA Electrophoresis 
GmbH, Heidelberg, Germany). 
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Fluorescence microscope image acquisition and analysis
Immunofluorescent image acquisition and analysis were described before [17]. In short, 
slides were scanned at 100x magnification using a high-resolution 12-bit CCD camera 
(Coolsnap HQ, Roper Scientific Inc., Trenton, NJ, USA) on a fluorescence microscope 
(Axioskop, Zeiss, Göttingen, Germany). This resulted in gray scale images, which were 
converted to binary images for further analysis. The tumor area was marked on the stained 
sections. Marker fractions were defined as the tumor area positive for the marker (binary 
images), divided by the total tumor area. Vascular density was calculated as the number 
of vascular structures per square millimeter. 
 For SLC1A5 and GLS2 staining, background intensity level hampered segmentation 
for binarizing the images. Therefore, these stainings required visual scoring. Fraction of 
tumor cells of the total tumor area stained for SLC1A5 and GLS2 were scored as <5%, 
5-20% and >20%. Slides were indivually scored by TM and JL. In case of disagreement, 
slides were discussed till agreement was reached.
Figure 1   Flowchart of available NSCLC tissue for mutation and metabolism-related 
marker analyses
Abbreviation: NSCLC, non-small cell lung carcinoma
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RT-PCR
Total RNA was isolated with the Norgen’s Total RNA purification kit (Norgen Biotek Corp., 
Thorold, Ontario, Canada), and reversed transcribed using Gibco SuperScript II Reverse 
Transcriptase (Life technologies, Carlsbad, CA, USA). GLUT1, CAIX, MCT1 and MCT4 
qPCR was described before [18]. qPCR was performed with specific primers for SLC1A5 
(FW: 5’- GAGCTGCTTATCCGCTTCTTC-3’, RV: 5’- GGGGCGTACCACATGATCC-3’), GLS 
(FW: 5’-AGGGTCTGTTACCTAGCTTGG-3’, RV: 5’- ACGTTCGCAATCCTGTAGATTT-3’), GAC 
(FW: 5’- GGTCTCCTCCTCTGGATAAGATGG-3’, RV: 5’- GATGTCCTCATTTGACTCAGGTGAC-3’) 
and GLS2 (FW: 5’- GCCTGGGTGATTTGCTCTTTT-3’, RV: 5’- CCTTTAGTGCAGTGGTGAACTT-3’) 
on a CFX96 real-time PCR detection system (Bio-Rad Laboratories Inc) using SYBR Green. 
Levels are expressed as ratios of hypoxanthine ribosyltransferase (HPRT) [20].
DNA isolation
DNA isolation was essentially performed as described before [21]. In short, 3 × 20 μm 
sections were digested at 56°C for 1 hour in the presence of TET-lysis buffer (10 mmol/L 
Tris/HCl pH8.5, 1 mmol/L EDTA pH8.0, 0.01% Tween-20) with 5% Chelex-100 (143 to 2832; 
Bio-Rad, Hercules, CA), 15 μg/mL GlycoBlue (AM9516; Thermo Fisher, Waltham, MA), 
and 400 μg proteinase K (19133; Qiagen, Valencia, CA), followed by inactivation at 95°C for 
10 minutes. The supernatant was cooled on ice and precipitated in the presence of 70% 
EtOH and 1/10 volume 3M NaAc (pH 5.2). Pellets were washed with cold 70% EtOH and 
dissolved in 80 μL Tris-EDTA, and DNA concentration was determined using the Qubit 
Broad Range Kit (Q32853; Thermo Fisher).
Mutation analysis
Library preparation and smMIP-based sequencing were performed as described by 
before [21,22]. 100 ng (in a maximum volume of 7 μl) of genomic DNA was used as 
input in a 20 μL volume with a total capture volume of 25 μL, including the (diluted) 
phosphorylated smMIP pool (smMIP:gDNA ratio of 3200:1), 1 unit of Ampligase DNA ligase 
(A0110K; EpiBio, Madison, WI) with Ampligase Buffer (A1905B, DNA ligase buffer), 3.2 units 
of Hemo Klentaq (M0332; New England Biolabs), and 8 μmol of dNTPs (28-4065-20/-12/-
22/-32; GE Healthcare, Little Chalfont, UK). After denaturation (95°C for 10 minutes) the mix 
was incubated for probe hybridization, extension, and ligation at 60°C for 18 hours and 
cooled before exonuclease treatment. Exonuclease I (10 units; M0293; New England 
Biolabs) and III (50 units; M0206; New England Biolabs) and Ampligase Buffer (see above) 
were added to the capture volume, adding up to a total of 27 μL, and incubated for 
45 minutes at 37°C, followed by inactivation at 95°C for 2 minutes. A total of 10 μL of 
the exonuclease-treated capture was used for PCR in a total volume of 25 μL with 25 nmol 
common forward primer and barcoded reverse primers and iProof high-fidelity master 
mix (1725310; Bio-Rad). The resulting PCR products were pooled before purification with 
0.8× volume of Agencourt Ampure XP Beads (A63881; Beckman Coulter, Brea, CA). 
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Hybridization reactions were pipetted using a Microlab STARplus robot (Hamilton, Reno, 
NV). The exonuclease treatment was performed manually to prevent exonuclease 
contamination in the pre- and post-PCR environments. The post-hybridization PCR was 
performed using a MicroLab STARlet Replicator Robot (Hamilton). All samples were 
subsequently pooled on a MicroLab Starlet Replicator Robot (Hamilton). 
 The purified libraries were denatured and diluted to a concentration of 1.2 pmol/L. 
Sequencing was performed on a NextSeq500 instrument (Illumina, San Diego, CA) 
according to the manufacturer’s protocol (300 cycles Mid Output sequencing kit, v2), 
resulting in 2 × 150 bp paired-end reads.
 Fastq files were analyzed using commercial analysis software (Sequence Pilot version 
4.2.0; JSI medical systems, Ettenheim, Germany). The following settings were used for 
 single-molecule–directed consensus: Tags active, yes; R1 tag length, 8; R2 tag length, 0; 
Min abs. cov. cons., 1; Min per. cov. cons., 50%; Ignore cons. read thresh., 30; Ignore N tags, 
yes, and Ignore low Qs tags, yes. Proper identification of sequence variants greatly relies 
on the variables for variant calling, such as the minimal number of mutant unique smMIPs 
(>2 in our settings) and the minimal mutant allele frequency (≥1%). The following settings 
were used for variant calling using Sequence Pilot: Required Coverage/Min abs. cov., 40 
combined; Mutations/Min abs. cov., 5 combined; Min % cov., 1% per dir. PIK3CA 
pseudogene reads were removed from the alignment and subsequent analysis. After 
variant calling using the commercial software, all variants were manually inspected and 
curated.
Statistics
Statistical analyses were performed using SPSS 22.0 statistical software (SPSS Inc., Chicago, 
IL, USA). The Pearson Chi-Square test and Spearman correlation were used to determine 
associations between clinicopathological characteristics, mutation status and metabo-
lism-related markers on a trichotomous scale. The correlation coefficient (r) between 
 metabolism-related markers on a continuous scale and clinicopathological parameters 
was calculated using the Pearson’s and Spearman’s Rank test where appropriate (testing 
for Gaussian distribution by One-Sample Kolmogorov-Smirnov Test). Differences in 
 metabolism-related marker expression between histological subtypes or mutated versus 
wildtype tumors were measured with the Mann-Whitney U test or the Independent- 
Samples T-test where appropriate. A p<0.05 was considered statistically significant. 
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Results
Glucose and glutamine metabolism-related markers in NSCLC 
histological subtypes
Adenocarcinomas showed higher expression of SLC1A5 and GLS2 on both protein (p=0.08 
and p=0.019 respectively) and mRNA level (p<0.001 and p=0.003 respectively) (Figure 2, 
Table 1A), compared to squamous cell carcinomas. Also, GLS mRNA level was higher in 
adenocarcinomas than squamous cell carcinomas (p<0.001) (Figure 2C). In adenocarcinomas, 
SLC1A5 mRNA expression correlated with tumor size (r(p)=0.41, p=0.005). Furthermore, 
SLC1A5 protein expression was significantly higher in adenocarcinomas with lymph node 
metastases compared to node negative tumors (r(s)=0.34, p=0.028) and in adenocarcinomas 
with higher pTNM stage (r(s)=0.39, p=0.009) (Table 1B). Glutamine metabolism-related 
markers and vascular density were not different within adenocarcinoma subclassifications. 
GLUT1 expression differed among adenocarcinoma subclassifications (p=0.002), and was 
significantly higher in predominantly solid compared to predominantly lepidic adeno-
carcinomas (p<0.01) (Figure 3). Squamous cell carcinomas had an even higher GLUT1 
expression compared to predominantly solid adenocarcinomas: median GLUT1 expression 
was 24.1% (range 5.5-62) versus a median expression of 12.6% (range 0.8-43.8) (p<0.05) 
(Figure 3).
Mutation analysis
Mutations are described in Table 2. TP53 and PIK3CA mutations were more prevalent in 
squamous cell carcinomas than in adenocarcinomas (97.4% versus 71.2%, p=0.001; 10.5% 
versus 0%, p=0.011 respectively). EGFR and KRAS mutations were more frequently observed 
in adenocarcinomas (10.2% versus 0%, p=0.042; 35.6% versus 5.3%, p=0.001 respectively). 
EGFR mutations were found in predominantly lepidic and acinar adenocarcinomas and 
not in adenocarcinomas with a predominantly papillary or solid growth pattern (not 
significant). Other mutations (AKT1, BRAF, IDH1/2, KIT, PDGFRA) were sporadically demonstrated. 
We did not observe ERBB2 and JAK2 mutations.
Association between metabolism-related marker expression and 
mutational status
EGFR mutated tumors showed lower GLUT1 protein expression (p=0.017; Figure 4A), 
corresponding with the fact that predominantly lepidic and acinar adenocarcinomas are 
EGFR mutated and demonstrate low GLUT1 expression. Furthermore, in EGFR mutated 
tumors, higher expression of GLS2 protein (p=0.025; Table 1C) and GLS2 mRNA was 
observed compared to EGFR wildtype tumors (p=0.004; Figure 4B).
 KRAS mutated tumors showed a trend towards lower GLUT1 protein expression 
(p=0.06; Figure 4C), and demonstrated a significantly lower CAIX protein expression 
(p=0.007; Figure 4D). KRAS mutation status correlated with higher glutamine metabolism, 
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Figure 2   Glutamine transporter and glutaminase expression in adeno- versus squamous 
cell non-small cell lung cancer
Expression of glutamine transporter SLC1A5 mRNA (A), glutaminase mRNA (B) and glutaminase 2 
mRNA (C) is higher in adenocarcinomas relative to squamous cell carcinomas. Levels are expressed 
as ratios of HPRT.
Figure D-E show immunofluorescent images of adeno NSCLCs showing SLC1A5 (D) and GLS2 (E) 
expression. Red, SLC1A5 or GLS2; green, vessels; magnification 100x; scale bars represent 100 µm.
Abbreviations: GLS: glutaminase; SLC1A5: solute-linked carrier family A1 member 5.
A
C
B
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Table 1   Glutamine metabolism-related markers in relation to clinicopathological 
 characteristics and EGFR mutation status 
A)   Glutamine transporter SLC1A5 and glutaminase GLS2 protein expression in  
adeno- versus squamous cell non-small cell lung cancer
Adenocarcinoma Squamous cell carcinoma p-value
SLC1A5 protein    
<5% 19 (44.2%) 21 (60%) p=0.08
5-20% 11 (25.6%) 10 (28.6%)
>20% 13 (30.2%) 4 (11.4%)
GLS2 protein
<5% 29 (67.4%) 31 (88.6%) p=0.019
5-20% 5 (11.6%) 3 (8.3%)
>20% 9 (20.9%) 1 (2.8%)  
Abbreviations: GLS2: glutaminase 2; SLC1A5: Solute Carrier Family 1 (Neutral Amino Acid Transporter) Member 5
Two tissue samples were missing for adenocarcinomas and one sample was missing for squamous cell 
carcinomas, resulting in 43 adenocarcinomas and 35 squamous cell carcinomas for glutamine metabolism- 
related marker analysis.
B)   Glutamine transporter SLC1A5 protein expression is higher in adenocarcinomas  
with a worse pTNM stage
SLC1A5 protein
<5% 5-20% >20% p-value
pTNM stage
Stage I 17 (65.4%) 2 (7.7%) 7 (26.9%) p=0.009
Stage II 1 (11.1%) 7 (77.8%) 1 (11.1%)
Stage III 0 (0%) 2 (28.6%) 5 (71.4%)
Stage IV 1 (100%) 0 (0%) 0 (0%)  
Abbreviations: SLC1A5: Solute Carrier Family 1 (Neutral Amino Acid Transporter) Member 5
Two tissue samples were missing for adenocarcinomas, resulting in 43 adenocarcinomas.
C)   Glutaminase GLS2 protein expression in EGFR wildtype versus EGFR mutated 
non-small cell lung cancer
 EGFR wildtype EGFR mutated p-value
GLS2 protein
<5% 51 (78.5%) 2 (40%) 0.025
5-20% 7 (10.8%) 0 (0%)
>20% 7 (10.8%) 3 (60%)  
Abbreviations: EGFR: epidermal growth factor receptor; GLS2: glutaminase 2
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as observed by a trend towards higher SLC1A5 mRNA expression (p=0.08; Figure 4E) and 
a significantly higher GLS mRNA expression (p=0.019; Figure 4F).
 TP53 mutation status correlated significantly with higher GLUT1 expression (p=0.009). 
Median GLUT1 expression was 0.3% (range 0-43.8%) for TP53 wildtype tumors versus 
13.3% (range 0-62%) for TP53 mutated tumors. Frequencies of other mutations were too 
low for correlation analysis with metabolism-related markers.
Figure 3   GLUT1 expression within NSCLC histological subtypes classified according  
to the WHO 2015 subclassification
Within adenocarcinomas, GLUT1 expression is highest in solid adenocarcinomas. Squamous cell 
carcinomas demonstrate an even higher expression of GLUT1 relative to solid adenocarcinomas.
GLUT1 fractions are based on immunofluorescent stainings and are defined as the tumor area 
positive for the marker, divided by the total tumor area.
Abbreviation: AC: adenocarcinoma; GLUT1: glucose transporter 1; SCC: squamous cell carcinoma
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Table 2  Mutation analysis in adeno- versus squamous cell non-small cell lung cancer
Mutation Adenocarcinomas (n=59)
All
(n=59)
Lepidic
(n=8)
Acinar
(n=26)
Papillary
(n=6)
Solid
(n=19)
AKT1 0 0 0 0 0
BRAF 1 (1.7%) 0 0 0 1 (5.3%)
EGFR 6 (10.2%) 2 (25%) 4 (15.4%) 0 0
ERBB2 0 0 0 0 0
IDH1 0 0 0 0 0
IDH2 1 (1.7%) 0 0 0 1 (5.3%)
JAK2 0 (0%) 0 0 0 0
KIT 2 (4.3%) 0 2 (7.7%) 0 0
KRAS 21 (35.6%) 4 (50%) 10 (38.5%) 1 (17%) 6 (31.6%)
PDGFRA 1 (1.7%) 0 0 0 1 (5.3%)
PIK3CA 0 0 0 0 0
TP53 42 (71.2%) 5 (62.5%) 19 (73.1%) 3 (50%) 15 (78.9%)
Mutation Squamous cell 
carcinoma (n=38)
p-value 
AC versus SCC
AKT1 1 (2.6%)
BRAF 0
EGFR 0 p = 0.042
ERBB2 0
IDH1 1 (2.6%)
IDH2 1 (2.6%)
JAK2 0
KIT 1 (2.6%)
KRAS 2 (5.3%) p = 0.001
PDGFRA 0
PIK3CA 4 (10.5%) p = 0.011
TP53 37 (97.4%) p = 0.001
Abbreviations: AKT: protein kinase B; BRAF: v-raf murine sarcoma viral oncogene homolog B; EGFR: epidermal 
growth factor receptor; IDH: isocitrate dehydrogenase; KIT: KIT proto-oncogene receptor tyrosine kinase; KRAS: 
Kirsten rat sarcoma viral oncogene; PDGFRA: platelet-derived growth factor receptor A; PIK3CA: gene encoding 
for the phosphatidylinositol 3-kinase (PI3K) catalytic subunit; TP53: transformation-related protein 53.
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Figure 4   Association of metabolism-related marker expression with mutation status  
in NSCLC
A) GLUT1 protein expression is higher in EGFR wildtype than EGFR mutated NSCLCs.
B) GLS2 mRNA expression is higher in EGFR mutated versus EGFR wildtype NSCLCs.
C) GLUT1 protein expression in KRAS wildtype versus KRAS mutated NSCLCs.
D) CAIX protein expression is higher in KRAS wildtype versus KRAS mutated NSCLCs.
E) SLC1A5 mRNA expression in KRAS wildtype versus KRAS mutated NSCLCs.
F) GLS mRNA expression is higher in KRAS mutated versus KRAS wildtype NSCLCs.
Abbreviations: CAIX: carbonic anhydrase IX; EGFR: epidermal growth factor receptor; GLUT1: glucose 
transporter 1; GLS: glutaminase; KRAS: Kirsten rat sarcoma viral oncogene; SLC1A5: solute-linked 
carrier family A1 member 5.
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Discussion
NSCLC tumor cell metabolism in relation to histological subtype and 
aggressive tumor behavior
Earlier we described the correlation between high GLUT1 expression with poor differentiation 
grade and lymph node metastasis at diagnosis in adenocarcinomas in this same cohort of 
NSCLC patients [17]. Also, we found a worse disease-free survival in adenocarcinomas with 
high GLUT1 expression or high total lesion glycolysis (TLG) on 18F-FDG PET/CT [17,18]. 
In this study, we further explored glucose metabolism-related markers in adenocarcinoma 
subtypes. We showed that the adenocarcinoma subtype with the most aggressive tumor 
behavior, i.e. predominantly solid adenocarcinoma, has the highest GLUT1 expression. 
This is in agreement with the fact that adenocarcinomas with a predominantly micro-
papillary or solid growth pattern exhibit higher maximum standardized uptake value 
(SUVmax) on 18F-FDG PET than predominantly acinar or papillary tumors. Predominantly 
lepidic adenocarcinomas demonstrate the lowest 18F-FDG uptake [23,24]. 
 In our study, several markers related to glutamine transport and metabolism, on both 
protein and mRNA level, were significantly higher in adeno- than squamous cell NSCLCs. 
This is in contrast to the findings of others, who demonstrated that SLC1A5 expression is 
associated with squamous cell histology [10,25,26]. However, we also examined GLS2 
protein expression and mRNA expression of SLC1A5, GLS and GLS2. All our findings 
indicate a higher glutamine consumption and metabolism in adenocarcinomas relative to 
squamous cell carcinomas. We showed that SLC1A5 protein expression was significantly 
higher in adenocarcinomas with lymph node metastases at diagnosis compared to node 
negative tumors, indicating more aggressive tumor behavior upon higher SLC1A5 
expression. In another study of adenocarcinomas, SLC1A5 expression also correlated with 
advanced tumor stage and lymph node metastasis [27]. Furthermore, a multivariate 
analysis demonstrated that SLC1A5 expression was an independent marker of poor overall 
survival for adenocarcinoma patients, while this was not observed for squamous cell 
NSCLCs [27]. Other studies showed that SLC1A5 overexpression in the primary tumor or 
lymph node metastasis was found to be an independent prognostic factor for overall 
survival for NSCLC [25,26]. However, these studies did not distinguish adeno- versus 
squamous cell NSCLC.
 High expression of LAT1 (L amino acid transporter) or SLC1A5, but especially coexpression 
of these transporters, correlated with worse overall survival in lung adenocarcinomas [28]. 
So, besides a higher glycolytic rate, also a higher rate of glutamine metabolism correlates 
with biologically aggressive tumor behavior and worse survival in lung adenocarcinomas. 
Oncogenic mutations that drive tumor metabolism in NSCLC
Wild-type p53 inhibits glycolysis by repressing glucose transporters and by upregulating 
expression of TP53-induced glycolysis and apoptosis regulator (TIGAR). Wild-type p53 also 
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supports expression of the tumor suppressor phosphatase and tensin homolog (PTEN), 
which inhibits AKT activity [7,9,29]. Thus, glycolysis can be promoted by loss of p53 
function. However, the stimulating effect on glycolysis varies among H1299 NSCLC cells 
with different mutational p53 proteins. In 2 of 9 p53 mutants, no increase in glycolysis was 
observed. So, mutant p53 proteins can have differential phenotypic impact on metabolic 
pathways [30]. Overall, the link between TP53 mutation and glycolysis is in agreement with 
our result showing higher GLUT1 expression in TP53 mutated tumors.
 Frequency of two other mutations rewiring tumor metabolism, i.e. EGFR and KRAS 
mutations, are much higher in adeno- than squamous cell carcinomas. In non-Asian 
cohorts, EGFR mutation frequencies of 10-30% are described in lung adenocarcinomas. 
KRAS mutations are found in 22-34% of adenocarcinomas, consistent with our observations 
[31]. The oncogene KRAS activates the RAF/MEK/ERK pathway, leading to upregulation of 
MYC transcription factor [32]. RAS promotes glucose uptake, glycolytic flux and channeling 
of intermediates into the pentose phosphate pathway through upregulation of GLUT1 
and hexokinase amongst others [9,33,34]. Furthermore, glutamine is the major carbon 
source for the tricarboxylic acid cycle when RAS is activated [34]. SLC1A5 is upregulated 
through KRAS signaling in colorectal cancer [35], and the conversion of glutamine to 
glutamate by GLS is modulated by RAS [34]. This is in agreement with our findings that 
KRAS mutated tumors show a trend towards a higher SLC1A5 mRNA expression and a 
significantly higher GLS mRNA expression. EGFR affects tumor metabolism through 
activation of the PI3K/AKT/mTOR signaling pathway [36]. In our study, EGFR mutated 
tumors had a higher expression of GLS2 protein and GLS2 mRNA compared to EGFR 
wildtype tumors. The EGFR tyrosine kinase inhibitor (EGFR-TKI) erlotinib reduces expression 
of glutamine transporters (SLC1A5 and SLC38A1) and GLS, and declines glutamine uptake 
[37]. 
 These results support the linkage between oncogenic mutated KRAS and EGFR 
signaling and aerobic glycolysis and glutamine metabolism in adenocarcinomas [34,36,38], 
and are in agreement with tumor microenvironmental characteristics: adenocarcinomas 
show better vascularization relative to squamous cell carcinomas, GLUT1 and MCT4 
expression in a non-hypoxia-related pattern, and a lower rate constant of cytoplasmic 
phosphorylation of 18F-FDG and higher blood volume fraction on dynamic 18F-FDG PET 
[17-19]. However, a limitation is the descriptive character of this study. These associations 
between mutations and expression of metabolism-related markers do not necessarily 
imply that these mutations regulate metabolism of lung adenocarcinoma.
 Squamous cell carcinomas are phenotypically characterized by a hypoxic tumor 
micro environment [17-19], a microenvironmental characteristic associated with radio-
resistance [39]. Squamous cell NSCLCs have a poor vascularization, show more often 
necrosis, demonstrate GLUT1 and MCT4 expression in a hypoxia-related pattern, and 
show a higher rate constant of cytoplasmic phosphorylation of 18F-FDG and lower blood 
volume fraction on dynamic 18F-FDG PET [17-19]. This hypoxic tumor microenvironment 
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activates the hypoxia-inducible factor 1 (HIF-1) pathway. HIF-1 initiates transcription of 
genes hat encode transporters and enzymes regulating glycolysis and the pentose 
phosphate pathway [6]. However, besides hypoxia, squamous cell carcinomas exhibit low 
frequencies of PIK3CA, AKT1 and PTEN mutations. In our study population, AKT1 and PIK3CA 
mutations were only found in squamous cell carcinomas, with frequencies of 2.6% and 
10.5% respectively. This is in agreement with literature, describing a higher frequency of 
PIK3CA mutations in squamous cell carcinomas (7.1-8.9%) than adenocarcinomas (0.9-2.9%) 
[40,41]. Also, PTEN mutations are more frequently observed in squamous cell carcinomas 
(10.7%) than adenocarcinomas (1.7%) [41]. The prevalence of AKT1 mutation is low, but 
related to squamous cell histology [42]. These mutations could regulate metabolism 
through PI3K/AKT signaling in a few squamous cell NSCLC. However, frequencies were too 
low to perform correlation analysis with metabolism-related markers. In our study, only 
gain- and loss-of-function mutations were assessed, but other genetic alterations, like 
amplifications, were not tested. PIK3CA gene amplification is found in 46% of squamous 
cell carcinomas, with a correlation between PIK3CA genomic copy number and PIK3CA 
and GLUT1 mRNA expression [43]. Squamous cell carcinomas exhibit increased AKT 
signalling activities compared to adenocarcinomas in terms of higher expression of p-AKT, 
and the downstream targets p-4EBP1 and p-S6, which promote HIF-1α mRNA translation 
[43,44]. AKT is activated by hypoxia, and this pathway is relevant for cell’s survival of 
hypoxia. So, besides the HIF-1 pathway, PI3K/AKT signaling induced by hypoxia seems to 
be important for hypoxic cell survival and regulation of metabolism in squamous cell 
carcinomas [44].
 The inverse relation between KRAS and EGFR mutation with GLUT1 expression seems 
to contradict the regulatory effect of these mutations on glycolysis. However, this finding 
might be biased by the fact that hypoxia is likely to be a very strong regulator of glycolysis 
in squamous cell carcinomas, in which KRAS and EGFR mutations are not (often) found. 
This inverse relationship is in agreement with the finding that SUVmax on 18F-FDG PET is 
significantly lower in KRAS or EGFR mutated NSCLCs [45]. 
Conclusion
NSCLC is a heterogeneous disease, with differences in mutational status and expression of 
metabolism-related markers between adeno- and squamous cell NSCLCs, but also within 
adenocarcinoma subtypes. GLUT1 and SLC1A5 expression correlate with aggressive tumor 
behavior in adenocarcinomas but not in squamous cell NSCLCs. This indicates that these 
markers could select a group of adenocarcinoma patients requiring intensification of 
treatment. 
 Regulation of tumor metabolism is complex. Associations found in this study suggest 
that EGFR, KRAS and TP53 mutations might drive tumor metabolism in adenocarcinomas. 
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In squamous cell carcinomas, TP53 mutations and hypoxia activating the HIF-1 pathway 
and PI3K/AKT signaling are associated with glucose metabolism-related markers and 
could be the main drivers of metabolism in this histological subtype.
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Abstract 
 
Purpose To assess whether dynamic 18F-FDG PET has added value over static 18F-FDG PET 
for tumor delineation in non-small cell lung cancer (NSCLC) radiotherapy planning using 
pathology volumes as Reference Standard, and to compare pharmacokinetic rate 
constants of 18F-FDG metabolism, including their regional variation, between NSCLC 
histological subtypes.
Materials and methods In this prospective observational study, one-hour dynamic 
18F-FDG PET/CTs were acquired in 35 patients (36 resectable NSCLCs) between 2009-2014. 
Static and parametric images of glucose metabolic rate (MRglc) were obtained to 
determine lesion volumes using three delineation strategies. Pathology volume was 
calculated from three orthogonal dimensions (n=32). Whole tumor and regional rate 
constants (K1-k3) and fractional blood volume (VB) were computed using compartment 
modeling.
Results Pathology volumes were larger than PET volumes (median difference 8.7-25.2 
cm3, Wilcoxon-signed-rank-test, p<0.001). Static FLAB volumes corresponded best with 
pathology volume (ICC=0.72, p<0.001). Bland-Altman analyses showed highest precision 
and accuracy for static FLAB volumes. MRglc and 18F-FDG phosphorylation rate (k3) were 
higher in squamous cell carcinomas than adenocarcinomas, whereas VB was lower (Mann-
Whitney-U-test or t-test, p=0.003, p=0.036, p=0.019). MRglc, k3 and VB were less 
heterogeneous in adenocarcinomas than squamous cell carcinomas (Friedman’s ANOVA).
Conclusion Parametric images are not superior to static images for NSCLC delineation. 
FLAB-based segmentation on static 18F-FDG PET is in best agreement with pathology 
volume and could be useful for NSCLC auto-contouring. Differences in glycolytic rate and 
VB between squamous cell carcinomas and adenocarcinomas are relevant for research in 
targeting tumor glucose metabolism.
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Introduction
Combined radiochemotherapy is standard treatment for irresectable stage III non-small 
cell lung cancer (NSCLC). Concurrent chemoradiation decreases locoregional progression 
rate from 34% to 28% at 3 years and improves overall survival, compared to sequential 
chemoradiation. This reflects the importance of optimizing locoregional therapy [1,2].
 Tumor delineation for radiotherapy planning using 18F-fluorodeoxyglucose positron 
emission tomography (18F-FDG PET) is classically based on static images. Using dynamic 
18F-FDG PET, distinction can be made between unmetabolized 18F-FDG and bound 
18F-FDG-6-phosphate [3,4]. Dynamic PET allows calculation of glucose metabolic rate 
(MRglc; nanomol.mL-1.min-1). MRglc images give an increased signal to background ratio 
relative to static images due to absence of unmetabolized 18F-FDG in the background [5]. 
Therefore, we hypothesized that tumor delineation using dynamic 18F-FDG PET is more 
accurate than static 18F-FDG PET, which might translate into improved locoregional 
treatment.
 Additionally, biological factors like reprogrammed tumor energy metabolism influence 
response to radiotherapy and might be a target to improve locoregional treatment [6]. 
Several metabolites, such as glucose, lactate and glutathione, differ between NSCLC and 
normal lung tissue [7-9]. Emerging evidence supports differences in glucose metabolism 
between adeno- and squamous cell carcinomas, based on the expression of metabolic 
transporters and enzymes, static 18F-FDG PET and level of several metabolites [10-12]. 
Compared to adenocarcinomas, squamous cell carcinomas show higher glucose 
transporter 1 (GLUT1) expression and standardized uptake values (SUV) on 18F-FDG PET 
[12,13]. Also, adenocarcinomas might be better vascularized/perfused than squamous cell 
carcinomas (higher vascular density on immunohistochemistry and higher Ktrans on 
dynamic contrast-enhanced computed tomography (CT) and magnetic resonance 
imaging (MRI)) [12-15]. However, blood flow and volume do not differ on these imaging 
modalities [14-16]. Insight into the metabolic rate of glucose metabolism and metabol-
ic-vascular heterogeneity is required to further phenotype NSCLC. This biological 
information is likely to be relevant for research in targeting agents and radiotherapy dose 
escalation. Using dynamic 18F-FDG PET, rate constants of 18F-FDG metabolism and blood 
volume can be calculated (Figure 1) [4]. 
 The aim of this prospective cohort study was dual: to assess whether dynamic 
18F-FDG PET has added value over static 18F-FDG PET for tumor delineation in NSCLC 
radiotherapy planning using pathology volumes as Reference Standard, and to compare 
pharmacokinetic rate constants of 18F-FDG metabolism, including their regional variation, 
between NSCLC histological subtypes. 
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Materials and methods
Study was approved by the Commission Medical Research Involving Human Subjects 
Region Arnhem–Nijmegen, the Netherlands. All patients gave written informed consent.
Patients
Therapy-naïve, non-diabetic patients with newly diagnosed or suspected NSCLC, stage 
IB-limited stage IIIA (TNM 7th edition), who underwent a primary resection were 
consecutively included in this prospective observational cross-sectional study between 
2009-2014. All subjects were routinely staged using contrast-enhanced CT of chest/upper 
abdomen and 18F-FDG PET/CT with additional histological staging of the mediastinum or 
other suspicious sites when necessary. Patients with histology proven non-NSCLC or high 
suspicion for metastasis were ineligible. Tumors had to be at least 30 mm to minimize 
partial volume effect [17]. Dynamic 18F-FDG PET was performed within 7 days of surgery. 
A total of 38 patients were included. Three patients were excluded because of no 
malignancy after lobectomy (infarction with inflammation), absence of 18F-FDG uptake on 
dynamic PET or severe mismatch between dynamic PET and CT which could not be 
correctly realigned before reconstruction. Thirty-six lesions in 35 patients remained (mean 
age of males 66 years (range 45-82); mean age of females 64 years (range 48-77); age not 
Figure 1  The irreversible, two-tissue compartment model for 18F-FDG metabolism 
The measured PET signal (thin dashed line) is a combination of the intracellular activity concentration 
of free 18F-FDG (18F-FDG in tissue), the intracellular activity concentration of 18F-FDG-6-phosphate 
(18F-FDG-6-PO4 in tissue) and a fraction of the activity concentration of 18F-FDG in blood plasma 
(VB).
In dynamic PET, pharmacokinetic rate constants K1 (rate constant of transport of 18F-FDG into tumor 
cells; mL.g-1.min-1), k2 (rate constant of export of 18F-FDG out of tumor cells; min-1) and k3 (rate 
constant of cytoplasmic phosphorylation of 18F-FDG; min-1), and VB (blood volume fraction; mL.mL-1) 
can be calculated using non-linear least squares regression.
Abbreviations: 18F-FDG: 18F-fluorodeoxyglucose; 18F-FDG-6-PO4: 18F-fluorodeoxyglucose-6-phosphate. 
The vertical dashed line represents the cell membrane.
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significantly different between males and females (Independent-Samples t test); one 
patient had two synchronous primary NSCLCs (an adenocarcinoma and a squamous cell 
carcinoma). Measurement of all pathology dimensions was not available in 3 cases and no 
resection took place in one patient due to detection of stage IV peroperatively (Figure 2). 
Clinicopathological characteristics, shown in Table 1, were similar for adenocarcinomas 
and squamous cell carcinomas (Table 2).
Dynamic PET acquisition and reconstruction
Patients fasted for at least 6 hours before imaging and were orally hydrated with 500 mL 
of water. One venous blood sample was drawn to measure blood glucose level. The first 
21 patients were scanned in a Biograph Duo PET/CT scanner (Siemens Medical Solutions 
USA, Inc., Knoxville, TN, USA). The last 17 patients were scanned in a Biograph 40 mCT 
(Siemens Medical Solutions USA, Inc., Knoxville, TN, USA).  The field of view (FOV) of the 
Biograph Duo PET/CT scanner was 162 mm and of the Biograph 40 mCT 216 mm. Patients 
were positioned such that the tumor was centrally located in the FOV. Prior to the PET 
scan, a low dose breath-hold CT was acquired for PET attenuation correction and 
anatomical matching. Free breathing images were acquired in 3D mode for a total duration 
of 60 minutes at a single bed position, starting directly before 18F-FDG infusion. 
Figure 2   Flowchart of available patients for PET analysis and measurement of pathology 
volumes
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Table 1  Clinicopathological characteristics of all NSCLCs
Characteristics All
carcinomas
n=36
Age (years)
Mean (range) 65 (45-82)
Sex
Male
Female
25 (69%)
11 (31%)
Smoking status 
Current smoker
Former smoker (>1 year)
Never
Unknown
15 (41%)
19 (53%)
1 (3%)
1 (3%)
Surgery
Lobectomy
Bilobectomy
Pneumectomy
No surgery because of stage IV peroperatively
25 (69%)
1 (3%)
9 (25%)
1 (3%)
Location
Upper lobe
Lower lobe
Middle lobe
Hilum
23 (64%)
10 (28%)
1 (3%)
2 (6%)
Maximum pathology tumor dimension (cm) *
Median (range) 5.2 (2.2-13.5)
Histology
Squamous cell carcinoma
Adenocarcinoma
   Solid acinar
   Micropapillary lepidic
   Acinar lepidic
   Acinar
   Solid
Large cell neuroendocrine 
   carcinoma
Neuroendocrine carcinoma
   and solid adenocarcinoma (mixed type)
Sarcomatoid pleiomorf
20 (56%)
12 (33%)
5
1
1
3
2
2 (6%)
1 (3%)
1 (3%)
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Table 1  Continued
Characteristics All
carcinomas
n=36
Differentiation 
Well
Moderate
Poor
1 (3%)
13 (36%)
22 (61%)
pT 
T1
T2
T3
T4
1 (3%)
23 (64%)
11 (31%)
1 (3%)
pN 
N0
N1
N2 unexpected
Unknown due to stage IV peroperatively
19 (53%)
12 (33%)
4 (11%)
1 (3%)
pTNM 7th edition 
Stage I
Stage II
Stage IIIA
Stage IV
8 (22%)
20 (56%)
7 (19%)
1 (3%)
Surgical margins 
Free
Not free
Rx #
32 (89%)
3 (8%)
1 (32.8%)
Invasion pleura
Pl0
Pl1
Pl2
Pl3
21 (58%)
9 (25%)
4 (11%)
2 (6%)
Adjuvant chemotherapy
Yes
No
Unknown
Stage IV peroperatively
17 (47%)
17 (47%)
1 (3%)
1 (3%)
Adjuvant radiotherapy
Yes
No
4 (11%)
32 (89%)
Days between dynamic PET and surgery
Median (range) 2 (0-7)
# Pathological margins were inconclusive. This patient did not receive postoperative radiotherapy
* Unknown for one patient, because stage IV was diagnosed during surgery
N/A Not applicable
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Table 2   Clinicopathological characteristics of squamous cell and adenocarcinomas 
separately
Characteristics Squamous cell 
carcinomas
 (n (%))
n=20
Adeno- 
carcinomas
(n (%))
n=12
p-value squamous 
cell versus 
adenocarcinomas
Age (years)
Mean (range) 67 (45-77) 65 (46-82) NS
Sex
Male
Female
14 (70%)
6 (30%)
8 (67%)
4 (33%)
NS
Smoking status 
Current smoker
Former smoker (>1 year)
Never
Unknown
8 (40%)
10 (50%)
1 (5%)
1 (5%)
5 (42%)
7 (58%)
0 (0%)
0 (0%)
NS
Surgery
Lobectomy
Bilobectomy
Pneumectomy
No surgery because of stage IV 
peroperatively
13 (65%)
0 (0%)
7 (35%)
0 (0%)
9 (75%)
1 (8%)
1 (8%)
1 (8%)
NS
Location
Upper lobe
Lower lobe
Middle lobe
Hilum
12 (60%)
6 (30%)
1 (5%)
1 (5%)
9 (75%)
3 (25%)
0 (0%)
0 (0%)
NS
Maximum pathology tumor 
dimension (cm) *
Median (range) 4.9 (3.2-11.0) 4.5 (2.2-13.5) NS
Differentiation 
Well
Moderate
Poor
1 (5%)
7 (35%)
12 (60%)
0 (0%)
6 (50%)
6 (50%)
NS
pT 
T1
T2
T3
T4
0 (0%)
14 (70%)
5 (25%)
1 (5%)
1 (8%)
6 (50%)
5 (42%)
0 (0%)
NS
pN 
N0
N1
N2 unexpected
Unknown due to stage IV peroperatively
11 (55%)
8 (40%)
1 (5%)
0 (0%)
5 (42%)
3 (25%)
3 (25%)
1 (8%)
NS
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Approximately 3.45 MBq.kg-1 of 18F-FDG was administered intravenously in an intracubital 
vein contralateral to the tumor, using a standardized injection protocol (8.0 mL, 0.2 mL.s-1) 
by a remote-controlled pump, followed by a saline flush (40 mL, 8.0 mL.s-1). A venous 
blood sample was drawn from the contralateral intracubital vein at 62-75 minutes (exact 
time point was registered), centrifuged and its activity concentration was determined in a 
well-type γ-counter (Wallac 1480 Wizard, Perkin Elmer Lifescience, Zaventem, Belgium), 
for quality assurance. 
Table 2   Continued
Characteristics Squamous cell 
carcinomas
 (n (%))
n=20
Adeno- 
carcinomas
(n (%))
n=12
p-value squamous 
cell versus 
adenocarcinomas
pTNM 7th edition 
Stage I
Stage II
Stage IIIA
Stage IV
4 (20%)
13 (65%)
3 (15%)
0 (0%)
3 (25%)
4 (33%)
4 (33%)
1 (8%)
NS
Surgical margins 
Free
Not free
Rx #
18 (90%)
1 (5%)
1 (5%)
10 (83%)
2 (17%)
0 (0%)
NS
Invasion pleura
Pl0
Pl1
Pl2
Pl3
13 (65%)
6 (30%)
0 (0%)
1 (5%)
5 (42%)
3 (25%)
3 (25%)
1 (8%)
NS
Adjuvant chemotherapy
Yes
No
Unknown
Stage IV peroperatively
8 (40%)
11 (55%)
1 (5%)
0 (0%)
7 (58%)
4 (33%)
0 (0%)
1 (8%)
NS
Adjuvant radiotherapy
Yes
No
1 (5%)
19 (95%)
3 (25%)
9 (75%)
NS
Days between dynamic PET and 
surgery
Median (range) 2 (0-7) 2 (0-5) NS
# Pathological margins were inconclusive. This patient did not receive postoperative radiotherapy
* Unknown for one patient with an adenocarcinoma, because stage IV was diagnosed during surgery
N/A Not applicable
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Data were acquired in list-mode, enabling retrospective time framing and image 
reconstruction. PET data from both scanners were reconstructed into 70 time frames: 20x 
5 s, 5x 10 s, 10x 15 s, 10x 30 s, 16x 75 s, 8x 150 s, 1x 600 s.
 Images acquired by the Biograph Duo PET/CT scanner were iteratively reconstructed in 
256x256 matrices by ordered subsets expectation maximization (OSEM) using 4 iterations / 
16 subsets (4i/16s) with a 5 mm Gaussian filter. The transaxial pixel size is 2.5x2.5 mm2, 
which is half the spatial resolution of the camera (5 mm FWHM). Therefore, the Nyquist 
criterion was met. 
 Reconstruction parameters for the Biograph mCT scans were: 3 iterations / 21 subsets 
(3i/21s), matrices 512x512 (pixel size is 1.5x1.5 mm2), 3 mm Gaussian filter, time of flight with 
point spread function (PSF)-based reconstruction. 
 Correction for photon attenuation (by using the LDCT), scatter, dead time and decay 
correction was performed for images obtained by both scanners. 
Creation of MRglc parametric maps
All following image analyses were done by TM (resident Radiation Oncology; 5 years 
experience) under supervision of DV (Nuclear Medicine Physician; 8.5 years experience) 
and LFdGO (Nuclear Medicine Physician; 18 years experience) and were performed using 
Inveon Research Workplace software (IRW 4.2, Siemens Healthcare).
 MRglc images were calculated based on tissue and blood time-activity concentration 
curves by the Patlak linearization approach, using data acquired between 15-60 minutes 
post-injection as described earlier [4]. A 10 mL volume of interest (VOI) of the descending 
aorta, drawn on the first 60 sec of the data, excluding endothelial wall and calcification to 
concern only blood, served as image-derived input function (IDIF). Correction for time-dif-
ference between arrival of the 18F-FDG bolus in the descending aorta and tumor was 
applied. A lumped constant (LC) of 1 was assumed [3,5]. In short: MRglc=Ki*(Cp,glu/LCFDG), 
where Ki is the 18F-FDG influx constant (slope of the Patlak-plot) and Cp,glu is plasma 
glucose concentration [4,5].
Image analysis of dynamic (MRglc) PET
Oversized container-VOIs for tumors surrounded by normal tissue were drawn on MRglc 
parametric maps, excluding any 18F-FDG avid non-tumor tissue (myocardium). Within this 
container-VOI, tumor was segmented using (i) threshold of 50% of maximum MRglc 
(MRglc;max) [18,19], (ii) threshold of 40% of MRglc;max adapted for background (threshold= 
MRglc;mean background+0.4*(MRglc;max tumor–MRglc;mean background)) [18,19], and (iii) 
fuzzy locally adapted Bayesian (FLAB) algorithm (Custom in-house developed software; 
ImageD, LaTim INSERM Laboratory, Brest, France; contours imported into IRW) [20]. 
A spherical 25 mL background-VOI was drawn at the same level as the location of 
the tumor in contralateral healthy lung tissue. Theoretically, adaptive 40% threshold is 
in best correlation with the true volume for larger tumors (diameter 15-50 mm) [21]. 
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The FLAB-approach is based on the probability for each voxel to belong to tumor tissue 
or background, by taking into account the intensity of the voxels in various regions of 
the image as well as the spatial correlation with neighboring voxels.
 MRglc;max and MRglc;mean, and volumes of the segmentation methods were recorded.
Static PET analysis
The last time frame (50-60 minutes post-injection) was extracted from the dynamic series 
and was used as static 18F-FDG PET, being equivalent to classic 18F-FDG PET starting 50 
minutes post-injection with 10 minutes acquisition time. The same tumor VOI-definitions 
were applied on static PET images. Resulting volumes were recorded.
Pharmacokinetic rate constants and blood volume analysis
Within the segmentation volume best corresponding to pathology volume (see below), 
pharmacokinetic rate constants (K1, k2, k3) and blood volume fraction (VB) were computed 
for the whole tumor based on tissue and blood time-activity concentration curves using 
unweighted (no Poisson weighting) nonlinear least squares (NLLS) regression analysis 
assuming a two-tissue, irreversible compartment model. The same IDIF was used. 
NLLS-optimization consisted of 99 random starting points with reproducible results and 
intervals for acceptable parameter values were set (0.0-2.0 for rate constants, 0.0-1.0 for VB). 
For the two patients that moved markedly halfway the acquisition, pharmacokinetic 
analysis was performed up to the time of movement, i.e. the first 32.5 and 22.5 minutes 
of data.
 For heterogeneity analysis, tumor volumes were segmented in 3 subregions of equal 
volume using descending MRglc-thresholds (VOIhigh, VOImedium, VOIlow). Within these 
subvolumes, K1-k3 and VB were determined using the above mentioned NLLS method.
Pathology
After surgery, the involved lung lobe was fixed in formaldehyde by inflating formaldehyde 
into the lobar/main bronchus and lobar/main artery. Macroscopic maximal orthogonal 
tumor dimensions (mm) in transversal (dx, dy) and craniocaudal direction (dz) were 
measured once 22 hours after fixation (n=25) by MLS (pathologist for 25 years, specialization 
thoracic pathology). Fixated tumors were cut into transversal slices. Here, maximum dx 
and dy were measured. Dz was calculated by: (craniocaudal length/number of slic-
es)*(number of slices minus 1). By subtracting 1, we took into account that the flanking 
slices mostly did not show full thickness tumor infiltration. Dimensions of seven tumors 
were measured on photographs of formaldehyde-fixed tissue (n=5) or by means of 
archived formaldehyde-fixed macroscopic tissue (n=2). The pathologist was blinded for 
the 18F-FDG PET results. Tumor volumes were estimated by an ellipsoid volume: 
V=(1/6)*π*dx*dy*dz.
 For WHO 2015 classification, all slides were revised by MLS.
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Statistics
Statistics were performed using SPSS 22.0 statistical software (SPSS Inc., Chicago, IL). 
The Pearson Chi-Square test and Spearman correlation were used to determine associations 
between histology and clinicopathological parameters. Pathology and PET volumes were 
compared using 2-related samples Wilcoxon signed-rank test. To quantify the agreement 
between pathology and PET volumes, the intraclass correlation coefficient (ICC) was used 
(two-way random, absolute agreement). Differences between pathology and PET volumes 
were quantified using Bland-Altman analysis, reporting the mean difference (accuracy) 
and the upper and lower limits defined as mean +/- 1.96*standard deviation (precision). 
Differences in continuous variables between histological subtypes were interpreted using 
the Mann-Whitney U test or the Independent-Samples t test. As the level of K1-k3 and VB 
in different regions within a tumor are highly related, they are considered as dependent. 
Therefore, comparison of multiple groups for heterogeneity analysis was performed by 
Friedman’s ANOVA, followed by Dunn’s post-hoc analysis, which is a Bonferroni multiplicity- 
adjustment of p-values. A p<0.05 was considered statistically significant.
Results
Correlation of pathology and PET volumes
Pathology and PET volumes are described in Table 3 for all tumors (n=32) and for 
carcinomas with (n=9) and without (n=23) macroscopic necrosis separately. Volume 
differences between pathology and PET are shown in Table 4. Pathology volumes were 
significantly larger compared to PET volumes, except for FLAB volumes in carcinomas 
without macroscopic necrosis (see Table 4 for statistics). Static PET volumes were 
significantly larger than MRglc-based volumes (p<0.001). Uptake-based, relative threshold 
volumes were smaller than FLAB volumes (p<0.001).
 Delineation using FLAB on static PET resulted in the smallest median difference with 
pathology volume (Table 4) and highest ICC (Table 5). Uptake-based, relative threshold 
methods were especially hampered by necrotic tumors (poor ICC), which was not the 
case for FLAB (Table 5). Bland-Altman analyses show highest precision and accuracy 
for static FLAB volumes (Figure 3). This is the case for carcinomas with and without 
macroscopic necrosis, but most markedly for carcinomas with macroscopic necrosis. 
(Figure 3-4).
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Glucose metabolism and heterogeneity within NSCLC histological subtypes
Pharmacokinetic analysis was performed using FLAB volumes. MRglc;mean and k3 were 
significantly higher in squamous cell carcinomas, whereas VB was significantly higher in 
adenocarcinomas (p=0.003, p=0.036 and p=0.019 respectively) (Figure 5A, 5C-D). K1 
(Figure 5B) and k2 did not differ between these histological subtypes.
Regional variation of K1-k3 and VB in adeno- versus squamous cell NSCLC is demonstrated 
in Figure 6. Adenocarcinomas were less heterogeneous than squamous cell carcinomas 
in terms of MRglc;mean, k3 and VB as is shown by the lower Friedman statistics in adeno-
carcinomas (Figure 6A, 6C-D). K3 and VB did not differ between VOIhigh-VOImedium and 
VOImedium-VOIlow in adenocarcinomas. In squamous cell NSCLC, VB significantly increased 
from VOImedium to VOIlow, while the opposite was found for k3 (Figure 6C-D) (adjusted 
p<0.05 for both). VB and k3 differed between VOIhigh and VOIlow in both squamous cell 
carcinomas and adenocarcinomas, with a higher significance level for squamous cell 
carcinomas (adjusted p<0.0001 versus p<0.01). No significant regional variation in K1 and 
k2 was observed, except a significant difference for K1 between VOIhigh-VOIlow (adjusted 
p<0.01 for both histological subtypes) (Figure 6B).
Table 3  Pathology and PET volumes
Volume parameter All
carcinomas
median (range) [cm3]
n=32
Carcinomas without 
macroscopic necrosis  
median (range) [cm3]
n=23
Carcinomas with 
macroscopic necrosis 
median (range) [cm3]
n=9
Pathology volume 37 (3.8 - 389) 26 (3.8 - 193) 86 (20 - 389)
50% static PET 17.3 (5.4 - 139) 13.1 (5.4 - 76) 21.6 (7.7 - 139)
A40% static PET 23.7 (7.5 - 166) 18.3 (7.5 - 97.5) 35.5 (11.6 - 166)
FLAB static PET 32.5 (8.2 - 182) 27.2 (8.2 - 155) 44.2 (16.1 - 182)
50% MRglc 14.1 (4.5 - 104) 12.1 (4.5 - 60) 16.8 (6.3 - 104)
A40% MRglc 22 (6.5 - 143) 17.2 (6.5 - 77.7) 32.3 (9.7 - 143)
FLAB MRglc 30 (8.3 - 174) 25.6 (8.3 - 107) 44.6 (14.3 - 174)
Abbreviations:
50% static PET: tumor delineation using a threshold of 50% of maximum activity concentration (Bq.cm3 -1) (static 
PET)
A40% static PET: tumor delineation using a threshold of 40% of maximum activity concentration (Bq.cm3 -1) 
adapted for background (static PET)
FLAB static PET: tumor delineation using the FLAB algorithm on static PET
50% MRglc: tumor delineation using a threshold of 50% of maximum metabolic rate of glucose (dynamic PET)
A40% MRglc: tumor delineation using a threshold of 40% of maximum metabolic rate of glucose adapted for 
background (dynamic PET)
FLAB MRglc: tumor delineation using the FLAB algorithm on parametric (MRglc) images obtained by dynamic PET
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Table 5  Correlation between pathology and PET volumes
PET parameter All
carcinomas
n=32
Carcinomas without 
macroscopic necrosis 
n=23
Carcinomas with  
macroscopic necrosis
n=9
50% static PET ICC=0.29, p=0.019 ICC=0.49, p=0.002 ICC=0.17, NS
A40% static PET ICC=0.45, p=0.001 ICC=0.60, p<0.001 ICC=0.33, p=0.096
FLAB static PET ICC=0.72, p<0.001 ICC=0.66, p<0.001 ICC=0.70, p=0.004
50% MRglc ICC=0.23, p=0.04 ICC=0.33, p=0.021 ICC=0.16, NS
A40% MRglc ICC=0.42, p=0.002 ICC=0.49, p=0.002 ICC=0.34, p=0.083
FLAB MRglc ICC=0.68, p<0.001 ICC=0.59, p=0.001 ICC=0.67, p=0.005
Abbreviations:
50% static PET: tumor delineation using a threshold of 50% of maximum activity concentration (Bq.cm3 -1) (static PET)
A40% static PET: tumor delineation using a threshold of 40% of maximum activity concentration (Bq.cm3 -1) 
adapted for background (static PET)
FLAB static PET: tumor delineation using the FLAB algorithm on static PET
50% MRglc: tumor delineation using a threshold of 50% of maximum metabolic rate of glucose (dynamic PET)
A40% MRglc: tumor delineation using a threshold of 40% of maximum metabolic rate of glucose adapted for 
background (dynamic PET)
FLAB MRglc: tumor delineation using the FLAB algorithm on parametric (MRglc) images obtained by dynamic PET
ICC: intraclass correlation coefficient
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Figure 3   Bland-Altman plots showing mean difference between pathology volume and 
PET volumes (accuracy) acquired by several segmentation methods on static 
(A-C) and dynamic PET (D-F) 
Mean, upper limit and lower limit (precision) are described for all carcinomas. Difference (cm3) is 
calculated pathology volume minus PET volume. Upper and lower limits are calculated by mean 
difference +/- 1.96 x standard deviation. Carcinomas with macroscopic necrosis are shown in blue 
and carcinomas without macroscopic necrosis in green.
Abbreviations:
50% static PET: tumor delineation using a threshold of 50% of maximum activity concentration 
(Bq.cm3 -1) (static PET)
A40% static PET: tumor delineation using a threshold of 40% of maximum activity concentration 
(Bq.cm3 -1) adapted for background (static PET)
FLAB static PET: tumor delineation using the FLAB algorithm on static PET
50% MRglc: tumor delineation using a threshold of 50% of maximum metabolic rate of glucose 
(dynamic PET)
A40% MRglc: tumor delineation using a threshold of 40% of maximum metabolic rate of glucose 
adapted for background (dynamic PET)
FLAB MRglc: tumor delineation using the FLAB algorithm on parametric (MRglc) images obtained 
by dynamic PET
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Figure 4   Mean difference (accuracy) between pathology volume and PET volumes 
for NSCLC without macroscopic necrosis (A) and NSCLC with macroscopic 
necrosis (B) separately
Difference (cm3) is calculated by pathology volume minus PET volume. Circles represent mean values and 
lines represent upper and lower limits (precision, as defined by mean +/- 1.96 x standard deviation).
Abbreviations:
50% static PET: tumor delineation using a threshold of 50% of maximum activity concentration 
(Bq.cm3 -1) (static PET)
A40% static PET: tumor delineation using a threshold of 40% of maximum activity concentration 
(Bq.cm3 -1) adapted for background (static PET)
FLAB static PET: tumor delineation using the FLAB algorithm on static PET
50% MRglc: tumor delineation using a threshold of 50% of maximum metabolic rate of glucose 
(dynamic PET)
A40% MRglc: tumor delineation using a threshold of 40% of maximum metabolic rate of glucose 
adapted for background (dynamic PET)
FLAB MRglc: tumor delineation using the FLAB algorithm on parametric (MRglc) images obtained by 
dynamic PET
A B
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Figure 5   Glucose metabolic rate constants and blood volume fraction in the major 
histological subtypes of NSCLC
(A) MRglc;mean  in adeno- versus squmaous cell carcinomas
(B) K1 in adeno- versus squmaous cell carcinomas
(C) k3 in adeno- versus squmaous cell carcinomas
(D) VB in adeno- versus squmaous cell carcinomas
Abbreviations:
K1: delivery of 18F-FDG into tumor cells (mL.g-1.min-1); k3: phosphorylation of 18F-FDG (min-1); 
MRglc;mean: mean metabolic rate of glucose (nmol.mL-1.min-1); NS: not significant; VB: blood volume 
fraction
The boxes represent lower quartile, median value and upper quartile, and whiskers represent minimum 
and maximum value.
A
C
B
D
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Figure 6   Heterogeneity of glucose metabolic rate constants and blood volume fraction 
in adeno- versus squamous cell carcinomas
(A) Heterogeneity of MRglc;mean  in adeno- versus squmaous cell carcinomas
(B) Heterogeneity of K1 in adeno- versus squmaous cell carcinomas
(C) Heterogeneity of k3 in adeno- versus squmaous cell carcinomas
(D) Heterogeneity of VB in adeno- versus squmaous cell carcinomas
Abbreviations:
AC: adenocarcinomas; K1: delivery of 18F-FDG into tumor cells (mL.g-1.min-1); k3: phosphorylation of 
18F-FDG (min-1); MRglc;mean: mean metabolic rate of glucose (nmol.mL-1.min-1); SCC: squamous cell 
carcinomas; NS: not significant; VOI: volume of interest; VB: blood volume fraction; *: p<0.05, **: 
p<0.01 (adjusted p-values calculated by Dunn’s (=Bonferroni) post-hoc test). The boxes represent 
lower quartile, median value and upper quartile, and whiskers represent minimum and maximum 
value.
A
C
B
D
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Discussion
Tumor volume delineation in NSCLC using 18F-FDG PET auto-contouring
Several studies with limited number of patients compared static 18F-FDG PET with NSCLC 
specimens. Different segmentation methods were in best agreement with pathology, for 
example source-to-background ratio [22] and 50% of maximum [23]. Cheebsumon et al. 
found several segmentation methods (50%, 41% adapted for background, and more) that 
measure maximum pathology diameter with moderate accuracy in 19 NSCLC [24]. Wanet 
et al. opt for gradient-based segmentation over uptake-based, relative thresholds [25].
 The question remains which autosegmentation to use in clinical practice. One of the 
problems to reach a final conclusion is that it is unclear whether pathology volume is a 
reliable representation of the true in vivo tumor volume, as lung and tumor tissue collapse 
after resection due to loss of negative intrathoracic pressure. We attempted to mimic the 
original pathology volumes by inflation and fixation of tissue with formaldehyde. However, 
this will not result in the exact in vivo volume, contributed by the fact that formaldehyde 
fixation also leads to shrinkage of tumor tissue in 10% of NSCLC [26]. To calculate pathology 
volumes, we assumed that tumors are ellipsoids. Yet, tumor boundaries usually have 
irregular shapes, for which this approximation is not perfectly valid. Also, differences 
between PET and pathology volumes in necrotic tumors arise due to the fact that the 
non-metabolic necrotic center is not included in the (metabolically-active) PET volume 
while it is included in the measurement of pathology specimens. A second problem is the 
fact that 18F-FDG PET has a lower spatial resolution relative to morphologic imaging 
modalities. Furthermore, autosegmentation has difficulty excluding normal tissue with 
high 18F-FDG uptake (like heart and liver) adjacent to tumor. Therefore, tumor volumes 
generated with automated segmentation on 18F-FDG PET can be useful as starting point, 
but should be manually adjusted using both 18F-FDG PET and CT [27,28]. This combined 
approach reduces interobserver variability and is less time consuming than complete 
visual delineation [22]. We suggest to apply and manually edit the FLAB method in clinical 
practice, as this method results in sufficient delineation of both necrotic and non-necrotic 
NSCLC. Uptake-based, relative threshold methods were especially hampered by necrotic 
tumors. Currently, internal target volume (ITV) instead of 3D tumor volume is more 
frequently used in NSCLC radiotherapy planning. ITV accounts for respiratory motion of 
the tumor. It is delineated on 4D-CT and with aid of static 18F-FDG PET/CT. Despite the 
blurring effect caused by respiration in static images, static PET underestimates the true 
ITV when compared with 4D-18F-FDG PET/CT reconstructed in 10 respiratory phases [29]. 
The addition of respiratory phased 4D-18F-FDG PET to 4D-CT for manual target volume 
delineation improves inter-observer agreement, especially for central lesions [30]. It would 
be interesting to examine whether the FLAB method is also applicable for the several 
respiratory phases or maximum intensity projection of 4D-18F-FDG PET/CT.
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Tumor glucose metabolism in NSCLC based on dynamic 18F-FDG PET
Differences in glucose metabolism between the major NSCLC histological subtypes were 
observed in this study: squamous cell carcinomas being highly glycolytic and less 
vascularized, while adenocarcinomas demonstrate a lower phosphorylation rate of 
glucose under better perfused (and likely oxygenated) conditions. Moreover, squamous 
cell carcinomas have a more heterogeneous metabolism throughout the tumor, showing 
increased transport and phosphorylation of glucose in areas of reduced blood volume [3]. 
This pattern is less obvious in adenocarcinomas. This is in agreement with histopathological 
findings of metabolic transporters and enzymes and level of metabolites [10-12]. 
Squamous cell carcinomas are characterized by high lactate and low glucose (i.e. glycolytic 
profile), and a high amount of glutamate and glutathione (i.e. glutaminolytic profile). 
Metabolic alterations in adenocarcinomas are related to phospholipid metabolism and 
protein catabolism [11]. However, range of dynamic PET parameters was quite large 
(Figure 5-6). Therefore, metabolism likely varies within adeno- and squamous cell NSCLC. 
An example of differences within NSCLC histology is the update of the world health 
organization (WHO) histological classification for adenocarcinomas in 2015, which is 
prognostic for tumor recurrence and survival. Micropapillary and solid adenocarcinomas 
have a more advanced TNM-stage at diagnosis, a higher recurrence rate, and a worse 
survival relative to lepidic-, acinic- and papillary-predominant subtypes [31]. Also, frequencies 
of driver mutations vary within adenocarcinoma subtypes [32]. So, adenocarcinomas 
cannot be regarded as just one entity. In line with this, the two adenocarcinomas with a 
lepidic component in our study had the lowest k3 and highest VB (data not shown). 
Unfortunately, our study population was too small to assess statistical differences. Earlier it 
was demonstrated that maximum standardized uptake value (SUVmax) is closely associated 
with adenocarcinoma subclassification, being highest in solid- and micropapillary- 
predominant subtypes and lowest in lepidic-predominant adenocarcinomas, corresponding 
with prognosis [33]. Further research is required to determine whether this difference in 
SUVmax might be affected by the spatial distribution of tumor cells caused by the growing 
pattern of each adenocarcinoma subtype.
 Despite the statistical differences in metabolic indices between the major NSCLC 
histological subtypes, these data cannot be applied in an individual patient basis because 
of the large overlap between the different tumor types. Regarding the differences in 
tumor metabolism between and likely within NSCLC histological subtypes, future 
preclinical and clinical studies should take into account that NSCLC is a heterogeneous set 
of diseases, with possibly dissimilar response to metabolic inhibitors and radiotherapy 
dose escalation towards regions with high 18F-FDG uptake.
This study has its limitations. First, the manual IDIF-VOI definition of the descending aorta 
might introduce inter- and intraobserver variability. However, Kramer et al. investigated 
the repeatability of 18F-FDG metrics in NSCLC. Double whole body static 18F-FDG PET/CT 
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scans were performed within 3 days. Correlations between test and retest scans for all 
uptake measures were high, also for SUVmean of the 3.3 mL VOI of the ascending aorta 
(ICC>0.98) [34]. Furthermore, high correlations were observed between MRglc based on 
IDIFs and serial arterial sampling-based MRglc (Reference Standard) (ICC=0.98 for ascending 
aorta, 0.94 for left ventricle, 0.96 for abdominal aorta). Therefore, using IDIF is accurate and 
represents a clinically viable alternative to arterial blood sampling [35]. We used the 
descending aorta as IDIF instead of the ascending aorta, as the ascending aorta was not 
fully imaged on all dynamic scans.
 Another limitation is the number of included patients. The study was a priori powered 
to be able to detect an expected correlation coefficient of 0.90 between pathology and 
PET volume [22], which is higher than the accepted minimal correlation coefficient of 
≥0.80 (alpha=0.05, power=0.80, one-tailed exact test). This required 54 evaluable patients. 
Due to logistic changes in clinical routine (reduced interval between diagnosis and 
treatment resulting in a reduced time window for participation), the inclusion rate 
dropped. Therefore, the study was terminated after including 38 patients with 36 evaluable 
lesions, leading to an achieved power of 0.65, or a somewhat lower acceptable correlation 
coefficient (=0.77, power=0.80) which we considered sufficient.
 Biological validation of K1-k3 and VB is hard due to sampling errors. Furthermore, 
expression of glucose transporters and hexokinases as assessed by immunohistochemical 
staining might not reflect transporter and enzyme activity. Despite these limitations, 
Okazumi et al. found a correlation (r=0.66) between hexokinase activity and k3 in liver 
tumors [36]. In colorectal tumors, a correlation of r=0.75 was obtained for the expression 
of six glucose transporters (assessed by gene array) and k1, and a correlation of r=0.61 was 
found for the expression of hexokinase 1-3 and k3 [37]. The limitation of true in vivo 
pathology volume has already been discussed earlier.
Conclusion
FLAB shows higher accuracy and precision for NSCLC tumor delineation on 18F-FDG PET 
compared to uptake-based relative threshold delineation, with no added value of dynamic 
over static imaging. This is the case for both non-necrotic and necrotic carcinomas, but 
most markedly for carcinomas with macroscopic necrosis. Therefore, applying FLAB is an 
appropriate automated tool for NSCLC delineation. However, automatically generated 
tumor volumes should always be manually edited using both 18F-FDG PET and CT, as no 
autosegmentation method is always reliable. 
 The found variations in glucose metabolism and vascularization between and likely 
within NSCLC histological subtypes might be relevant for further research in targeting 
tumor glucose metabolism.
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Abstract
Radiotherapy, an important treatment modality in oncology, kills cells through induction 
of oxidative stress. However, malignant tumors vary in their response to irradiation as a 
consequence of resistance mechanisms taking place at the molecular level. It is important 
to understand these mechanisms of radioresistance, as counteracting them may improve 
the efficacy of radiotherapy. 
 In this review we describe how the hypoxia-inducible factor 1 (HIF-1) pathway has a 
profound effect on the response to radiotherapy. The main focus will be on HIF-1 controlled 
protection of the vasculature post-irradiation and on HIF-1 regulation of glycolysis and the 
pentose phosphate pathway. This aberrant cellular metabolism increases the antioxidant 
capacity of tumors, thereby countering the oxidative stress caused by irradiation. From 
the results of translational studies and the first clinical phase I/II trials it can be concluded 
that targeting HIF-1 and tumor glucose metabolism at several levels reduces the antioxidant 
capacity of tumors, affects the tumor microenvironment, and sensitizes various solid 
tumors to irradiation. 
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Introduction
When ionizing radiation is absorbed in tissue, free radicals are produced as a result of 
ionizations either directly in the DNA molecule itself or indirectly in other cellular 
molecules, primarily water (H2O), and diffuse far enough to reach and damage critical 
targets. This indirect effect leads to the production of radical reactive oxygen species 
(ROS), which are molecules that contain chemically active oxygen molecules, thereby 
inducing oxidative stress. These ROS, for example hydroxyl radicals, can diffuse to the DNA 
to produce free radicals. These free radicals are highly reactive molecules, and break 
chemical bonds and initiate the chain of events that results in DNA damage. Oxygen 
molecules are able to react with the free radicals to yield a stable change in the chemical 
composition of the DNA damage. In this way, oxygen chemically ‘fixes’ DNA damage and 
this is the basic mechanism for the therapeutic use of ionizing radiation in cancer [1]. 
Hypoxia, a pathophysiological characteristic of solid malignancies (Figure 1), interferes 
with the fixation of DNA damage and is therefore a major cause of resistance to irradiation 
[2-5]. A number of therapeutic approaches have been designed to overcome tumor 
hypoxia [2,4,6]. Also in the presence of reducing species, the unstable free radial molecules 
can restore its original form [1].
 The hypoxia-inducible factor 1 (HIF-1) pathway enables tumor cells to survive by 
changing glucose metabolism towards a glycolytic phenotype, by inducing angiogenesis, 
and by regulating pH balance and proliferation rate. This review describes how the HIF-1 
pathway impacts on radioresistance of solid tumors, with special focus on HIF-1 induced 
changes in tumor glucose metabolism. Furthermore, inhibition of HIF-1 and glucose 
metabolism is discussed as a new method to overcome radioresistance. 
HIF-1 pathway
HIF-1
HIF-1 is a heterodimeric protein consisting of an O2-regulated HIF-1α and a constitutively 
expressed HIF-1β subunit. Under normoxia, HIF-1α is rapidly degraded, whereas hypoxia 
leads to stabilization and accumulation of HIF-1α (Figure 1-2) [7,8]. However, under certain 
normoxic conditions, HIF-1α expression can be increased; for example, mutations in the 
von Hippel-Lindau protein stabilize HIF-1α protein and PI3K/AKT/mTOR activity stimulates 
translation of HIF-1α mRNA [7-11]. Moreover, reactive oxygen and nitrogen species inhibit 
proteasomal degradation of HIF-1α [10,12]. After stabilization of HIF-1α, the heterodimeric 
protein activates transcription of numerous genes involved in angiogenesis, proliferation, 
glycolytic tumor metabolism and pH regulation [7,10,13] (Figure 2B). 
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Glycolytic cancer cell metabolism and aggressive tumor behavior
Under aerobic conditions, normal cells generate energy by processing glucose both via 
inefficient glycolysis and via more efficient mitochondrial oxidation. As hypoxia decreases 
the rate of mitochondrial oxidation, tumor cells switch to glycolysis under very hypoxic 
circumstances [14]. This process, in which pyruvate, lactate and hydrogen ions are 
produced, is called anaerobic glycolysis or Pasteur effect [9,15]. However, a hallmark of 
cancer cells is a high rate of glucose consumption and lactate generation even in the 
presence of oxygen (aerobic glycolysis or Warburg effect) [9,16-18].
 HIF-1 initiates transcription of genes that encode transporters and enzymes regulating 
glycolysis (Figure 3) [8,19]. The glycolytic products pyruvate and lactate induce HIF-1α 
accumulation [20,21], suggesting a feed-forward mechanism in which HIF-1 causes a 
glycolytic metabolism with elevated pyruvate/lactate concentrations, which in turn 
increase HIF-1 activity (Figure 2B) [19,22]. Besides HIF-1, activated oncogenes (e.g. RAS, 
MYC) and the PI3K/AKT/mTOR pathway are involved in the regulation of the metabolic 
shift to (aerobic) glycolysis [9,16,18]. 
Figure 1   Immunofluorescent image of a human head and neck squamous cell 
carcinoma xenograft tumor (SCCNij172) showing HIF-1α expression in hypoxic 
regions as assessed by pimonidazole staining 
Red: HIF-1α; green: pimonidazole; white: vessels; N: necrosis. Magnification 100x. Scale bar represents 
100 μm.
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The glycolytic switch may appear counter-intuitive, given the less efficient energy 
production by glycolysis compared to mitochondrial oxidation. However, the glycolytic 
intermediate glucose-6-phosphate is also utilized in the pentose phosphate pathway. This 
pathway synthesizes precursors of nucleotides and amino acids, which are macromolecules 
required for tumor cell growth and proliferation. When cells do not require these 
macromolecules for metabolism, intermediates of pentose phosphate pathway (fruc-
tose-6-phosphate and glyceraldehyde-3-phosphate) can be recycled back into glycolysis 
to produce pyruvate and lactate (Figure 3). During the pentose phosphate pathway, CO2 is 
released, leading to extracellular matrix acidification by carbonic anhydrase IX (CAIX) 
(Figure 3) [18,23].
Figure 2  Schematic representation of the HIF-1 pathway
Figure A) Under normoxic conditions, HIF-1α is rapidly degraded due to hydroxylation of HIF-1α by 
prolyl hydroxylase and subsequent binding of the von Hippel-Lindau protein. 
Figure B) Physiolocial stress (hypoxia, oxygen and nitrogen species), mutations in the von Hippel- 
Lindau protein and PI3K/AKT/mTOR activity contribute to HIF-1α stabilization and accumulation. 
Upon stabilization of HIF-1α, it binds to HIF-1β. This HIF-1 complex binds to the hypoxia responsive 
element (HRE) of the DNA, thereby initiating the transcription of its target genes. This results in a 
glycolytic tumor metabolism amongst others. The glycolytic end products pyruvate and lactate 
induce HIF-1α accumulation, which in turn increases HIF-1 activity.
Abbreviations: AKT: protein kinase B; EGFR: epidermal growth factor receptor; HIF-1: hypoxia- 
inducible factor 1; HRE: hypoxia responsive element; mTOR: mammalian target of rapamycin; PI3K: 
phosphatidylinositol-3-kinase; VHL protein: von Hippel-Lindau protein
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Figure 3  Tumor glucose metabolism and aggressive tumor behavior 
HIF-1 activates transcription of transporters and enzymes regulating glycolysis and the pentose 
phosphate shunt. These transporters and enzymes are involved in glucose delivery into the cell 
(GLUT1 and GLUT3), phosphorylation of glucose to form glucose-6-phosphate (HK), conversion of 
glucose-6-phosphate into 6-phosphogluconolactone to support the pentose phosphate shunt 
(G6PD), conversion of pyruvate into lactate (LDH-A), lactate transport (MCT4) and pH regulation 
(CAIX, NHE1). Furthermore, activation of PDK1 by HIF-1 inhibits the conversion of pyruvate to acetyl 
CoA, which results in a decreased flux through oxidative phosphorylation.
Glycolysis is involved in aggressive tumor behavior, since it causes radioresistance, it creates a tumor 
microenvironment favorable for tumor cell migration, it induces angiogenesis and it contributes to 
the immunological escape of tumors. 
HIF-1 regulated transporters and enzymes are shown in orange, blocked lines indicate an inhibitory 
effect.
Abbreviations: CAIX: carbonic anhydrase IX; GLUT1: glucose transporter 1; GLUT3: glucose transporter 3; 
G6PD: glucose-6-phosphate dehydrogenase; HK: hexokinase; LDH-A: lactate dehydrogenase A; 
MCT4: monocarboxylate transporter 4; NHE1: sodium-hydrogen exchanger 1; P: phosphate; P2: 
biphosphate; PDK1: pyruvate dehydrogenase kinase 1; PDH: pyruvate dehydrogenase; ROS: reactive 
oxygen species; TCA: tricarboxylic acid cycle; TKL/TAL: transketolase/transaldolase; VEGF: vascular 
endothelial growth factor
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Moreover, glycolytic metabolism in malignancies correlates with radioresistance as will 
be described in detail below [24,25] and lactate accumulation predicts for metastases 
formation during follow-up in different tumor entities [26-28]. The higher incidence of 
metastases could be explained by the fact that the glycolytic products lactate and acid 
induce secretion of matrix-degrading hyaluronidase and metalloproteinases by tumor- 
associated fibroblasts, creating a tumor microenvironment favorable for tumor cell 
migration [9,15,29,30]. Furthermore, lactate inhibits the activity of dendritic cells and 
T-cells, which contribute to the immunological escape of tumors [31,32]. Finally, lactate is 
able to induce angiogenesis (Figure 3) [29]. These findings all indicate that a glycolytic 
tumor cell metabolism contributes to aggressive tumor behavior.     
HIF-1 and radioresistance
Activation of the HIF-1 pathway after radiotherapy
Radiation-induced reoxygenation is the process by which the surviving hypoxic tumor 
cells become better oxygenated after irradiation due to the aerobic population being 
killed. As a result, the fraction of hypoxic tumor cells falls. This is a highly variable process 
within tumors, however, with the final level of oxygenation depending on the degree of 
reoxygenation [1,33]. 
 This process elicits a cascade of HIF-1 related events. Within hours post-irradiation, 
intratumoral HIF-1 activity decreases due to von Hippel-Lindau-dependent HIF-1α 
degradation under these reoxygenated conditions [34]. However, due to reoxygenation, 
ROS arise which induce HIF-1α stabilization [12]. As a result, HIF-1 expression increases in 
a hypoxia-independent manner 18-24 hours after radiotherapy in in vivo mice studies 
[34-38]. This upregulation endures up to one week [38]. In an in vivo tumor model it was 
demonstrated that some HIF-1 target genes are also upregulated after irradiation, including 
vascular endothelial growth factor (VEGF) and CAIX [36-38]. Furthermore, radiation- 
induced reoxygenation causes a significant increase in glucose uptake, and blockade of 
oxidative stress using a superoxide dismutase mimic concurrently with radiation prevents 
this increase in aerobic glycolysis [39]. These data suggest that changes in glucose demand 
are most likely associated with stabilization of HIF-1α by ROS during reoxygenation [39]. 
In these preclinical studies, tumors were irradiated with three fraction of 5 Gy or single 
fractions of 5-8 Gy. However, during fractionated radiotherapy in clinical practice, these 
processes are likely to be much more complex with schedules of 25-35 fractions of 1.8-2 
Gy, delivered over several weeks. Initially, the responses in the tumor microenvironment 
regarding reoxygenation, ROS and HIF-1 upregulation may to some extent follow the 
patterns described above. However, with increasing cumulative dose towards the end of 
the treatment it is conceivable that there will be a progressive disregulation of the 
response pathways and disruptions of the microenvironmental structure. It remains to 
532953-L-sub01-bw-Meijer
Processed on: 20-8-2019 PDF page: 118
118
Chapter 6
be elucidated whether HIF-1 upregulation by cycles of reoxygenation- induces ROS can 
be sustained for several weeks.
 Several other reoxygenation-dependent mechanisms are also able to upregulate 
HIF-1 and its downstream targets post-irradiation, including depolymerization of 
cytoplasmic stress granules containing HIF-1 regulated mRNA transcripts [36,40,41] and 
AKT/mTOR signaling [35]. Furthermore, nitrogen monoxide (NO), which is a free radical 
produced by tumor infiltrating macrophages, prevents HIF-1α from degradation after 
radiotherapy [42,43]. Without continued treatment and due to renewed tumor progression, 
after one or two weeks post-irradiation, hypoxia will increase again with a resulting rise in 
tumor HIF-1 levels [33,44].
HIF-1 and vascular radiosensitivity
Apart from the radiosensitivity of tumor cells as an important determinant of tumor 
response [45], the degree of radiation-induced microvascular destruction might contribute 
to tumor cell death [46-49]. Radiation-induced endothelial apoptosis starts at exposure to 
single dose radiation of 8-10 Gy, being maximal at 20-25 Gy [46]. Tumor blood flow 
decreases after a single dose of 10-15 Gy with subsequently indirect killing of tumor cells. 
Doses higher than 15-20 Gy cause a marked and lasting deterioration of the vasculature 
[50]. In the clinical situation, radiation-induced vascular damage may thus contribute to 
tumor response in case of high-dose hypofractionated treatment regimens [46,50]. The 
effect of standard fractionation using 1.5-2 Gy per fraction on endothelial cells may be 
minor [50], albeit that this will also depend on the total dose delivered. 
 During fractionated radiotherapy, the tumor microvasculature is protected through 
action of HIF-1. HIF-1 upregulation stimulates tumor cells to produce VEGF and other 
pro-angiogenic factors, which induce angiogenesis and protect the microvasculature 
from radiation-induced endothelial apoptosis [36,46,51-53]. Moreover, vasculogenesis is 
responsible for the recovery of tumor blood flow and the recurrence of glioblastomas 
after ionizing radiation in an in vivo tumor model [44]. Irradiation induces influx of bone 
marrow-derived cells. HIF-1-dependent upregulation of stromal-derived factor 1 (SDF1) 
and VEGF plays a crucial role in the recruitment of these bone marrow-derived cells 
[44,54]. These cells promote neovascularization, thereby restoring the radiation-damaged 
vasculature and stimulating regrowth of surviving tumor cells. Furthermore, VEGF and 
SDF1 activate resident endothelial cells [10]. In short, HIF-1 is responsible for vascular 
protection, recovery of tumor blood and nutrient supply and tumor recurrence post- 
irradiation by stimulating angiogenesis and/or vasculogenesis (Figure 4). 
 High HIF-1α expression correlates with poor loco(regional) control and an increased 
risk of tumor related death in patients with head and neck, cervical and prostate cancer 
treated with radiotherapy [55-60]. Preclinical research strongly suggests that HIF-1-mediated 
vascular protection is also responsible for tumor resistance to irradiation in patients 
[36,37,61]. 
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Figure 4   HIF-1 pathway and tumor glucose metabolism as cellular defense mechanisms 
against radiotherapy
Ionizing irradiation induces production of DNA-damaging ROS and free radicals through a direct 
and indirect effect. Oxygen molecules are able to react with free radicals to yield a stable change in 
the chemical composition of the DNA damage. So, oxygen chemically ‘fixes’ DNA damage and 
hypoxia interferes with the fixation of DNA damage.
Another cellular defense mechanism against ionizing irradiation is activation of the HIF-1 pathway. 
In response to HIF-1 upregulation after radiotherapy, tumor cells secrete VEGF and SDF1, which 
stimulate angiogenesis and vasculogenesis. This results in recovery of tumor blood and nutrient 
supply and tumor recurrence.
An active HIF-1 pathway also leads to changes in tumor glucose metabolism with accumulation of 
lactate, pyruvate, gluthathione and NAD(P)H. These molecules effectively scavenge free radicals and 
ROS, thereby protecting the tumor cell from free radical-mediated DNA damage. Furthermore, 
lactate stimulates endothelial cells to produce VEGF, thereby contributing to angiogenesis.
HIF-1 regulated transporters and enzymes are shown in orange. Blocked lines show the inhibitory 
effect of pyruvate, lactate, NADPH and glutathione on free radicals and ROS. 
Abbreviations: BMDC: bone marrow-derived cells; E4P: erythrose-4-phosphate; F6P: fructose-6-phos-
phate; GLUT1: glucose transporter 1; G3P: glyceraldehyde-3-phosphate; G6P: glucose-6-phosphate; 
GSH: glutathione (reduced form); GSSH: glutathione disulfide (oxidized form); HK: hexokinase; LDH-A: 
lactate dehydrogenase A; MCT4: monocarboxylate transporter 4; R•: free radicals; R5P: ribose-5- 
phosphate; ROS: reactive oxygen species; SDF1: stromal-derived factor 1; TKTL1: transketolase-like 
protein-1; VEGF: vascular endothelial growth factor
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HIF-1 inhibition, tumor microenvironment and response to radiotherapy 
Several existing classes of drugs such as anthracyclines (doxorubicin), EGFR inhibitors 
(cetuximab), and topoisomerase I inhibitors (topotecan) inhibit HIF-1 activity and tumor 
xenograft growth [10]. 
 Topotecan inhibits HIF-1α mRNA translation [62] and recently, the effect of this 
compound on the tumor microenvironment was studied in 16 patients with advanced 
solid tumors expressing nuclear HIF-1α [63]. After treatment, nuclear HIF-1α expression 
decreased, becoming undetectable in four out of seven available patients. Furthermore, 
the HIF-1 downstream targets glucose transporter 1 (GLUT1) and VEGF decreased after 
HIF-1 inhibition. Decreased tumor blood flow on dynamic contrast-enhanced magnetic 
resonance imaging was seen in 7 of 10 patients after 1 cycle of topotecan. These results 
indicate that HIF-1α inhibition lowers the level of HIF-1α and the downstream targets and 
affects tumor vascularization in patients. Only one patient in this study had a partial 
response lasting for 6 cycles of topotecan together, which was accompanied by both a 
reduction in HIF-1α level and a decreased tumor blood flow [63]. 
 Newly developed drugs with HIF-1 inhibitory capacity are YC-1 (3-(5’-hydroxymethyl- 
2’furyl)-1-benzyl indazole) and PX-478 (S-2-amino-3-[4’-N,N,-bis(chloroethyl)amino]phenyl 
propionic acid N-oxide dihydrochloride). PX-478 is an agent that inhibits HIF-1α by 
reducing HIF-1α mRNA levels and by inhibiting HIF-1α translation [64]. YC-1 induces HIF-1α 
protein degradation [65], and it inhibits the translation of HIF-1α mRNA via suppression of 
the PI3K/AKT/mTOR pathway and AKT/NF-κB signaling [11]. Further, YC-1 regulates HIF-1α 
functional activity at the post-translational level [66].
 In in vivo mice studies, YC1-treated stomach, renal and cervical carcinomas are smaller 
and less vascularized. These tumors express lower levels of HIF-1α and VEGF with higher 
hypoxic fractions compared to control tumors [34,67]. Apparently, YC-1 seems to halt 
tumor growth by blocking HIF-1 activity and subsequent vascularization [67]. Treatment 
of tumor-bearing mice with radiotherapy followed by YC1 suppresses upregulation of 
HIF-1 activity, dramatically increases radiation-induced vascular destruction and delays 
tumor growth [34,36]. Adversely, administration YC-1 before radiotherapy increases tumor 
hypoxia and suppresses the therapeutic effect of irradiation [34]. Also PX-478 radio-
sensitizes glioma tumor xenografts through inhibition of HIF-1-dependent pro-angiogenic 
signaling [38]. 
 PX-478 was tested in 40 patients with advanced solid tumors in a phase I dose 
escalation trial (NCT00522652) [68]. Only a limited number of severe events were reported, 
including severe thrombocytopenia without bleeding (n=1), anemia (n=1), acute renal 
failure (n=1), hypotension (n=1), and elevated liver enzymes (n=1). A relatively high 
proportion of patients (39%) achieved stable disease. This single agent study excluded 
patients who received radiation therapy within four weeks prior to entry into the study. 
Therefore, no conclusions can be drawn about potential interactions of PX-478 treatment 
with radiotherapy.  
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As HIF-1α is not expressed in all cancer cells in a tumor, inhibition of HIF-1 activity is 
probably not effective as monotherapy. Therefore, clinical trials should combine HIF-1 
inhibition with radiotherapy and should focus on optimal patient selection [37]. Furthermore, 
establishing optimal timing of HIF-1 inhibitory treatment relative to fractionated radio - 
therapy is a prerequisite for positive results.
Tumor glucose metabolism and radioresistance
Tumor glucose metabolism, the cellular redox status and radioresistance
Hypoxic tumor cells are more resistant to radiotherapy as a consequence of the interference 
of hypoxia with the fixation of free radical-induced DNA damage (Figure 4). Besides this 
protective mechanism, tumor cells counter the direct and indirect action of radiotherapy, 
i.e. radiation-induced radical and oxidative stress, by upregulation of their endogenous 
antioxidant capacity through accumulation of pyruvate, lactate, and the redox couples 
glutathione/glutathione disulfide and NAD(P)H/NAD(P)+ [69,70]. These molecules 
constitute an intracellular redox buffer network that effectively scavenges free radicals 
and ROS, and are products of glucose metabolism [69,71]. 
 The major pathways of glucose metabolism after the first step of glycolysis, i.e. the 
conversion of glucose into glucose-6-phosphate via action of hexokinase, are glycolysis 
and the pentose phosphate pathway (Figure 3-4). Tumor cells predominantly employing 
glycolysis produce pyruvate and lactate, and demonstrate an increase in the cytosolic 
NADH/NAD+ ratio due to decreased NADH oxidation by oxidative phosphorylation in the 
mitochondria [72]. The pentose phosphate pathway regenerates NADPH from NADP+. 
Glutathione is quantitatively the most important cellular redox system and controls the 
redox state of all subcellular compartments including the nucleus [69,73,74]. NADPH 
obtained from the pentose phosphate pathway is required to keep glutathione in the 
reduced state [69,75]. Furthermore, pyruvate contributes to the recovery of the glutathione 
pool after reoxygenation [76]. In this way, tumor glucose metabolism is involved in the 
production of reducing species, which protect the DNA from free radical-mediated 
damage (Figure 4) [69].
 Lactate accumulation has been related to radioresistance in tumor xenografts derived 
from human head and neck squamous cell carcinomas [24,25]. This lactate-associated ra-
dioresistance was hypoxia independent, i.e. well-oxygenated high-lactate tumors were 
radioresistant as well [24]. Lactate is able to scavenge superoxide and hydroxyl radicals in 
vitro [77]. Monocarboxylate transporters (MCTs) are involved in lactate transport. Therefore, 
MCT activity could influence the capacity of tumors to counter oxidative or radical stress. 
The effect of MCT inhibition on the intracellular redox status has been studied in human 
glioma cells [78]. Gliomas are highly glycolytic and produce large amounts of lactate. 
Surprisingly, when lactate efflux in glioma cells is blocked by α-Cyano-4-hydroxycinnamic 
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acid (ACCA), the level of intracellular lactate and glutathione decreases, which is 
accompanied by enhanced radiosensitivity. Colen et al. suggested that pyruvate is 
redirected into mitochondrial respiration as a consequence of lactate efflux inhibition [78]. 
Since ROS are synthesized during mitochondrial respiration, an increased rate of 
mitochondrial oxidation might exacerbate the ROS-induced DNA damage caused by 
radiotherapy [70,78]. 
 Pyruvate can be reduced to acetate, thereby scavenging hydrogen peroxide, which is 
a source of hydroxyl radicals [69,76]. Evidence shows that pyruvate is present in the cellular 
nucleus [69]. Despite the fact that pyruvate is theoretically an efficient radical scavenger, it 
does not predict the radiosensitivity of tumors in an in vivo tumor model [25]. However, 
the ratio lactate:pyruvate reaches 200:1 in malignancies [69], possibly minimizing the 
antioxidant contribution of pyruvate, and explaining the lack of correlation between 
pyruvate and radioresistance.
 In conclusion, redox adaptation is an important mechanistic concept that explains 
why cancer cells become resistant to radiotherapy [70]. Several preclinical studies have 
shown that tumor glucose metabolism is likely to be involved in alterations of cellular 
redox status and radioresistance. Interfering with glucose metabolism of tumor cells to 
reduce the levels of antioxidant metabolites could therefore improve response to 
radiotherapy [29]. 
Modulating tumor glucose metabolism and the cellular redox status to 
overcome radioresistance
Tumor glucose metabolism can be targeted at several levels, directly via inhibiting 
enzymes and transporters involved in glucose metabolism, and indirectly by anti-HIF-1 
therapy [72]. HIF-1 inhibition results in metabolic changes with a decreased rate of glucose 
uptake and lactate production in vitro [79], and an increase in oxygen consumption 
reflecting enhanced mitochondrial oxidation in in vivo mice studies [79,80]. As ROS are 
produced during mitochondrial oxidation, these metabolic alterations could enhance the 
therapeutic efficacy of radiotherapy [70]. 
 2-Deoxyglucose competes with glucose for transmembrane transport. Hexokinase 
converts 2-deoxyglucose into 2-deoxyglucose-phosphate, which cannot be further 
metabolized within the cancer cell. Treatment with 2-deoxyglucose is cytotoxic and radio-
sensitizes human glioma, cervical carcinoma and pancreatic carcinoma cells [75,81,82]. 
The combination of radiotherapy with 2-deoxyglucose demonstrates a trend towards 
increased growth delay of pancreatic carcinomas in an in vivo tumor model, relative to 
either agent alone [75]. This cytotoxic and radiosensitizing effect of 2-deoxyglucose is 
mediated by disruptions in glutathione metabolism and decreased NADPH content 
[75,82], which reflects the close link between tumor glucose metabolism and an altered 
cellular redox status. However, glycolysis inhibitors have therapeutic efficacy not only 
through disruptions in the cellular redox status, but also by depletion of ATP levels [72]. 
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Inhibition of GLUT1 and hexokinase decreases ATP levels resulting in reduced cancer cell 
viability in vitro, which inhibits tumor growth in in vivo tumor models [83,84]. Addition of 
ATP rescues GLUT1-inhibited cancer cells [84], suggesting that glycolysis inhibition has an 
anti-cancer effect partially through ATP depletion. 
 Phase I/II clinical trials examined the effect of the combination of 2-deoxyglucose 
with hypofractionated radiotherapy in cerebral glioma patients [85,86]. 2-Deoxyglucose 
was given 30 minutes before every fraction of radiotherapy in a dose escalation regimen 
[86]. This treatment strategy was well tolerated without severe acute toxicity and did not 
lead to any apparent increase in the late radiation damage to normal brain tissue [86]. This 
regimen resulted in a moderate increase in survival with a significantly improved quality 
of life [85]. Daily administration of 2-deoxyglucose in combination with docetaxel has 
been tested in 34 patients with advanced lung, breast, gastric, pancreatic and head and 
neck cancer in a phase I dose escalation trial (NCT00096707) [87]. The most common 
adverse events were fatigue, sweating, dizziness and nausea mimicking hypoglycemic 
symptoms. Adverse events at higher doses (63-88 mg/kg) were  gastrointestinal bleeding 
(6%) and reversible grade 3 QTc prolongation (22%) [87]. One other 2-deoxyglucose study 
has been terminated due to slow accrual (NCT00633087) and a third trial has been 
cancelled prior to enrollment of patients because of logistic reasons (NCT00247403).
 Another target of tumor glucose metabolism is the pentose phosphate pathway, 
which is closely connected to glycolysis via the glycolytic intermediate glucose-6-phosphate. 
Lowering the amount of glucose-6-phosphate through inhibition of hexokinase may 
reduce flux into the pentose phosphate pathway. The enzyme transketolase (TKT) has a 
key role in the regulation of the pentose phosphate pathway [88]. Transketolase-like protein-1 
(TKTL1) is significantly overexpressed in different human cancers and is responsible for 
60% to 70% of transketolase activity in human colon cancer cells [88,89]. TKTL1 increases 
the generation of fructose-6-phosphate and glyceraldehyde-3-phosphate, accompanied 
by significantly enhanced levels of pyruvate and lactate in vitro. These data indicate that 
TKTL1 overexpression increases glycolysis (Figure 3-4) [22]. Human colon carcinoma cells 
with suppressed TKTL1 activity display reduced cell proliferation, lactate production, 
glutathione content and NADPH/NADP+ ratio, as well as an increase in ROS-induced 
apoptosis. Lower amounts of these antioxidants may alter the ability of cells to detoxify 
ROS [90]. The cellular redox status can also be modulated by directly targeting glutathione. 
Glutathione depletion followed by radiotherapy results in large areas of apoptosis and 
significantly enhances the sensitivity of xenografted head and neck squamous cell 
carcinomas and non-small cell lung carcinomas to irradiation [91,92]. 
 Besides the alteration of the cellular redox status as described above [78], Sonveaux 
et al. identified another mechanism explaining the radiosensitizing effect of MCT inhibition 
[93]. Lactate produced by glycolytic hypoxic tumor cells can be taken up through MCT1 
and utilized as fuel for mitochondrial oxidation by aerobic tumor cells [93-96]. The use of 
lactate instead of glucose by oxygenated cells saves glucose for the hypoxic cells to 
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support glycolysis. MCT1 inhibition blocks lactate uptake and forces aerobic cells to use 
glucose for their energy metabolism. As a consequence, hypoxic cells located at large 
distance from the vasculature are deprived of glucose and die. MCT1 inhibition induces 
extensive necrosis, decreases tumor hypoxia and delays tumor growth in in vivo tumor 
models. Combining MCT1 inhibition with irradiation further delays tumor growth. 
Radiotherapy may complement MCT1 inhibition by eliminating the remaining oxygenated 
tumor cells in the vicinity of blood vessels [93].  
 CAIX inhibition with indanesulfonamide (11c) also results in a significantly slower 
tumor growth in a colorectal carcinoma tumor model. Tumor growth is further delayed by 
combining 11c with single dose radiotherapy. However, in vitro incubation of colorectal 
carcinoma cells with 11c before irradiation does not enhance the effect of radiotherapy. 
Targeting CAIX under hypoxia reduces the rate of extracellular acidification and 
proliferation, and induces apoptosis of colorectal carcinoma cells [97]. Therefore, CAIX 
inhibition might kill hypoxic cells, whereas radiotherapy attacks normoxic cells, resulting 
in the therapeutic enhancement of the combined treatment strategy in the colorectal 
carcinoma tumor model. However, the effect of intracellular acidification on tumor 
metabolism and the cellular redox status has not yet been determined.
 In conclusion, blocking tumor glucose metabolism at several levels has been shown 
to decrease the amount of antioxidant molecules and to radiosensitize different solid 
tumors in preclinical studies. The administration of the glycolysis-inhibitor 2-deoxyglucose 
combined with hypofractionated radiotherapy shows promising results in the first phase 
I/II clinical trials without severe toxicity. However, daily use of anti-glucose metabolism 
treatment for several weeks, which might be useful as an additive treatment in combination 
with daily-fractionated radiotherapy, could cause more severe side effects. For example, 
the brain is highly dependent on glucose for its energy metabolism. Therefore, more 
clinical studies examining the efficacy and side effects of targeting tumor metabolism in 
combination with radiotherapy are required.
Conclusions and future perspectives
This review describes that the HIF-1 pathway is involved in the tumor-protective response 
to radiotherapy, both via vascular protection post-irradiation and via enhancing the tumor 
antioxidant capacity through initiating a glycolytic tumor metabolism. Targeting HIF-1 
and tumor glucose metabolism affects the tumor microenvironment, induces metabolic 
alterations and sensitizes various solid tumors to irradiation. 
 Future studies should examine whether HIF-1 and glucose metabolism inhibitors are 
useful in clinical practice. Special attention should be paid to the effect of HIF-1 inhibition 
on the glycolytic and redox status of tumors, and optimal timing of these inhibitory 
treatments in relation to radiotherapy. Furthermore, validation of imaging techniques, 
532953-L-sub01-bw-Meijer
Processed on: 20-8-2019 PDF page: 125
125
HIF-1, tumor glucose metabolism and radioresistance
6
which establish HIF-1 expression and glucose metabolism and predict response to 
radiation, is required for optimal patient selection.
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Abstract
Purpose Metabolic inhibition might sensitize tumors to irradiation. Here, we examined 
the effect of lonidamine (several metabolic effects, inhibiting hexokinase amongst others) 
and/or 968 (glutaminase inhibitor) on tumor cell metabolism, cell growth, cytotoxicity 
and radiosensitivity in NSCLC cell lines in vitro in relation to histology.
Materials and methods Adeno- (H23, HCC827, H1975) and squamous cell carcinoma 
(H520, H292, SW900) NSCLC cells were treated with lonidamine and/or 968 for 72 hours 
under physiological levels of glucose (1.5 mM). Cells were irradiated with 0, 4 or 8 Gy. Cell 
growth of H2B-mCherry transduced cells and cytotoxicity (CellTox™ Green Cytotoxicity 
Assay) were measured using live cell imaging (IncuCyte). Inhibitory effects on metabolic 
profiles was determined using the Seahorse XF96 extracellular Flux analyzer.
Results NSCLC cell lines responded differently to glycolysis (lonidamine) and/or glutaminase 
(968) inhibition, largely corresponding with changes in glycolytic and mitochondrial 
metabolism upon treatment. Response patterns were not related to histology. 968 was 
cytotoxic in cell lines with high glutaminase C expression (H1975 and H520), whereas 
combination treatment was cytotoxic in KRAS mutated cell lines SW900 and H23. H292 
and HCC827 were resistant to combination treatment. Treatment with 968 and especially 
lonidamine resulted in radiosensitization of H292 and HCC827 in terms of decreased 
relative cell growth and increased cytotoxicity.
Conclusion NSCLC is a heterogeneous disease, which is reflected in the response of 
different cell lines to the treatment (combinations) reported here. Only a part of NSCLC 
patients may benefit from the combination of radiation therapy and metabolic inhibition, 
making predictive markers necessary.
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Introduction
Standard treatment for irresectable stage III non-small cell lung cancer (NSCLC) is 
concurrent/ sequential chemoradiation. Despite this intensive therapy, prognosis remains 
poor with 5-year survival of 13-36% [1]. Locoregional progression and distant metastases 
remain a major issue [2]. Therefore, further intensification of treatment is required.
 The metabolic switch from oxidative phosphorylation of pyruvate towards glycolysis 
with production of lactate is involved in metastasis formation, immune escape of tumor 
cells, angiogenesis and radio- and chemoresistance [3-7]. Areas with residual 18F-fluorode-
oxyglucose (18F-FDG) uptake after radiotherapy correspond with the high 18F-FDG uptake 
regions pre-radiotherapy in NSCLC, indicating radioresistance [8]. Glutamine metabolism 
of malignant cells contributes to the synthesis of ATP, lipids, amino acids and nucleotides 
required for proliferation, and to glutathione production for protection against oxidative 
stress [9]. Essential for NSCLC growth in vitro is the glutaminase 1 (GLS1) splice variant 
glutaminase C (GAC), an enzyme that catalyzes the hydrolysis of glutamine to glutamate, 
which is used in the citric acid cycle of cancer cells as a source for anaplerosis [10]. Increased 
expression of the glutamine transporter SLC1A5 is a poor prognostic factor in NSCLC [11]. 
Targeting SLC1A5 induces an increase in intracellular reactive oxygen species (ROS) and 
apoptosis in SLC1A5-high expressing NSCLC cell lines, and attenuates NSCLC tumor 
growth in vivo [11,12]. Glutamine inhibition increases radiation-induced ROS and sensitizes 
pancreatic carcinoma to radiation in vitro and in an in vivo mice study [13]. So, inhibiting 
glucose and/or glutamine metabolism might optimize treatment for stage III NSCLC via 
depletion of energy and macromolecules as well as sensitization to chemoradiation. 
 Emerging evidence supports differences in metabolism between adeno- and squamous 
cell NSCLC, based on the expression of metabolic transporters and enzymes, 18F-FDG PET, 
and the level of metabolites. Squamous cell carcinomas demonstrate an anaerobic 
(hypoxic) glycolytic profile, i.e. poor vascularization, large necrotic areas, high lactate level 
together with low glucose level and elevated expression of glucose transporter 1 (GLUT1), 
combined with a glutaminolytic profile (increased levels of glutamate and glutathione). 
Adenocarcinomas have a better vascularization and likely oxygenation, and appear to 
have a glycolytic metabolism under aerobic conditions [11,12,14-17]. Based on these 
findings, it is of interest to exploit glucose and glutamine metabolism in therapies allied to 
NSCLC histological subtypes. 
 Lonidamine (1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) is an agent with 
several effects on cell energy metabolism. It inhibits glycolysis through interference with 
the function of mitochondrial-bound hexokinase II, the enzyme that catalyzes the phos-
phorylation of glucose into glucose-6-phosphate. Furthermore, it induces lactate 
accumulation and thereby intracellular acidification, and it inhibits the formation of 
fumarate and malate. Finally, it disturbs the mitochondrial transmembrane potential, 
decreases the oxygen consumption rate, induces ROS through respiratory complex II 
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(succinate dehydrogenase) inhibition, and reduces levels of NADPH and glutathione in 
part by inhibition of flux through the pentose phosphate pathway [18,19]. 968 (5-(3-Bro-
mo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthri-
din-4(1H)-one) is an allosteric inhibitor, which preferentially binds to and stabilizes the 
inactive, monomeric state of GAC, thereby preventing it from undergoing conformational 
changes to the active tetramer [20,21]. If GAC reaches an activated state before 968 
binding, then 968 is unable to inhibit enzyme activity. So, protein turnover is required in 
order to prevent the activation of GAC [20,21].
 The aim of this study is to investigate the effect of treatment with lonidamine and/or 
968 on metabolism, tumor cell growth, cytotoxicity and radiosensitivity in 6 NSCLC cell 
lines in vitro (3 adeno- and 3 squamous cell carcinoma) in relation to histology.
Materials and methods
Cell lines
Three adenocarcinomas (HCC827, H1975, H23) and three squamous cell carcinomas (H292, 
SW900, H520) were used for the experiments described below. Cell lines were 
authenticated by STR analysis. H1975 and HCC827 harbor an EGFR mutation (H1975: 
c.2369C>T (p.(Thr790Met)) (exon 20) and c.2573T>G (p.(Leu858Arg) (exon 21); HCC827: 
c.2236_2250del (p.(Glu746_Ala750del)) (exon 19)). H23 and SW900 harbor a KRAS 
mutation. For live-cell imaging quantification of cell numbers, cell lines were labeled with 
nuclear localized H2B-mCherry by lentiviral transduction using a pLenti6.2/V5 DEST 
Gateway vector (Invitrogen). Subsequently, cells were selected for blasticidin resistance, 
and fluorescent cells were isolated by flow cytometry. mCherry fluorescence signal 
diminished in H23 and H520, and could therefore not be used to determine cell count in 
these cell lines. All experiments were performed with RPMI medium (P04-17550, 
PAN-Biotech GmbH, Aidenbach, Germany), supplemented with 10% (v/v) fetal bovine 
serum, 1.5 mM D-glucose and 2 mM L-glutamine, 20 mM Hepes, 1x non-essential amino 
acids, 20 U/ml penicillin, 20 ug/ml streptomycin (all from Gibco). To mimic the tumor mi-
croenvironment, we decided to use a physiological concentration of 1.5 mM glucose 
(unless otherwise specified). A higher non-physiological glucose concentration of 10 mM 
results in a significant higher glucose consumption and lactate production [22].
Glycolysis and mitochondrial metabolism by using Seahorse
Cells were seeded at an optimized cell density: 12.500 (H292), 20.000 (SW900), 25.000 
(H1975 and HCC827) or 30.000 (H520 and H23) cells/well and incubated the day after for 
24h with vehicle (DMSO 0.075%), lonidamide (150 uM), 968 (10 uM) or a combination of 
both. Metabolic profiles were generated using the Seahorse XF96 extracellular Flux 
analyzer (Seahorse Bioscience) as previously described [23]. Baseline oxygen consumption 
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rate (OCR) and extracellular rate of acidification (ECAR) were determined after replacing 
the growth medium with assay medium, containing the inhibitors or vehicle (without 
serum), according to the manufacturer’s protocol [24]. A mitochondrial stress test was 
performed after subsequent injections of oligomycin (1 uM; ATP synthase inhibitor), 
optimized FCCP (0.2 uM for HCC827, 0.4 uM for H23 and 1 uM for the other cell lines) and a 
mixture of rotenone and antimycin A (both 1 uM) (all from Sigma-Aldrich) to measure 
changes in OCR for the evaluation of mitochondrial ATP production, spare respiratory 
capacity and proton leak respectively. A glycolysis stress test was performed to measure 
changes in ECAR upon addition of glucose (10 mM), optimized oligomycin (1 uM for 
SW900 and H520, 2.5 uM for H23, HCC827 and H1975 and 5 uM for H292) and 2-deoxyglucose 
(2-DG, 0.1 M) (all from Sigma-Aldrich) to evaluate glycolysis and glycolytic reserve. The 
addition of glucose increases ECAR; this is reported as the rate of glycolysis under basal 
conditions. Oligomycin inhibits mitochondrial ATP production, thereby pushing cells to 
use glycolysis maximally. The subsequent increase in ECAR is a parameter of the cellular 
maximum glycolytic capacity. Finally, 2-DG is added, a glucose analog that inhibits 
glycolysis through competitive binding to hexokinase. The resulting decrease in ECAR 
confirms that the ECAR produced in the experiment is due to glycolysis. The difference 
between glycolytic capacity and glycolysis defines glycolytic reserve. The glycolytic 
reserve indicates how glycolytic a cell is, i.e. a small glycolytic reserve means that the cells 
are more glycolytic. Cellular respiration was corrected for total protein content, measured 
using the Pierce BSA protein assay kit (Thermo Fisher).
Cell cycle
Cells were seeded at 10e6 cells/well, allowed to attach overnight and afterwards incubated 
with inhibitors or vehicle as described above. Cell Cycle distribution was assessed by flow 
cytometry (FACSCanto II, BD Biosciences) after 30 min incubation with 10 µg/ml PI, 100 µg/
ml RNAse A and 0.1% TritonX-100 in PBS. Histograms were analyzed using FlowJo v10.0.8 
(Tree Star) software and percentage cells in G0/G1, S or G2/M-phase were calculated.
Real time PCR
Cells cultured in RPMI supplemented with 1.5 mM D-glucose and 2 mM L-glutamine were 
collected. Total RNA was isolated with the Norgen’s Total RNA purification kit (Norgen 
Biotek Corp., Thorold, Ontario, Canada), and RNA (0.5 μg) was reverse transcribed with the 
iScript cDNA synthesis kit (Bio-Rad). qPCR was performed in triple with specific primers for 
GLS1 (FW: 5’-AGGGTCTGTTACCTAGCTTGG-3’, RV: 5’-ACGTTCGCAATCCTGTAGATTT-3’) and 
GAC (FW: 5’-GGTCTCCTCCTCTGGATAAGATGG-3’, RV: 5’-GATGTCCTCATTTGACTCAGGT-
GAC-3’) on a CFX96 real-time PCR detection system (Bio-Rad Laboratories Inc, Richmond, 
CA) using SYBR Green. Levels are expressed as ratios of HPRT [25].
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Cell growth and cytotoxicity 
To assess the effect of metabolic inhibition on cell growth and cytotoxicity, cells were 
seeded in a 96-wells plate (#3596, Corning; 1 column for each condition) and exposed to: 
control-vehicle (DMSO 0.075%), 150 μM lonidamine (Sigma-Aldrich chemie) [19], 10 μM 
968 (Calbiochem) [26], combination treatment with lonidamine and 968. Dose of 
lonidamine was based on the data of Guo et al. showing decreased level of the cellular 
antioxidants glutathione and NADPH upon treatment with 150 μM lonidamine [19], and 
dose response experiments demonstrating a decrease in confluence of about 50% for all 
six cell lines after 72 hours of treatment with 150 μM lonidamine (Supplementary Data 1). 
Decreased amounts of reducing equivalents could enhance the radiosensitivity of tumor 
cells and may therefore be important for radiation experiments [5]. For H292, H23, H1975 
and HCC827 4000 cells were seeded; 2000 cells for SW900 and 8000 for H520. To settle, 
cells were left at room temperature for 20 minutes. Thereafter, plates were placed in the 
IncuCyte ZOOM Live-Cell Analysis System (Essen BioScience) at 37°C. Every 2 hours, images 
were taken of each well at 4x magnification for the entire experiment. When a confluence 
of 20-25% (i.e. 20-25% of the well occupied by tumor cells; bright-field images) was 
reached, cells were treated with lonidamine and/or 968, or vehicle (control), and CellTox 
Green (1:4000, diluted in RPMI without glucose and glutamine; Promega) was added to 
measure cytotoxicity. Image processing was performed using Zoom2016A software 
(Essen BioScience). Images of red signal (mCherry), green signal (CellTox) and confluence 
were binarized for further analysis. For segmentation, thresholds were interactively set for 
cell lines individually at intensities where the steepest gradient occurred between 
background and foreground intensity levels. With these binary images, confluence, 
mCherry count mm-2 and cytotoxicity count mm-2 were calculated. Cytotoxicity index 
was calculated by cytotoxicity count mm-2/ mCherry count mm-2 (or confluence in case of 
unstable mCherry). Correlation coefficients of mCherry count mm-2 and confluence were 
0.997-0.999 for all control cell lines with stable mCherry.
Radiation experiments
The same amounts of cells as described above were seeded in a 96-wells plate (#3596, 
Corning), and CellTox green was added. Six hours after placing 96-wells plates in the 
IncuCyte, cells were treated with lonidamine and/or 968. Twenty-four hours later, cells 
were irradiated with 0 Gy (control), 4 Gy or 8 Gy (XRAD 320ix, PXI precision X-ray, North 
Brandfod, CT). Confluence, mCherry count mm-2 and cytotoxicity count mm-2 were 
measured in pictures taken every 2 hours at 4x magnification, and analyzed as described 
above. This time point of radiation was chosen based on the observation that mCherry 
and confluence lines are separating relative to control for both compounds after 24 hours 
of treatment, reflecting inhibitory efficacy (fourth panel of Figure 1 and Supplementary 
Data 2). Data from irradiated conditions were normalized to their non-irradiated counterpart 
to measure the radiosensitizing effect of metabolic inhibitors. 
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Statistics
Statistics were performed using Prism 4. Differences in glycolysis, mitochondrial metabolism, 
cell growth and cytotoxicity between treatment groups were assessed using Kruskal-Wallis 
test, followed by Dunn’s post-hoc analyses. A p<0.05 was considered statistically significant.
Results
Metabolism in 6 NSCLC cell lines
Seahorse experiments (at 10 mM glucose) showed that adenocarcinoma cell lines (H23, 
HCC827, H1975) were more glycolytic relative to squamous cell carcinoma cell lines (H520, 
H292, SW900) as their glycolytic reserve is smaller (p<0.0001; Figure 1, Supplementary Data 2, 
upper panel), corresponding to earlier results of 18F-FDG PET and tissue analysis in patients 
which show glucose consumption under better vascularized conditions in adenocarcinomas 
[14,15,17]. A similar pattern, although with a lower glycolytic rate, was observed for 
experiments with 1.5 mM glucose (Supplementary Data 3).  H1975 showed the highest 
GLS1 and GAC mRNA levels (Figure 2).
Effect of lonidamine and/or 968 on metabolism and cell cycle
In general, lonidamine decreased the glycolytic rate (significant for H1975, p<0.05) (Figure 1, 
Supplementary Data 2, upper panel). Baseline oxygen consumption rate (OCR) was 
significantly affected after treatment in H520 (p=0.045) and H1975 (p=0.034). 968 
attenuated baseline OCR in H520 and especially H1975, corresponding with GAC mRNA 
levels (Figure 1-2, Supplementary Data 2, second panel). 968 remarkably decreased 
mitochondrial ATP production in H1975, H520, HCC827 and H23. Combination treatment 
clearly decreased mitochondrial ATP production in all cell lines (p<0.05 for H520), except 
in H292. Mitochondrial ATP production was fully blocked in SW900 and H23. Other signs 
of inhibition of mitochondrial metabolism are the decrease in spare respiratory capacity 
and increase in proton leak, which are observed for monotherapy, and significantly for 
combination therapy (spare respiratory capacity: H292: p<0.05; proton leak: H292, H520 
and H1975: p<0.01) (Figure 1, Supplementary Data 2, third panel). Metabolic inhibition for 
24h did not affect cell cycle in any of the cell lines (Supplementary Data 4).
Effect of lonidamine and/or 968 on cell growth and cytotoxicity
Decrease in cell growth after treatment with lonidamine correlated partly with glycolytic 
rate as measured in Seahorse. HCC827 and H1975, cell lines with the highest rate of 
glycolysis, showed a clear response to lonidamine 72 hours after treatment (43% and 53% 
cell growth relative to control respectively). H292 and H520, cell lines with a lower glycolytic 
profile, demonstrated less response to lonidamine (60% and 67% cell growth relative to 
control respectively). However, glycolytic rate and response to lonidamine did not 
correlate for SW900 and H23 (Figure 1, Supplementary Data 2, upper and fourth panel). 
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Figure 1   Effect of metabolic inhibition on glycolysis, mitochondrial metabolism,  
cell growth and cytotoxicity, and radiosensitivity for H292, H1975 and SW900
Upper panel: Effect of 968 and/or lonidamine on glycolytic rate as assessed by extracellular acidification 
rate (ECAR). Cell lines are cultured in RPMI medium with 10 mM glucose. Bars represent mean value.
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In the six cell lines, three patterns were observed after treatment with lonidamine and/or 
968: decrease in cell growth without cytotoxicity, cytotoxicity due to treatment with 968 
only, and a severe cytotoxic effect of the combination treatment. 
 H292 and HCC827 demonstrate a decrease in cell growth after (combination) treatment 
(p<0.001 for both) without an increase in cytotoxicity (Figure 1, Supplementary Data 2, 
fourth and fifth panel). Three days after (combination) treatment, cells remained viable 
(Figure 3, Supplementary Data 5). This corresponds with small changes in baseline OCR 
and mitochondrial ATP production upon (combination) treatment in H292 (Figure 1, 
second and third panel). 
 Treatment with 968 was detrimental for the viability of H1975 cells (Figure 4); it increased 
cytotoxicity significantly (p<0.05) (Figure 1, fourth and fifth panel). This corresponds with 
the high mRNA level of GAC in H1975 (Figure 2) and decrease in baseline OCR (Figure 1, 
second panel). Lonidamine decreased H1975 cell growth (p<0.01) without a cytotoxic 
effect; combination treatment was very cytotoxic (p<0.001) (Figure 1, fourth and fifth 
panel; Figure 4). This pattern was also observed for H520, although, to a lesser extent 
(Supplementary Data 2, fourth and fifth panel; Supplementary Data 6). 
 Combination treatment was detrimental for cell growth and viability in SW900 
(p<0.001 for both) and H23 (cell growth: p<0.001; cytotoxicity: p<0.01) (Figure 1, 
Supplementary Data 2, fourth and fifth panel; Figure 5, Supplementary Data 7). Cytotoxicity 
was significantly increased after combination therapy in SW900 (p<0.001), corresponding 
to the drastic decrease in mitochondrial metabolism in this cell line (full inhibition of 
mitochondrial ATP production, very high proton leak, drastic decrease in OCR; Figure 1, 
second and third panel). This pattern was partly observed for H23 (total inhibition of 
mitochondrial ATP production and a very high proton leak, but no decrease in OCR) 
(Supplementary Data 2, second and third panel).
Second panel: Effect of 968 and/or lonidamine on baseline oxygen consumption rate (OCR). Cell 
lines are cultured in RPMI medium with 4.5 g/l glucose. Bars represent mean value.
Third panel: Effect of 968 and/or lonidamine on mitochondrial ATP production, spare respiratory 
capacity and proton leak. Cell lines are cultured in RPMI medium with 4.5 g/l glucose. Bars represent 
mean value.
Fourth panel: Effect of 968 and/or lonidamine on cell growth (mCherry count 
(mm-2)) up to three days after treatment.
Fifth panel: Effect of 968 and/or lonidamine on cytotoxicity up to three days after treatment.
Sixth panel: Radiosensitizing effect (in terms of mCherry count) of metabolic inhibition three days 
after radiation. Irradiated control data are normalized relative to control 0 Gy, irradiated 968 data are 
normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of metabolic inhibitors.
Seventh panel: Radiosensitizing effect (in terms of cytotoxicity index) of metabolic inhibition three 
days after radiation. Irradiated control data are normalized relative to control 0 Gy, irradiated 968 
data are normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of metabolic 
inhibitors.
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Radiosensitivity after metabolic inhibition
As combination therapy was very cytotoxic for most cell lines, effect of combined metabolic 
inhibition on radiation response could not be assessed under these circumstances. The same 
applies to the combination of 968 and radiation in H1975 and H520.
 Two squamous cell carcinoma cell lines (H292 and H520) were remarkably resistant 
to radiation doses up to 8 Gy (decrease in cell growth of only 9-15% at 8 Gy relative to 
0 Gy), while the other cell lines showed a decrease in cell growth of 36-64% (Figure 1, 
Supplementary Data 2, sixth panel). Unfortunately, treatment with lonidamine or 968 
did not sensitize the H520 cell line to radiation (Supplementary Data 2, sixth panel). 
Interestingly, the two cell lines that were resistant to (combination) metabolic inhibitors, 
i.e. H292 and HCC827, did demonstrate a radiosensitizing effect upon treatment with 
968 and especially with lonidamine in terms of relative cell growth. Also, cytotoxicity 
index increased substantially after treatment with lonidamine and irradiation (Figure 1, 
Supplementary Data 2, sixth and seventh panel; Supplementary Data 8). 
A summary of results is shown in Table 1.
Figure 2  mRNA levels of glutaminase in 6 NSCLC cell lines
A) GLS1 mRNA level
B) GAC mRNA level
Cell lines are cultured in RPMI medium with 1.5 mM glucose and 2 mM glutamine.
Abbreviations:
GAC: glutaminase C; GLS1: glutaminase 1. mRNA levels are expressed as ratios of HPRT.
A B
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Discussion 
Different response to metabolic inhibitors in NSCLC cell lines
Earlier studies support a difference in metabolism between adeno- and squamous cell 
NSCLC: squamous cell carcinomas demonstrate an anaerobic (hypoxic) glycolytic profile 
combined with glutaminolysis, while adenocarcinomas have a better vascularization/
oxygenation and seem to have a glycolytic metabolism under aerobic conditions 
[11,12,14-17]. In this study, a varying response to metabolic inhibition was observed across 
different NSCLC cell lines. However, this response was not determined by histology, with 
both adeno- and squamous cell carcinoma cell lines exhibiting different phenotypes. So, 
a generalized metabolic inhibition approach for NSCLC seems not to be possible and 
predictive markers are required for selection of treatment. 
 Combination treatment of lonidamine and 968 was detrimental for cell growth and 
viability in the two KRAS-mutated cell lines (SW900 and H23). Monotherapy decreased 
cell growth, but did not affect cytotoxicity. Likely, these cell lines are able to compensate 
for blocking of only one of these metabolic routes. For example, glutaminolysis in the 
citric acid cycle can be increased upon treatment with lonidamine [19]. Furthermore, 
Table 1  Summary of results
Adenocarcinomas Squamous cell carcinomas
H23 HCC827 H1975 H520 H292 SW900
GAC mRNA + + +++ ++ + +
KRAS mutation Yes No No No No Yes
Growth reduction
Lonidamine + ++ ++ + ++ ++
968 + + + + + +
Combination +++ +++ +++ ++ +++ +++
Cytotoxicity
Lonidamine - - - - - +
968 - - + + - -
Combination ++ - ++ ++ - +++
Radiosensitizing effect
Lonidamine - ++ - - ++ -
968 - + - - + -
Cytotoxicity after radiation
Lonidamine - + - - + -
968 - - -  - - -
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the mitochondrial isoform of phosphoenolpyruvate carboxykinase (PCK2) is expressed 
and active in NSCLC, including H23 [27,28]. PCK2 expression and activity are enhanced 
under low-glucose conditions. Under limited availability of glucose, PCK2 converts 
glutamine- derived oxaloacetate into the glycolytic intermediate phosphoenolpyruvate 
(PEP). Glutamine-derived PEP is used to fuel biosynthetic pathways normally sustained 
by glucose through gluconeogenesis (i.e. the opposite direction of glycolysis), thereby 
replenishing other glycolytic intermediates. These can be used in a number of biosynthetic 
processes, such as serine and glycerol synthesis, nucleotide synthesis and NADPH 
generation via the pentose phosphate pathway [27,28]. Also uptake of lactate may serve 
as a gluconeogenic precursor through PCK2 activity [27]. In this way, PCK2 activity helps 
to adapt to low-glucose conditions and enables glucose-independent cell proliferation. 
PCK2 inhibition leads to a significant increase in glucose depletion-induced apoptosis in 
H23 and A549 cells (both KRAS mutated) but not in H1299 cells (KRAS wildtype). Under 
high glucose conditions (20 mM), PCK2 inhibition has no effect in H23 and H549 [27]. 
In oncogenic KRAS- or BRAF-driven NSCLC cells, autophagy provides an intracellular 
glutamine supply to sustain mitochondrial function [29]. Moreover, reprogramming of 
glutamine metabolism mediated by oncogenic KRAS in pancreatic ductal adenocarcinoma 
cells results in the conversion of glutamine-derived aspartate into pyruvate through malic 
enzyme 1 with the production of NADPH for maintaining redox homeostasis [30,31]. 
RAS-driven cancer cells display aerobic glycolysis and glutamine can provide carbon for 
anaplerosis in these cells [9,32,33]. So, KRAS mutation might be a predictive marker for 
response to combination inhibition of glycolysis and glutamine metabolism. 
 NSCLC cell lines show a variable range of glutamine dependency [10]. Glutaminase 
inhibition by 968 was cytotoxic for cell lines with high GAC mRNA level (H1975 and H520). 
Therefore, GAC expression could be a predictive marker for response to 968 monotherapy. 
H292 and HCC827 demonstrated a decrease in cell growth after (combination) treatment 
without an increase in cytotoxicity. Apparently, these cell lines are able to compensate for 
this (combination) therapy. Remarkably, H292 showed only a small decrease in baseline 
OCR and had the highest mitochondrial ATP production after combination treatment 
(Figure 1, second and third panel; Figure 3), possibly due to metabolism of other fuels like 
lipids and lactate instead of glucose and glutamine [34-36]. Recently, it was demonstrated 
that lactate-derived carbons are detected in citric acid cycle intermediates in tumors 
derived from HCC827 cell line [35]. Furthermore, HCC827 and H292 showed a substantial 
increase in basal respiration when exposed to glucose-free medium containing fatty acids 
relative to medium containing glucose, while this increase was not observed for H1975 
(preliminary unpublished data). This observation further strengthens our hypothesis that 
H292 and HCC827 cells are able to survive inhibition of glucose and glutamine metabolism 
by fueling fatty acids in mitochondrial respiration.
 Goodwin et al. performed glycolysis inhibition experiments in adeno- (A549 and 
H522) and squamous cell (HCC95 and HCC1588) NSCLC cell lines by using GLUT1 knockdown, 
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72-deoxyglucose and WZB117 (a selective, small-molecule GLUT1 inhibitor) [37]. GLUT1 knockdown decreased glucose uptake, markedly suppressed the proliferative capacity of 
the squamous cell carcinoma cell lines HCC95 and HCC1588, accompanied by extensive 
apoptosis and cell death, and lower amount of intracellular ATP and NAD(P)H. GLUT1 
knockdown also decreased glucose uptake in adenocarcinoma cell lines A549 and H522. 
In contrast to squamous cell carcinoma cell lines, these adenocarcinoma cell lines showed 
only moderately suppressed proliferation upon GLUT1 knockdown without induction of 
apoptosis or cell death and no changes in intracellular amount of ATP [37]. GLUT1 
knockdown significantly inhibited in vivo growth of HCC95 tumors, but did not affect in 
vivo growth of H549 and H522 tumors. Squamous cell carcinoma cell lines HCC95 and 
HCC1588 were more apoptotic upon treatment with 2-deoxyglucose or WZB117 compared 
to A549 and H522 adenocarcinoma cell lines, despite similar decrease in glucose uptake 
and extracellular acidification rate. 2-Deoxyglycose-treated or WZB117-treated HCC1588 
squamous cell carcinoma tumors exhibited significant in vivo tumor growth reduction, 
with no anti-tumor activity in treated A549 adenocarcinomas [37].
Figure 3  Cell growth and cytotoxicity after metabolic inhibition in H292
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Red: mCherry, green: cytotoxicity.
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This selective cytotoxicity of glycolysis inhibition in squamous cell carcinomas observed 
by Goodwin et al. suggests a specific reliance on glucose metabolism in squamous cell 
carcinomas and metabolic compensatory mechanism to maintain bioenergetics, cellular 
viability and proliferative capacity in adenocarcinomas. We also found metabolic flexibility 
among NSCLC cell lines, but we could not support this histology-based difference in our 
in vitro experiments, possibly due to the fact that lonidamine has multiple effects on 
metabolism apart from glycolysis inhibition. Furthermore, heterogeneity is likely to exist 
within these histological subtypes. For example, the A549 adenocarcinoma cell line was 
more sensitive to GLUT1 knockdown compared to H522 adenocarcinoma cell line, in 
agreement with higher GLUT1 mRNA and protein expression in A549. Moreover, in 
adenocarcinoma patient tumors, predominantly micropapillary and solid adenocarcino-
mas exhibit higher GLUT1 expression and 18F-FDG uptake compared to adenocarcinomas 
with a predominantly lepidic, acinar or papillary growth pattern [38,39], further supporting 
heterogeneity among subclassifications. Heterogeneity might also exist among squamous 
cell carcinoma cell lines, as the HCC2450 squamous cell carcinoma tumor line exhibits 
much lower GLUT1 mRNA and protein compared to the examined HCC1588 and HCC95 
cell lines. Unfortunately, HCC2450 was not exposed to GLUT1 knockdown, 2-deoxyglucose 
or WZB117 in the study by Goodwin et al [37].
 An interesting observation in our study is the increase in proton leak for both 
compounds, but especially for combination treatment in all cell lines. Proton leak gives an 
indication about the leakage of protons out of the mitochondrial space. Oxidative phos-
phorylation runs according to the following principles: i) Electrons of the tricarboxylic acid 
cycle donate their energy in a series of redox reactions, in which oxygen is reduced into 
water; ii) This energy is used to create a proton gradient; iii) This proton gradient drives ATP 
synthesis. So, compounds disturbing the mitochondrial transmembrane structure or 
potential could influence proton leak. Lonidamine is known to disturb the mitochondrial 
transmembrane potential [18], and thus is likely to influence proton leak. For 968, this 
effect has not been described.
Metabolic inhibition and response to radiation in NSCLC
Lonidamine and 968 resulted in a radiosensitizing effect in H292 and HCC827. Sappington 
et al. observed that BPTES, a GLS-1 specific inhibitor, reduced cell viability and proliferation 
and substantially reduced extracellular glutathione excretion in H460 and H549 cells. 
GLS-1 inhibition markedly resulted in a radiosensitizing effect in these cell lines, suggesting 
the importance of glutamine-derived glutathione in redox control and radioresistance 
[40]. A key metabolic role of oncogenic KRAS is to maintain redox balance, by regulating 
metabolism of glutamine amongst others [41]. Glutamine deprivation sensitized the KRAS 
mutated NSCLC cell line HCC44 to radiation, but not the KRAS wildtype H522 [30]. 
We could not confirm the radiosensitizing effect of glutamine inhibition in KRAS mutated 
cell lines. The effect of glutaminase inhibition on the redox status (higher ROS, and 
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decrease in glutathione and NADPH) and radiosensitivity has also been observed for 
cervical and pancreatic cancer cells [13,42]. Also lonidamine induces ROS formation and 
inhibits NADPH and glutathione generation [19]. However, in four NSCLC cell lines, we did 
not observe a radiosensitizing effect of metabolic inhibitors. Conversely, metabolic 
inhibition might result in radioresistance in H1975, SW900, H23 an H292. We hypothesized 
that metabolic inhibition resulted in cell cycle arrest due to depletion of energy and 
macromolecules, but we were unable to confirm this hypothesis. Han et al. showed that 
968 inhibited NSCLC cell proliferation and arrested G0/G1 phase of cell cycle in A549 and 
H23 [43]. These different observations between studies might be due to the heterogeneity 
of NSCLC cell lines and differences in experimental set-up, like glucose concentration and 
time of treatment with metabolic inhibitor. Furthermore, 968 and combined treatment 
could be too cytotoxic to be able to demonstrate a radiosensitizing effect in H1975, 
SW900, H23 and H292 (Figure 4-5, Supplementary Data 6-7). A lower compound dose, 
probably resulting in less cytotoxicity, may increase the radiation effect.
Figure 4  Cell growth and cytotoxicity after metabolic inhibition in H1975
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Red: mCherry, green: cytotoxicity.
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The diversity in response of NSCLC cell lines to the combination of metabolic inhibition 
and radiation therapy may explain the negative result of the prospective randomized 
comparison of radiation therapy plus lonidamine versus radiation therapy alone for 
non-resectable NSCLC [44]. A trend towards better local control was observed for patients 
treated with lonidamine and radiation, which suggests that only a part of patients benefit 
from treatment with lonidamine, underlining the need to better select patients for such 
treatment modifications [44]. Thus, a general approach regarding metabolic inhibition to 
improve radiotherapy efficacy is not possible for NSCLC and predictive markers are 
required.
Translation of in vitro results into in vivo
The tumor microenvironment can affect cancer cell metabolism [34]. For this reason, we 
mimicked the tumor microenvironment by using a more physiological concentration of 
1.5 mM glucose [22]. Glucose concentrations vary within tumors, and many tumors have 
average levels between 1 and 2 mM. However, other nutrients like glutamine are also in 
Figure 5  Cell growth and cytotoxicity after metabolic inhibition in SW900
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Red: mCherry, green: cytotoxicity.
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excess in standard culture medium and might also have an impact on our results. 
Furthermore, in standard culture conditions, oxygen is abundant (21%), while oxygen 
levels in even the best perfused tissues are 9% or less and can be very low in tumors [34]. 
As oxygen level influences metabolism [45], this could have an impact on the response to 
metabolic inhibitors in vivo. Moreover, human NSCLC tumors demonstrate metabolically 
heterogeneous regions within tumors related to the degree of perfusion [46]. All together, 
this implies that the tumor microenvironment, including tumor vasculature supplying 
nutrients and oxygen, influences the metabolic phenotype of cancer cells and sensitivity 
to metabolic inhibitors. 
Conclusion
NSCLC is a heterogeneous set of diseases. Cell lines responded differently to glycolysis 
and/or glutaminase inhibition, largely corresponding with changes in glycolytic and 
mitochondrial metabolism upon treatment, but response patterns were not related to 
histological subtype. Interestingly, response patterns were associated with KRAS mutation 
status and level of GAC mRNA expression. The glutaminase inhibitor 968 decreased cell 
growth and was cytotoxic in cell lines with high GAC mRNA expression (H1975 and H520), 
whereas combination treatment was detrimental for cell growth and viability in the KRAS 
mutated cell lines (SW900 and H23). Two of six cell lines (H292 and HCC827) were quite 
resistant to combination treatment and may depend on or switch to other fuels like 
phospholipids and lactate. 968 and especially lonidamine were able to radiosensitize the 
H292 and HCC827 NSCLC cell lines. Therefore, only a part of NSCLC patients may benefit 
from the combination of radiation therapy and metabolic inhibition, making predictive 
markers necessary. As the tumor microenvironment affects the metabolic phenotype of 
tumor cells, these observations should be confirmed in in vivo models and patients. 
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Supplementary Data
Supplementary Data 1  Lonidamine dose response experiments
Dose response experiments in six non-small cell lung cancer cell lines using lonidamine 50 μM, 100 
μM, 150 μM, 200 μM and 400 μM, relative to control. After 72 hours of treatment with lonidamine 150 
μM, confluence decreased with about 50% for all six cell lines.
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Supplementary Data 2  Effect of metabolic inhibition on glycolysis, mitochondrial 
metabolism, cell growth and cytotoxicity, and radiosensitivity for HCC827, H520 and H23
Upper panel: Effect of 968 and/or lonidamine on glycolytic rate as assessed by extracellular 
acidification rate (ECAR). Cell lines are cultured in RPMI medium with 10 mM glucose. Bars represent 
mean value.
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Supplementary Data 2  Continued
Second panel: Effect of 968 and/or lonidamine on baseline oxygen consumption rate (OCR). Cell 
lines are cultured in RPMI medium with 4.5 g/l glucose. Bars represent mean value.
Third panel: Effect of 968 and/or lonidamine on mitochondrial ATP production, spare respiratory 
capacity and proton leak. Cell lines are cultured in RPMI medium with 4.5 g/l glucose. Bars represent 
mean value.
Fourth panel: Effect of 968 and/or lonidamine on cell growth (confluence or mCherry count (mm-2)) 
up to three days after treatment.
Fifth panel: Effect of 968 and/or lonidamine on cytotoxicity up to three days after treatment.
Sixth panel: Radiosensitizing effect (in terms of confluence or mCherry count (mm-2)) of metabolic 
inhibition three days after radiation. Irradiated control data are normalized relative to control 0 Gy, 
irradiated 968 data are normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of 
metabolic inhibitors.
Seventh panel: Radiosensitizing effect (in terms of cytotoxicity index) of metabolic inhibition three 
days after radiation. Irradiated control data are normalized relative to control 0 Gy, irradiated 968 
data are normalized relative to 968 0 Gy etc. to measure the radiosensitizing effect of metabolic 
inhibitors.
Supplementary Data 3  Glycolytic rate in 6 NSCLC cell lines
Glycolytic rate as assessed by extracellular acidification rate (ECAR). Cell lines are cultured in RPMI 
medium with 1.5 mM glucose. Bars represent mean value.
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Supplementary Data 4  Cell cycle after metabolic inhibition
Cell cycle after 24h metabolic inhibition with 968, lonidamine (lon) or combination treatment in H23 
(A), HCC827 (B), H1975 (C), H520 (D), H292 (E), and SW900 (F). Y-axis represents the percentage of cells 
in G0/G1 phase, S phase, and G2/M phase.
A
C
E
B
D
F
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Supplementary Data 5  Cell growth and cytotoxicity after metabolic inhibition in HCC827
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Red: mCherry, green: cytotoxicity.
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Supplementary Data 6  Cell growth and cytotoxicity after metabolic inhibition in H520
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Green: cytotoxicity.
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Supplementary Data 7  Cell growth and cytotoxicity after metabolic inhibition in H23
Microscopic images three days after metabolic inhibition for control-vehicle, 968, lonidamine and 
combination treatment. Magnification 4x. Scale bar represents 400 µm. Green: cytotoxicity.
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Supplementary Data 8  Radiosensitizing effect of lonidamine in H292
Microscopic images three days after (sham)radiation for control-vehicle and treatment with lonidamine. 
Magnification 4x. Scale bar represents 400 µm. Red: mCherry, green: cytotoxic.
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Abstract
Background and purpose Prognosis of locally advanced non-small cell lung cancer 
remains poor despite chemoradiation. This planning study evaluated a stereotactic boost 
after concurrent chemoradiotherapy (30x2 Gy) to improve local control. The maximum 
achievable boost directed to radioresistant primary tumor subvolumes based on 
pre-treatment fluorine-18 fluorodeoxyglucose positron emission tomography/computed 
tomography (18F-FDG PET/CT) (pre-treatment-PET) and on early response monitoring 
18F-FDG PET/CT (ERM-PET) was compared. 
Materials and methods For ten patients, a stereotactic boost (VMAT) was planned on 
ERM-PET (PTVboost;ERM) and on pre-treatment-PET (PTVboost;pre-treatment), using a 70% 
SUVmax threshold with 7 mm margin to segmentate radioresistant subvolumes. Dose was 
escalated till organ at risk (OAR) constraints were met, aiming to plan at least 18 Gy in 3 
fractions (EQD2 84 Gy/BED 100.8 Gy).  
Results In five patients, PTVboost;ERM was 9-40% smaller relative to PTVboost;pre-treatment. 
Overlap of PTVboost;ERM with OARs decreased also compared to overlap of PTVboost;pre-treat-
ment with OARs. However, any overlap with OAR remained in 4/5 patients resulting in 
minimal differences between planned dose before and during treatment. Median dose 
(EQD2) covering 99% and 95% of PTVboost;ERM were 15 Gy and 18 Gy respectively. Median 
boost volume receiving a physical dose of ≥18 Gy (V18) was 88%. V18 was ≥80% for 
PTVboost in six patients.
Conclusions A significant stereotactic boost to volumes with high initial or persistent 
18F-FDG uptake could be planned above 60 Gy chemoradiation. Differences between 
planned dose before and during treatment were minimal. However, as an ERM-PET also 
monitors changes in tumor position, we recommend to plan the boost on the ERM-PET.
532953-L-sub01-bw-Meijer
Processed on: 20-8-2019 PDF page: 163
163
18F-FDG PET-based SBRT boost in locally advanced NSCLC
8
Introduction
Dose escalation up to a total dose of 60 Gy yields a greater proportion of disease control 
and better survival compared to 40-50 Gy for the treatment of irresectable locally 
advanced non-small cell lung cancer (NSCLC) [1]. However, about 30% of patients treated 
with 60 Gy radiotherapy have loco-regional recurrence in absence of distant metastasis 
[2], with a higher risk of local than regional failure [3]. A meta-analysis showed that with 
combined sequential or concurrent chemoradiotherapy, dose escalation beyond 60 Gy 
does not lead to further improvements in overall survival [4]. The RTOG 0617 trial 
demonstrated that 74 Gy in 2 Gy fractions concurrent chemoradiation might even result 
in a survival decrement compared to 60 Gy in 2 Gy fractions [5]. In case of radiation therapy 
alone, higher radiation dose results in longer survival without an upper dose level above 
which there is no further benefit [4]. Therefore, radiation dose intensification combined 
with chemotherapy should not be discouraged based on the RTOG 0617 results. Especially 
since in RTOG 0617 compliance with normal tissue dose constraints was not mandatory 
and older (less conformal) radiotherapy techniques were allowed [5,6].
 Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy 
(VMAT) enable more conformal irradiation, thereby lowering dose to organs at risk (OAR) [7]. 
Currently, it is possible to identify subvolumes within the planning target volume (PTV) that 
are more radioresistant [8-10]. Usmanij et al. demonstrated that NSCLC metabolic non-
responders, as determined by a poor decrease in total lesion glycolysis (TLG) on fluorine 18 
fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) 
at the beginning of third week of radiotherapy, have a worse progression-free survival compared 
to early metabolic responders [9]. Thus, early response measurement using 18F-FDG PET/CT 
enables the identification of patients that may benefit most from dose escalation.
 Stereotactic body radiotherapy (SBRT) delivers very conformal high radiation doses 
resulting in excellent local control rates (>90%) with low toxicity in inoperable stage I-II 
NSCLC patients [11]. It was shown that a biologically effective dose (BED) prescription of at 
least 100 Gy is required for acceptable tumor control probability [12]. Therefore, a SBRT 
radiation boost directed towards 18F-FDG PET/CT defined radioresistant subvolumes may 
increase local control in locally advanced NSCLC. Furthermore, by using SBRT, high 
maximum dose (Dmax) within the PTV is achieved with limited dose to OAR due to steep 
dose decline just outside the PTV, enabling higher dose escalation compared to other 
approaches. Limiting prolongation of overall treatment time (OTT) is another advantage 
of SBRT boosting as the booster dose is delivered in only a few fractions. 
 The aim of this study was to compare the maximum achievable dose escalation for 
locally advanced NSCLC treated with concurrent chemoradiation by using a stereotactic 
boost directed to radioresistant subvolumes of the primary tumor as determined by an 
18F-FDG PET/CT before start of chemoradiation (pre-treatment PET) and an early response 
monitoring 18F-FDG PET/CT (ERM-PET). 
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Material and methods
Patients
18F-FDG PET/CTs acquired for the ERM study by Usmanij et al. were used for this planning 
study [9]. This ERM study was approved by the Institutional Review Board of the Radboud 
university medical center. All patients gave written informed consent. Twenty-eight patients 
with stage IIIA-B NSCLC eligible for concomitant chemoradiotherapy were enrolled in this 
study. A prescription dose of 60 Gy in 2 Gy fractions was applied in this planning study for 
the entire tumor and involved lymph nodes with margin (PTV60Gy). Detailed information 
upon radiation treatment planning for PTV60Gy is described in Supplementary material 1.
 For every patient, a pre-treatment 18F-FDG PET/CT was acquired with a median 
interval of 11 days (range 1-27 days) before start of chemoradiation and an ERM 18F-FDG 
PET/CT was performed at the beginning of the third week of treatment (after a median 
dose of 20 Gy; range 20-24 Gy). Timing of the ERM-PET was specifically chosen at the 
beginning of third week of treatment. A decrease in uptake early during chemoradiation 
reflects tumor response, whereas this decrease in uptake may disappear later in the course 
of chemoradiation due to the onset of treatment induced inflammation [9]. 
 We selected those fourteen patients with a poor response to treatment as assessed 
by a TLG decrease <45% on the ERM-PET relative to the pre-treatment PET. These poor 
responders showed worse disease-free survival, possibly due to the fact that they harbour 
more radioresistant tumors [9]. Three patients were ineligible for this planning study, 
because they had only a small primary tumor with the bulk of gross tumor volume (GTV) 
located in the mediastinum. Furthermore, one radiotherapy CT and radiation treatment 
plan could not be restored. So, ten patients were included in this planning study. Patient 
characteristics are listed in Table 1. 
18F-FDG PET/CT image acquisition
All PET scans were performed with a hybrid PET/CT scanner (Biography Duo Siemens 
Medical Solutions, USA, Inc.). Patients fasted for at least six hours. A venous blood sample was 
drawn to measure blood glucose level (<8.2 mmol/L in all patients (mean, 6.0 mmol/L)). 
Prior to the PET scan, a low dose CT during free-breathing was acquired for PET attenuation 
correction and anatomical matching. Sixty minutes after intravenous injection of 18F-FDG 
(3.45 MBq/kg; Covidien) and furosemide (10 mg), static emission scans in three-dimensional 
mode were obtained with an acquisition time of four minutes per bed position. Images 
were iteratively reconstructed in 128x128 matrices by ordered subsets expectation 
maximization (OSEM) algorithm using four iterations/sixteen subsets (4i/16s) with a 5 mm 
Gaussian filter. Correction for photon attenuation (by using the low dose CT) and decay of 
18F-FDG was performed for images. Rigid co-registration (starting with a bone match and 
visually checking the plausibility of the match regarding tumor and surrounding normal 
tissue) of the PET scans to the radiotherapy planning CT was performed.
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Boost volume definition
Radioresistant subvolumes of the primary tumor, to which the boost must be directed, 
were delineated on the pre-treatment PET and ERM-PET. For automated segmentation of 
biological target boost volumes (BTVboost), a threshold of 70% of maximum intensity level 
was used to identify tumor subvolumes at greatest risk of relapse [10]. Adding a 7 mm 
circumferential margin to BTVboost created PTVboost. Volumes (cm3) of PTVboost based on 
the pre-treatment PET (PTVboost;pre-treatment) and ERM-PET (PTVboost;ERM) were recorded. 
To assess the effect of timing of PET scans on the planned dose to PTVboost, a stereotactic 
boost was planned for all ten patients on both the pre-treatment PET and the ERM-PET.
Organs at risk definition and constraints 
The bronchial tree (up to and including lobar bronchi), heart, great vessels, esophagus, 
lungs minus GTV60Gy (i.e., lung volume minus the volume of the GTV planned to receive 60 
Gy), spinal cord and brachial plexus were considered OAR. Adding a 5 mm margin to the 
first four OAR contours created the planning OAR volumes (PRV) [13]. For the latter two 
OAR, PRVs were created adding a 2 mm margin as breathing induced movement is 
assumed to be smaller/absent for this nerve tissue. No PRV margin was used for the lungs. 
The following constraints were applied: Lungs minus GTV60Gy: mean lung dose <20 Gy, 
V20<35% (Vx is the relative volume receiving x Gy); V5<65-70% for lungs minus GTV60Gy 
and V5<55% for contralateral lung (‘soft’ constraint) [14-16]. PRV esophagus: Dmax 70 Gy 
equivalent dose in 2 Gy fractions (EQD2) (α/β-value 3 Gy) [17] PRV brachial plexus: Dmax 66 
Gy EQD2 (α/β-value 2 Gy) [13]. PRV heart, great vessels, bronchial tree: Dmax 94 Gy EQD2 
(α/β-value 3 Gy) [13]. PRV spinal cord: Dmax 53 Gy EQD2 (α/β-value 2 Gy) [13].
Boost planning
Doses to OARs were determined for the 60 Gy treatment plan. Except for the Vx doses and 
mean dose to the lungs, these doses can be converted into EQD2 doses using the formula 
EQD2=total dose*((fraction dose+ α/β)/(2+α/β)). Thereafter, the extra allowed EQD2 dose 
to OAR was calculated (i.e., maximum allowed EQD2 minus maximum EQD2 delivered after 
60 Gy). Subsequently, this extra allowed EQD2 was converted into a physical dose (planned 
to be delivered in three fractions). This physical dose was calculated for every separate 
OAR and used as maximum allowed dose for boost treatment planning. This strategy was 
performed for both the whole OAR and the part of the OAR in close proximity to the 
boost volume, to take into account the spatial component of the maximum dose of the 60 
Gy treatment plan. So, also the maximum dose of the OAR subvolume near PTVboost was 
determined in the conventionally fractionated 60 Gy radiotherapy plan. This dose was 
used to calculate the maximum tolerable dose for that subvolume of the OAR bordering 
the PTVboost.  Higher dose escalation of the boost volume could be achieved with this 
strategy. Boosts were planned using the Pinnacle3 (Version 8.0–9.2; Philips Radiation 
Oncology Systems, Fitchburg, WI) treatment planning system. 
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A BED prescription dose of at least 100 Gy is required for acceptable tumor control 
probability [12]. A dose of 60 Gy in 2 Gy fractions is 60 Gy EQD2 and is equal with a BED of 
72 Gy (α/β-value=10 Gy for tumor). Delivering 18 Gy in three fractions results in a boost of 
24 Gy EQD2 (total EQD2 84 Gy) and a BED of 28.8 Gy (total BED 100.8 Gy). Therefore, it was 
attempted to plan a boost with a minimum dose of 18 Gy in three fractions. The final 
planned dose to PTVboost depended on the maximum tolerable dose for the OAR. The 
majority of tumors in this study were located near critical organs at risk, as is often the case 
in irresectable stage III NSCLC, resulting in a small therapeutic window for planning a 
stereotactic radiation boost. Radiation dose was escalated till OAR constraints were met. 
In case a higher dose than 18 Gy could be planned this was done. However, in case 18 Gy 
could not be planned due to critical OAR, a lower dose had to be accepted.
 All boost plans were generated using a single VMAT arc avoiding the contralateral 
lung. To ensure a rapid dose decline outside the PTV, a ring contour (1 cm) around the PTV 
was created. In case of overlap of PTVboost with PRV, two separate PTVs were created: PTV 
inside PRV and PTV outside PRV. This enabled better dose coverage for the PTV outside 
the PRV, thereby limiting underdosage of the PTV. The optimization objectives for the 
PTVboost and the ring contours were individually set according to calculated constraints 
for OAR. No hard constraints were set for the maximum allowed dose within PTVboost, 
because the maximum doses reached in this setting will never approach the maximum 
allowed (EQD2) dose that is clinically accepted in SBRT for limited stage lung cancer. We 
allowed a maximum dose as high as needed to enable a steep dose decline outside 
PTVboost, without exceeding the maximum total dose (EQD2) accepted in SBRT for limited 
stage lung cancer. 
Results
PTVboost volumes
In only two of ten patients, PTVboost volumes did not overlap with any of the PRVs (Table 1). 
In five of ten patients, PTVboost;ERM was 9-40% smaller relative to PTVboost;pre-treatment. 
However, for the other five patients, PTVboost;ERM remained stable or increased compared 
to PTVboost;pre-treatment (range 0-50%) (Table 2). 
 Furthermore, it was examined whether the changes in PTVboost resulted in less 
overlap with PRVs (Supplementary material 2). Overlap did decrease in five patients with 
6-100%. Unfortunately, overlap with PRVs disappeared in only one of these five patients 
(Figure 1, Supplementary material 2). Overlap with PRVs increased for two patients 
(Supplementary material 2). Dose limiting OAR for boost planning, allowed dose to OAR and 
planned dose to OAR are shown in Table 3 and Supplementary material 3.
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PTVboost and BTVboost dose
Dose delivered to 99% of PTVboost (D99; EQD2), dose delivered to 95% of PTVboost (D95; 
EQD2), Dmax (EQD2), and percentage of PTVboost receiving ≥18 Gy (V18; physical dose) were 
assessed for PTVboost;pre-treatment and PTVboost;ERM. Median D99 and D95 of PTVboost;pre-treat-
ment were 17 Gy (range 4-31) and 19 Gy (range 7-42), respectively. Median V18 of PTV-
boost;pre-treatment was 93% (range 56-100). Median D99 and D95 of PTVboost;ERM were 15 Gy 
(range 3-30) and 18 Gy (range 6-32), respectively. Median V18 of PTVboost;ERM was 88% 
(range 51-100). 
 Differences between the planned dose in week 0 and 3 were minimal due to the fact 
that overlap of PTVboost;ERM with PRVs remained in most patients. V18 in week 3 was higher 
in five patients compared to V18 in week 0. However, planning results were somewhat 
worse for four patients in week 3 relative to week 0. For patient number 3, differences in 
coverage of PTVboost;pre-treatment and PTVboost;ERM were very large due to changes in 
atelectasis and thereby a shift in tumor position towards the heart in week 3, resulting in 
overlap of PTVboost;ERM with heart PRV limiting dose escalation (Table 4; Figure 2; 
Supplementary material 2). 
 In seven patients, D95 PTVboost was substantially higher than the prescribed dose 
(74 Gy) of the RTOG 0617 study. The total D95 PTVboost;pre-treatment was ≥80 Gy in five 
patients and for four patients a total D95 PTVboost;ERM ≥80 Gy could be planned (Figure 2A; 
Table 4). The summed D95 of PTVboost minus overlap with PRV was ≥80 Gy in seven 
Table 2   Boost planning target volume determined on pre-treatment and early 
response monitoring 18F-FDG PET/CT
Patient PTV0 (cm3) PTV3 (cm3) Absolute 
difference (cm3)
Relative difference 
(%)
1 19 19 0 0
2 214 183 -31 -15
3 14 21 7 50
4 164 98 -66 -40
5 94 56 -38 -40
6 127 133 6 5
7 43 34 -9 -21
8 208 189 -19 -9
9 14 15 1 7
10 15 16 1 7
Abbreviations: PTV0: boost planning target volume determined on pre-treatment 18F-FDG PET/CT; PTV3: boost 
planning target volume determined on the early response monitoring 18F-FDG PET/CT; Absolute difference: PTV3 
volume minus PTV0 volume; Relative difference: (absolute difference/PTV0)*100
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Table 3  Dose limiting organs at risk for boost planning
Patient Dose limiting
OAR
1 Esophagus
2 Esophagus
3 Heart
4 Lungs
5 Heart, bronchial tree and esophagus
6 Esophagus
7 Heart
8 Heart, esophagus, brachial plexus and spinal cord
9 Lungs
10 Heart
Figure 1   Boost PTVs of two patients delineated on 18F-FDG PET/CT scans before start of 
treatment and at the beginning of week 3 during treatment
18F-FDG PET/CT scans of patient number 4 and 8. The green line represents PTVboost before start of 
treatment (upper panel), the red line represents PTVboost at the beginning of third week of treatment 
(lower panel). For patient number 4 (left), there was a remarkable decrease in PTVboost volume in 
contrast to PTVboost volume of patient number 8 (right) whose PTVboost volume was similar for both 
time points. The blue line indicates the planning organs at risk volumes.
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patients and for another patient this summed D95 was 79 Gy (Figure 2B). V18, which equals 
an ablative dose, was ≥80% for the whole PTVboost in six patients (Figure 2D) and ≥80% in 
eight patients for PTVboost minus overlap with PRV (Figure 2E). 
 In clinical practice, clinical target volume (CTV) coverage is also evaluated in case of 
overlap with OAR. D95 BTVboost (considering BTVboost as CTV) was considerably larger 
than D95 PTVboost (Figure 2C): for seven patients a summed BTV dose of ≥80 Gy could be 
planned. BTVboost;ERM V18 was (almost) 100% in six patients (Figure 2F). In the other 
patients, BTV-PRV overlap hampered planning of an ablative dose for the complete 
BTVboost.
Table 4  Dose planned to PTVboost
Patient PTVboost
D99 (EQD2) D95 (EQD2) Dmax (EQD2) V18
week 0 week 3 week 0 week 3 week 0 week 3 week 0 week 3
1 24 25 26 28 92 85 99 100
2 18 19 22 21 41 41 93 91
3 31 13 42 18 87 80 100 91
4 23 30 28 32 51 48 99 100
5 5 11 8 13 68 55 63 60
6 5 7 7 9 55 41 56 51
7 17 18 17 19 48 59 49 61
8 4 3 7 6 47 51 72 73
9 30 28 32 31 75 77 100 100
10 15 12 17 16 66 66 82 84
Dose in EQD2, except for V18. Abbreviation: PTVboost: boost planning target volume; D99: dose planned to 99% 
of PTVboost (EQD2); D95: dose planned to 95% of PTVboost (EQD2); Dmax: maximum dose (EQD2); V18: percentage of 
planning target volume receiving ≥18 Gy (physical dose); week 0: boost plan based on pre-treatment 18F-FDG 
PET/CT; week 3: boost plan based on early response monitoring 18F-FDG PET/CT
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Discussion
This study compared the maximum achievable dose escalation for locally advanced 
NSCLC treated with concurrent chemoradiation by using a stereotactic boost directed to 
radioresistant subvolumes of the primary tumor as determined by a pre-treatment PET 
and an ERM-PET. In five of ten patients, PTVboost;ERM was 9-40% smaller relative to PTV-
boost;pre-treatment. However, differences between the planned dose before and during 
treatment were minimal due to the fact that overlap of PTVboost;ERM with PRVs remained in 
most patients. V18, which equals an ablative dose, was ≥80% for PTVboost in six patients.
 Some studies have investigated the feasibility of dose escalation in locally advanced 
NSCLC, all with different treatment strategies [13,18,19]. For example, a prospective single 
institution trial examined stereotactic boosting (two fractions of 10 Gy, or three fractions 
of 6.5 Gy) of residual primary tumor <5 cm 1-2 months after chemoradiation (60 Gy). Mean 
coverage of SBRT boost was 96.4%, but was not described for patients individually [18]. 
Disadvantage of this strategy is prolonging of OTT, which is biologically less effective. 
Furthermore, only small tumors were eligible. Delivering three additional SBRT boost 
fractions immediately after 60 Gy results in a minimal prolongation of the OTT and the 
boost dose is not delivered simultaneously with chemotherapy. 
 Another study, the RTOG 1106 study, is an ongoing phase 2 randomised trial 
comparing 60 Gy in thirty fractions (IMRT) versus adaptive radiotherapy to residual tumor 
based on during-treatment 18F-FDG PET (fraction 18-19) to deliver a boost in the final nine 
fractions (2.2-3.8 Gy/fraction) to a maximum total physical dose of 80.4 Gy in thirty 
fractions. Primary goal of this study is to determine whether dose can be escalated to 
improve locoregional control. Contrary to our study, a simultaneously integrated boost 
(SIB) is planned. The SBRT boost may be advantageous over this SIB procedure due to its 
dose inhomogeneity with high Dmax resulting in a higher biologically effective tumor 
dose. 
 Van Elmpt et al reported on the PET-boost randomized phase II trial that randomized 
patients between dose-escalation (IMRT-SIB) of the entire primary tumor or dose-escalation 
of the high FDG uptake region (>50% SUVmax) inside the primary tumor [13]. Mean boost 
dose was 79.2 Gy for the entire tumor and 86.9 Gy for the high FDG uptake area (p=0.001). 
However, in case of overlap of PTV with an OAR, PTV was allowed to have a reduced 
coverage for 15% of the volume. D95-99 for boost volumes were not described. 
 In general, the feasibility of dose escalation fully depends on the accepted dose to 
OAR and related toxicity. For example, it is suggested that the negative result of the RTOG 
0617 trial is due to cardiac toxicity as compliance with normal tissue dose constraints 
was encouraged but not necessary. The effect of heart dose on overall survival is complex. 
It is advised to keep heart V50 <25% [20]. This constraint was met in our study 
(Supplementary material 4). Hepel and colleagues tried to deliver a SBRT boost in two 
fractions with a total boost dose of 16-28 Gy on primary and nodal disease after 50.4 Gy 
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concurrent chemoradiation (phase I dose escalation trial) [19]. There was no dose 
constraint for the proximal bronchial-vascular tree. One of twelve patients (8.3%) died due 
to fatal bronchopulmonary hemorrhage. Dose delivered to 4 cm3 of bronchial-vascular 
tree was substantially higher in this patient: 20.3 Gy (EQD2 53.4 Gy, α/β-value 3 Gy) for SBRT 
boost and total dose of 73.5 Gy (EQD2 105.5 Gy, α/β-value 3 Gy). So, a mediastinal SBRT 
boost may increase the risk of fatal toxicity substantially and therefore a dose constraint to 
the bronchial-vascular tree is mandatory. Our maximum dose of 94 Gy (EQD2) delivered to 
the bronchial-vascular tree PRV is considered safe [13]. Severe late esophageal toxicity 
(stenosis and fistula) is observed in 6% of patients receiving a maximum dose of ≥70 Gy 
[17]. Based on these results we set a maximum of 70 Gy to the esophagus with 0.5 cm 
margin. However, the RTOG 1106 protocol allows a maximum dose of 74-76 Gy.
 Besides the above mentioned issue regarding treatment-related toxicity, some 
technical aspects such as boost volume definition and tumor motion management need 
further discussion. It is not known which segmentation method is optimal for boost 
volume segmentation. Aerts et al. conclude that residual metabolic-active areas after 
(chemo)radiation have a high overlap with pre-treatment volume defined by 50% SUVmax 
[8]. However, defining the boost volume using a threshold of 50% SUVmax may result in too 
large boost volumes because this threshold is in general regarded as a segmentation 
method to quantify 18F-FDG avid areas of the entire tumor [21]. Therefore, it is likely that 
residual metabolic active disease remains within this 50% SUVmax volume. Calais et al. 
propose a 70% SUVmax threshold on pre-treatment 18F-FDG PET/CT scans to define 
treatment resistant tumor subvolumes [10]. This smaller volume will facilitate radiotherapy 
dose escalation. Therefore we decided to use this segmentation method notwithstanding 
that a threshold of 80-90% could be sufficient as well resulting in even smaller boost 
volumes.
 For adequate radiotherapy delivery, determination of tumor movement is important. 
The ERM study by Usmanij et al., however, was performed when four-dimensional 
planning CT was not standard of care yet. Therefore, for this planning study, three-dimen-
sional planning CTs were used. It was therefore not possible to assess individual PTV 
margins for BTVboost such as with the midventilation approach in stereotactic radiotherapy 
[22]. We decided to use a 7 mm PTV margin for BTVboost, as this is a common PTV margin 
for the midventilation concept in our experience. However, in case of implementation of 
this stereotactic boost planning study into clinical practice, a four-dimensional CT should 
be performed for all patients to assess individual PTV margins for the BTVboost [22]. 
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Conclusion
A stereotactic boost to primary tumor subvolumes with initial high or persistent 18F-FDG 
uptake (poor-responding areas) could be planned in combination with 60 Gy concurrent 
chemoradiation. V18, which equals an ablative dose, was ≥80% for PTVboost in six/ten 
patients. Therefore, a stereotactic boost to regions with high 18F-FDG uptake is an 
attractive treatment strategy to optimize NSCLC therapy. Differences between the 
planned dose before and during treatment were minimal due to the fact that the spatial 
relationship of PTVboost;ERM with PRVs remained largely unchanged in most patients. 
However, as an ERM-PET also monitors changes in tumor position, planning the boost on 
the ERM-PET should be considered.
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Supplementary material 1
Radiation treatment planning for PTV60Gy
Both 18F-FDG PET/CTs were transferred to the Pinnacle3 treatment planning system 
(Version 9.10; Philips Radiation Oncology Systems, Fitchburg, WI) and rigid fusion of these 
images with the initial radiotherapy planning CT was performed. The initial gross target 
volume (GTV) had been depicted on the 3 dimensional (3D) radiotherapy planning CT 
using the information of the pre-treatment 18F-FDG PET/CT and consisted of the primary 
tumor and involved lymph nodes. The clinical target volume (CTV) enclosed the GTV of 
the primary tumor and lymph nodes with 10 mm and 5 mm margins, respectively. 
Isotropic expansion of 5 mm of the CTVs created the planning target volume (PTV). Dose 
coverage for all the initially created PTVs was re-planned by an experienced radiation 
treatment planning technician (PvK, 25 years of experience in radiation treatment 
planning). Using a VMAT technique, a prescription dose of 60 Gy in 30 fractions was 
applied, based on our national treatment protocol and ESMO guideline [1]. A standard 10 
MV photon arc beam set-up was used avoiding the contralateral uninvolved lung. 
Predicted dose deposition was calculated using a 3D collapsed-cone convolution 
superposition algorithm. According to the ICRU 50/62 guidelines the -5% and +7% dose 
heterogeneity criteria for the PTV were aimed for [2,3]. Planning parameters for PTV60Gy 
are described in the table below.
1  Eberhardt WEE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally 
advanced stage III non-small-cell lung cancer. Annals of Oncology 2015;26(8):1573-1588
2  Prescribing, recording and reporting photon beam therapy. Report 50. Bethesda: International Commission 
on Radiation Units and Measurements; 1993.
3  Prescribing, recording and reporting photon beam therapy. Report 62; supplement to report 50. Bethesda: 
International Commission on Radiation Units and Measurements; 1999.
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Planning parameters for PTV60Gy
ROI Type Target Gy Volume 
percentage
Weight a
PTV Max dose 63 40
PTV Max dose 61 40
PTV Uniform dose 60 80
PTV Min dose 59.5 100
Contralateral lung minus PTV 
plus 18 mm
Max EUD 7 1 1
Ipsilateral lung minus PTV plus 
18 mm
Max EUD 15 1 1
External minus all ROIs Max DVH 20 5 1
8 mm ring outside PTV (Rout) Max DVH 56 5 1
Spinal cord plus 3 mm Max dose 40 100
4 mm ring inside PTV located 
in lung
Min dose 59 100
4 mm ring inside PTV not 
overlapping with lung and 
esophagus with 2 mm margin
Min dose 59 80
1 cm ring outside Rout Max DVH 50 10 60
Heart outside PTV plus 18 mm Max EUD 15 1 1
Esophagus with 2 mm margin 
outside PTV and Rout
Max dose 37 1
Esophagus with 2 mm margin 
inside PTV and Rout
Max dose 59 1
Brachial plexus Max dose 55  1  
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Supplementary material 4
Heart dose
Patient Heart V50 Heart Dmean
1 4.5 7.9
2 6.6 32.4
3 15.0 19.3
4 7.7 17.6
5 5.2 11.3
6 9.4 11.2
7 5.6 7.5
8 0.0 2.1
9 5.7 17.0
10 12.0 16.1
Mean dose (Dmean) and percentage of heart receiving ≥50 Gy (V50) (summed physical dose) for individual 
patients of total radiation plan (60 Gy treatment plan plus boost planned on early response monitoring 18F-FDG 
PET/CT).
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General discussion and future perspectives
Metabolism of NSCLC histological subtypes
This thesis shows that non-small cell lung cancer (NSCLC) is a heterogeneous set of 
diseases and unravels differences in metabolism between the major NSCLC histological 
subtypes: adenocarcinomas and squamous cell carcinomas. Based on the expression of 
metabolism-related markers, and static and dynamic 18F-FDG PET, it was shown that 
squamous cell carcinomas exhibit a much higher glycolytic rate relative to adenocarcinomas. 
Glycolysis in adenocarcinomas seems to be aerobic, while the very high glycolytic rate 
in squamous cell carcinomas is likely to be principally driven by a hypoxic tumor 
micro environment (anaerobic glycolysis) (chapter 2-5) [1-3]. Squamous cell carcinomas are 
highly glycolytic (high glucose transporter 1 (GLUT1) expression and high 18F-FDG uptake), 
less vascularized and show more often necrosis, while adenocarcinomas demonstrate 
lower GLUT1 expression and a lower phosphorylation rate of glucose under better 
vascularized/perfused (and likely oxygenated) conditions. Moreover, squamous cell 
carcinomas have a more heterogeneous metabolism throughout the tumor, showing 
higher GLUT1 and monocarboxylate transporter 4 (MCT4) expression at larger distance 
from the vasculature, and increased transport and phosphorylation of glucose in areas of 
reduced blood volume. This pattern is less obvious in adenocarcinomas. This is in 
agreement with the level of metabolites, which shows low amounts of glucose and a high 
lactate level for squamous cell carcinomas [4]. Also, mRNA-sequencing gene expression 
profiles demonstrate an elevation of key genes belonging to glycolysis and pentose 
phosphate pathway in squamous cell carcinomas relative to adenocarcinomas [5]. These 
results regarding differences in glucose metabolism could also apply for other tumor 
entities. For example, GLUT1 expression and maximum standardized uptake value 
(SUVmax) on 18F-FDG PET are higher for cervical and esophageal squamous cell carcinomas 
relative to non-squamous cell carcinomas [6-8]. However, the tissue of origin might also 
affect the metabolic pathway [9].
 Another important nutrient for bioenergetics and macromolecular synthesis is 
glutamine, as described in the introduction of this thesis (chapter 1). Glutamine is 
transported across the cell membrane by at least 3 different amino acid transporters: 
sodium-neutral amino acid transporters, alanine-serine-cysteine transporter 2 (ASCT2, 
also called SLC1A5), and large neutral amino acid transporter 1 (LAT1). These transporters 
function as transporters for multiple amino acids. SLC1A5 appears to be the most 
prominent transporter for glutamine uptake in many cancer cells, including lung cancer 
[10-12]. Based on the mRNA and protein level of SLC1A5 and glutaminases, our findings 
suggest a higher glutamine usage in adenocarcinomes relative to squamous cell 
carcinomas, in contrary to the results of others who demonstrated that SLC1A5 expression 
and a glutaminolytic profile (i.e. high amount of glutamate and glutathione) are associated 
with squamous cell histology [4,10,11,13]. Regarding the higher proliferative rate in 
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squamous cell NSCLCs requiring more macromolecules, a higher glutamine consumption 
in this histology compared to adenocarcinomas is plausible. However, transporter and 
enzyme expression might not reflect the functional activation status. Functional imaging 
of glutamine metabolism is currently under investigation. Two glutamine tracers 
(5-11C-(2S)-glutamine (11C-Gln) and 18F-(2S,4R)4-fluoroglutamine (18F-(2S,4R)4-FGln)) are 
useful for probing in vivo metabolism of glutamine in cancer cells [12]. In lung and 
colorectal carcinoma xenograft tumors, the uptake of 18F-(2S,4R)4-FGln correlates with 
SLC1A5 expression assessed by histology and immunoblotting analysis [14]. 18F-(2S,4R)4-
FGln accumulation was significantly elevated in spontaneously arisen lung tumors of 
genetically engineered mice, relative to normal lung and cardiac tissues [14]. In an in vivo 
mice study, 11C-Gln uptake was higher in a squamous cell carcinoma than an adeno-
carcinoma (although both n=1) [15]. Thus far, no human imaging studies of 11C-Gln have 
been reported, likely because of the short physical half-life and complicated radiolabeling 
and purification steps. 18F-(2S,4R)4-FGln uptake was assessed in a preliminary human 
glutamine PET trial of 25 patients with solid tumors, in which, however, only one lung 
cancer patient was examined. This lung tumor did show avidity for 18F-(2S,4R)4-FGln [16]. 
It would be of interest to study the uptake of glutamine tracers in NSCLC patients to 
validate the mRNA and protein expression profiles, and to get more insight in glutamine 
metabolism of adeno- versus squamous cell NSCLC. 
 Despite the statistical differences in metabolic indices between the major NSCLC 
histological subtypes described in chapter 2-5, these data show overlap between the 
different tumor types. In line with this, response patterns to inhibition of glycolysis and/or 
glutamine metabolism are not related to histology in NSCLC cell lines (chapter 7). So, this 
distinction in tumor metabolism between adeno- and squamous cell NSCLCs is likely to 
be a simplified representation of reality, as genetic and environmental parameters 
influence the phenotype and thus cell metabolism resulting in metabolic heterogeneity. 
Hypoxia and tumor acidosis fluctuate with time and may influence metabolism in specific 
tumor areas at a given time [17]. Stable isotopes (e.g. 13C) can be used to investigate 
cellular metabolism, because 13C enrichment downstream of the labeled nutrient informs 
about the metabolic route. Hensley et al. infused nine NSCLC patients intraoperatively 
with 13C-glucose to compare glucose metabolism between tumors and normal lung 
tissue [18]. Histology of these tumors were adenocarcinoma (n=7 (solid: n=1; acinar: n=2; 
papillary: n=2; acinar/papillary: n=1; mixed: n=1)), squamous cell carcinoma (n=1) and large 
cell neuro-endocrine carcinoma (n=1). Lactate was more enriched in tumor than normal 
lung tissue, indicating a greater propensity to convert 13C-glucose to 13C-lactate for tumor 
tissue than non-cancerous lung. Also, several metabolites related to the tricarboxylic acid 
(TCA) cycle were more present in tumors, reflecting enhanced TCA cycle activity relative 
to normal lung tissue. Furthermore, they suggest other nutrients including lactate as a 
potential carbon source for the TCA cycle, especially in well-perfused tumor regions. 
Metabolic heterogeneity was identified between but also within lung tumors [18]. This 
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metabolic heterogeneity is also reflected by the differential GLUT1 expression within 
adenocarcinoma subclassifications, described in chapter 4. 
 Also, metabolic flexibility might exist in tumor cells to adapt to changes in nutrient 
availability. In chapter 7 it is described that two of six NSCLC cell lines (HCC827 
(adenocarcinoma) and H292 (squamous cell carcinomas)) are able to compensate for 
inhibition of both glucose and glutamine metabolism. Besides glucose and glutamine, 
fatty acids can be an important nutrient for tumor cells, as fatty acids can contribute to 
acetyl-CoA generation to fuel mitochondrial respiration [17]. Indeed, these cell lines show 
a substantial increase in basal respiration when exposed to glucose-free medium 
containing fatty acids relative to medium containing glucose, indicating that H292 and 
HCC827 cells are able to survive inhibition of glucose and glutamine metabolism by 
fueling fatty acids in mitochondrial respiration. A study performed in vitro and in vivo in 
mice shows that GLUT1 knockdown in HCC95 and HCC1588 (squamous cell carcinoma cell 
lines) suppresses proliferation, induces apoptosis, lowers intracellular ATP and NAD(P)H, 
and inhibits tumor growth. In contrast, GLUT1 knockdown in adenocarcinoma cell lines 
A549 and H522 only moderately suppresses proliferation with no induction of apoptosis, 
does not affect intracellular ATP, and does not delay tumor growth, supporting that other 
metabolic pathways within some adenocarcinomas are able to maintain bioenergetics 
and cellular viability under low glucose conditions [5]. Genes associated with fatty acid/
lipid transport and metabolism are highly expressed in adenocarcinomas relative to 
squamous cell carcinomas (patient study) [19]. In another patient cohort, Nuclear Magnetic 
Resonance (NMR) spectroscopy shows that metabolic alterations in adenocarcinomas are 
related to phospholipid metabolism [4]. In this respect, adenocarcinomas mostly originate 
from alveolar type 2 cells, which use lipid metabolism for surfactant production [19]. 
However, differential use of fatty acids in adeno- versus squamous cell carcinomas could 
not be demonstrated in our panel of NSCLC cell lines (chapter 7). 
 Relevance and consequences of the metabolic diversity among NSCLC histological 
subtypes for 18F-FDG PET interpretation, prognosis, metabolic targeting and future 
perspectives in clinical practice will be further discussed here. 
Prognostic value of metabolism-related markers and 18F-FDG PET 
in relation to histology
The differences in glucose metabolism between adeno- and squamous cell NSCLC affect 
18F-FDG PET interpretation and prognosis in the clinic. As described in chapter 3, 18F-FDG 
PET imaging has stronger prognostic value if histology is incorporated in the interpretation 
of this imaging modality. Although squamous cell carcinomas exhibit higher 18F-FDG 
uptake than adenocarcinomas, which is regarded as a poor prognostic factor, adeno-
carcinomas have a higher metastatic potential and a worse disease-free survival (DFS) [3]. 
In contrast, progressive localized disease is more often found for squamous cell histology 
[20]. In curatively resected patients, high 18F-FDG uptake correlates with a worse DFS in 
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adenocarcinomas, but not in squamous cell carcinomas [3,21]. In line with this, high GLUT1 
expression indicates aggressive tumor behavior in only adenocarcinomas, as shown by 
the association with positive lymph nodes at diagnosis, poor differentiation grade and a 
significantly worse DFS (chapter 2) [2]. Furthermore, GLUT1 expression and 18F-FDG uptake 
are highest in predominantly micropapillary and solid adenocarcinomas (chapter 4) 
[22,23], which have a more aggressive biological behavior with early distant metastasis 
and a worse survival relative to predominantly lepidic, acinar and papillary subtypes [24]. 
So, it could be that especially these adenocarcinoma subclassifications give rise to the 
association of high GLUT1 expression and 18F-FDG uptake with worse survival. Our cohort 
of lung cancer patients was too small to perform a multivariate analysis. In other patient 
cohorts, GLUT1 positivity is an independent risk factor for a worse survival rate in only lung 
adenocarcinoma patients, but adenocarcinoma subclassification was not a variable in 
these analyses [22,25]. Four studies provide multivariate analysis of maximum standardized 
uptake value (SUVmax) on DFS for adenocarcinoma patients, with a pooled hazard ratio 
(HR) of 2.92 (95% confidence interval: 1.19-7.17, p=0.005) [26]. These findings are also 
observed for adeno- and squamous cell carcinomas of the cervix and esophagus. Adeno-
carcinomas of these tumor entities have a higher potential to metastasize relative to 
squamous cell carcinomas, and metabolic tumor volume on 18F-FDG PET is of prognostic 
value only for esophageal adenocarcinomas [8,27,28]. 
 In chapter 4, it is described that SLC1A5 protein expression is significantly higher in 
adenocarcinomas with lymph node metastases at diagnosis compared to node negative 
tumors and in adenocarcinomas with worse pTNM stage. Furthermore, SLC1A5 mRNA 
expression correlates with tumor size in this histology. In another study of NSCLC adeno-
carcinomas, SLC1A5 expression also correlated with advanced tumor stage and lymph 
node metastasis [29]. In our cohort of NSCLC patients, expression of markers related to 
glutamine metabolism was not associated with a poor survival. However, others 
demonstrated that SLC1A5 expression is an independent marker of poor overall survival 
for patients with surgically resected adenocarcinoma, while this is not observed for 
squamous cell NSCLCs [29]. All these findings indicate more aggressive tumor behavior 
upon higher SLC1A5 expression only in adenocarcinomas. 
Metabolic targeting: what to target?
As a multitude of transporters and enzymes are involved in glucose and glutamine 
metabolism, these could theoretically all serve as a therapeutic  target. In chapter 7, 
lonidamine (hexokinase 2 inhibitor) and 968 (glutaminase C (GAC) inhibitor) were 
examined in six NSCLC cell lines under the assumption that targeting ‘at the beginning’ of 
the metabolic route has the most pronounced effect. For example, by inhibiting 
hexokinase, both glycolysis and the pentose phosphate pathway are blocked. However, 
several isoforms exist for most transporters and enzymes, like GLUT1 and GLUT3, 
glutaminase 1 and 2 including splice variants, and hexokinase 1 and 2 [30]. While GLUT1 is 
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for example by far the most significantly expressed glucose transporter in NSCLC [5], 
when blocking GLUT1, tumor cells might adapt through upregulation of other isoforms. 
Also, tumor cells can switch to other nutrients to fuel metabolism in case of inhibition of 
only glycolysis or glutamine metabolism, as was observed for SW900 and H23 cell lines 
(chapter 7). Thereby, dual blockage is likely to be necessary for most tumors. Moreover, 
some tumors are able to fuel fatty acids in mitochondrial respiration in case of inhibition 
of both glucose and glutamine metabolism, as was seen for H292 and HCC827 cell lines 
(chapter 7). So, for some tumors triple targeting of glycolysis, glutamine and fatty acid 
metabolism might be required. Despite the fact that metabolic transporters and enzymes 
are upregulated in tumor versus normal tissue [30], all these transporters and enzymes are 
also required for normal cellular metabolism. For example, the brain is highly dependent 
on glucose for its energy metabolism. Glutaminase 1 is highly expressed in normal kidney 
tissue, and glutaminase 2 in normal liver tissue. The splice variant of glutaminase 1, GAC, 
is more tumor-specific and is essential for cancer cell growth in NSCLC [31,32]. Taking this 
all together, targeting tumor metabolism is quite complex and toxicity is one of the 
concerns, certainly for dual or triple targeting of glucose, glutamine and fatty acid 
metabolism. Selective targeting of only tumors cells is required to reduce toxicity. 
For example, paclitaxel/lonidamine loaded EGFR-targeted nanoparticles were tested in 
a breast cancer model in nude mice. This nanocarrier system showed superior efficacy 
relative to treatment in solution form and was considerably less toxic [33]. Other nanocarrier 
systems will only release the drugs they contain in specific pH ranges. The pH of tumors is 
around 6.8, while normal tissue has a pH of around 7.4. An acidic environment degrades 
the structure of the nanocarrier, thereby releasing the drug [34].
 Daily administration of 2-deoxyglucose (competitive inhibitor of hexokinase) in 
combination with docetaxel has been tested in 34 patients with advanced/metastatic 
NSCLC (n=7), breast, gastric, pancreatic and head and neck cancer in a phase I dose escalation 
trial (NCT00096707) [35]. The most common adverse events were fatigue, sweating, 
dizziness and nausea mimicking hypoglycemic symptoms. Adverse events at higher 
doses (63-88 mg/kg) were confusion, weakness and dizziness in all patients indicating a 
significant block of glycolysis, gastro intestinal bleeding (6%) and reversible grade 3 QTc 
prolongation (22%). Maximum tolerated dose of 2-deoxyglucose was 63 mg/kg/day [35]. 
Myalgia (15%), asthenia (6%), testicular pain (1.5%), loss of appetite (6%) and joint pain (3%) 
are the most common grade 3 toxicities of lonidamine 450-900 mg/day [36]. Dose-limiting 
toxicity of lonidamine is skeletal muscle discomfort and a dose of 250-300 mg/m2/day is 
tolerated well [37]. GAC inhibition by 968 (5-(3-Bromo-4-(dimethylamino)phenyl)-2,2- 
dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one) is not yet tested in phase I 
clinical trials. CB-839, an inhibitor of the glutaminase 1 splice variants kidney-type (KGA) 
and GAC, is currently tested in several phase 1-2 studies in hematological and metastatic 
solid tumors including NSCLC [38]. Two studies involving hematological tumors are 
complete but results are not yet available [38].
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Challenges in radiotherapy dose escalation based on 18F-FDG PET
Concurrent chemoradiotherapy for locally advanced NSCLC results in an improved overall 
survival compared to sequential chemoradiotherapy or radiotherapy alone, which is 
mainly attributed to a better local tumor control [39,40]. Still, 1- and 2-year local failure 
rates are 16% and 26% respectively. Rates of regional failure at 1- and 2 year are lower (8% 
and 14% respectively), due to the difference in volume of the primary tumor and involved 
lymph nodes [41]. Lack of locoregional disease control leads to death from local progression 
and/or subsequent distante site seeding [42]. So, one could explore new radiotherapy 
strategies with different prescription doses to the primary tumor and involved lymph 
nodes to improve treatment for irresectable stage III NSCLC. One of the possibilities is 
radiotherapy dose escalation directed towards 18F-FDG PET–based resistant primary 
tumor areas combined with chemoradiation, an approach examined in the planning 
study described in chapter 8. The maximum achievable dose escalation by using a 
stereotactic boost directed to radioresistant subvolumes of the primary tumor as 
determined by an 18F-FDG PET/CT before start of chemoradiation (pre-treatment PET) and 
an early response monitoring 18F-FDG PET/CT (ERM-PET) was compared in this study. 
Stereotactic body radiotherapy (SBRT) delivers very conformal high radiation doses 
resulting in excellent local control rates (>85-90%) with low toxicity in inoperable stage I-II 
NSCLC patients [43,44]. A biologically effective dose (BED) prescription of at least 100 Gy 
(i.e. ≥84 Gy equivalent dose in 2 Gy fractions (EQD2)) is required for acceptable tumor 
control probability [44,45]. It was possible to plan a substantial stereotactic radiation boost 
to primary tumor subvolumes with initial high or persistent 18F-FDG uptake (poor- 
responding areas) in combination with 60 Gy concurrent chemoradiation without 
exceeding the dose constraints for the organs at risk. The median dose (EQD2) covering 
95% of the boost planning target volume (D95) based on ERM-PET (PTVboost;ERM) was 18 
Gy (range 6-32 Gy), which in total allowed a median EQD2 of 78 Gy (range 66-92 Gy), 
compared to 60-66 Gy obtained with a standard radiotherapy schedule of 2 Gy per 
fraction. Boost volume receiving a physical boost dose of ≥18 Gy (V18), which equals a 
EQD2 of ≥84 Gy, was ≥80% for PTVboost;ERM in six/ten patients. Differences between the 
planned dose before and during treatment were minimal due to the fact that the spatial 
relationship of PTVboost;ERM with organs at risk remained largely unchanged in most 
patients. However, as an ERM-PET also monitors changes in tumor position, planning 
the boost on the ERM-PET should be considered. Despite the fact that a stereotactic 
boost to regions with residual high 18F-FDG uptake is an attractive treatment strategy to 
optimize therapy for locally advanced NSCLC, several challenges regarding this treatment 
strategy require discussion. Firstly, identification of patients and tumor sites (i.e. primary 
tumor and/or involved lymph nodes) that benefit most from dose escalation, and 
secondly, identifying the radioresistant subvolume of the tumor. Lastly, effective therapy 
escalation must be administered without a substantial increase in toxicity.
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Patient and tumor site selection for radiotherapy dose escalation
Usmanij et al. have shown that patients with a poor metabolic response on ERM-PET have 
a worse progression-free survival compared to early metabolic responders [46]. Therefore, 
it seems reasonable that these poor metabolic responders benefit most from a stereotactic 
boost, and for this reason these patients were selected for the planning study (chapter 8). 
Albain et al. have shown that patients with advanced stage NSCLC without disease 
progression on computed tomography (CT) after 45 Gy concurrent chemoradiation 
benefit from local treatment (lobectomy) in terms of overall survival relative to continuation 
of chemoradiotherapy up to 61 Gy [47]. However, a lot of patients are inoperable owing to 
comorbidity or tumors are still irresectable after initial treatment due to tumor location. 
An SBRT boost with a total BED ≥100 Gy can be considered as a good alternative for this 
surgical approach. In the study of Albain et al., patients underwent complete surgical 
resection including mediastinal lymph node dissection 3-5 weeks after completion of 
chemoradiotherapy [47]. Patients allocated to surgery received 45 Gy radiotherapy instead 
of full dose radiotherapy, resulting in a pathological complete response of mediastinal 
lymph nodes of only 38%. So, no further mediastinal treatment is likely to be insufficient 
by using this treatment strategy. In the proposed treatment strategy described in chapter 
8, involved mediastinal lymph node receive standard radiotherapy dose up to 60 Gy. In 
this setting, the risk of local failure is much higher than regional failure [41]. However, a 
secondary analysis of the ACRIN 6668/RTOG 0235 trial demonstrates that residual PET 
avidity in lymph nodes approximately 14 weeks after concurrent chemoradiation using 
radiation dosis ≥60 Gy independently predicts locoregional failure without affecting 
overall survival [48]. Nevertheless, delivering a stereotactic boost to mediastinal sites will 
substantially increase the risk of grade 5 toxicity, as will be explained below. For this reason, 
only boosting the primary tumor is proposed in chapter 8.
 Also histology could influence the decision to apply a boost. In general, squamous 
cell carcinomas present with larger and more hypoxic tumors compared to adenocarcino-
mas [3]. Frequency of local recurrence is much higher in squamous cell carcinomas (66%) 
than adenocarcinomas (10%) [20,49], which was however not confirmed in another patient 
cohort [41]. Furthermore, adenocarcinomas have a much higher potential to metastasize 
[3]: 53% of adenocarcinomas demonstrate distant metastases at diagnosis versus 27% of 
squamous cell carcinomas (paper in concept, E.A. Usmanij et al). So, especially squamous 
cell carcinomas may benefit from dose escalation, while adenocarcinomas may require 
intensification of systemic treatment.
Identifying the radioresistant subvolume
Aerts et al. demonstrated that residual metabolic-active areas three months after (chemo)
radiation have a high overlap with pre-treatment volume defined by 50% SUVmax [50,51]. 
This suggests that FDG avid areas are radioresistant and are spatially consistent throughout 
the course of treatment. However, a recently published study found contradicting results 
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and showed that FDG spatial consistency is highly variable among patients three months 
post-treatment, with a median overlap fraction of only 0.63 (range 0-1) [52]. 18F-FDG PET 
scan 3 months after radiotherapy may represent treatment-induced inflammation instead 
of residual disease. Overlap fraction of 18F-FDG uptake 10 days after radiotherapy (defined 
as ≥80% SUVmax) with pre-treatment 18F-FDG uptake (defined as ≥50% SUVmax) is higher 
(0.8) [53]. These findings imply that an 18F-FDG PET scan can select the radioresistant 
subvolume. However, it is not known which segmentation method is optimal for boost 
volume segmentation. Defining the boost volume using a threshold of 50% SUVmax as 
proposed by Aerts et al. and applied in the PET boost trial may result in too large boost 
volumes because this threshold is in general regarded as a segmentation method to 
quantify 18F-FDG avid areas of the entire tumor [50,51,54,55]. Therefore, it is likely that 
residual metabolic active disease remains within this 50% SUVmax volume. Calais et al. 
propose a 70% SUVmax threshold on pre-treatment 18F-FDG PET/CT scans to define 
treatment resistant tumor subvolumes [49]. This smaller volume will facilitate radiotherapy 
dose escalation. Therefore this segmentation method was used in chapter 8, notwith-
standing that a threshold of 80-90% could be sufficient as well, resulting in even smaller 
boost volumes that consequently are easier to apply.
Toxicity of dose escalation
The RTOG 0617 trial showed that dose escalation up to 74 Gy for the entire target volume 
resulted in a lower overall survival compared with the standard radiotherapy dose of 
60 Gy in the control arm [56]. This may be the result of toxicity as older (less conformal) 
radiotherapy techniques were allowed, and compliance with normal tissue dose 
constraints and use of image-guided radiation therapy were encouraged but not 
mandatory in this trial. It was concluded from a secondary analysis of the RTOG 0617 trial 
that intensity-modulated radiation therapy (IMRT) was associated with lower rates of 
≥ grade 3 pneumonitis (7.9% versus 3.5%) and lower cardiac doses than three-dimensional 
conformal radiotherapy (3D-CRT), despite the fact that the IMRT group had larger planning 
treatment volumes (PTV) and the volume of the heart inside the PTV was not different. 
The volume of the heart receiving 40 Gy (V40) was significantly associated with overall 
survival, while radiotherapy technique did not influence survival [57]. Another study found 
a substantially lower overall survival for a heart V50 of >25% [58]. A recently published 
safety analysis of a randomized phase II trial reporting on 36 patients shows that 
dose-escalated concurrent chemoradiotherapy to a maximum of 84 Gy (in 2 Gy fractions, 
6 fractions/week; the amount of additional fractions depended on normal tissue 
constraints) delivered to primary tumor and nodal disease is hazardous, with high risk of 
excessive toxicity, resulting in a worse overall survival relative to 68 Gy chemoradiation 
(in 2 Gy fractions; 5 fractions/week) [59]. Lung V20 had to be <35-50% depending on lung 
function, and a maximum of 30% of the circumference of the esophagus was allowed to 
receive a dose of 78 Gy with a mean esophageal dose of <45 Gy. Seventy-two percent of 
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patients received 84 Gy. Five grade 5 reactions ocurred in the dose-escalated arm 
including esophageal perforation (n=3) and pneumonitis (n=2) in contrast to one fatal 
esophageal perforation and one fatal pneumonitis in the standard arm [59]. Based on 
these results, the trial was prematurely terminated.
 So, dose escalation of the entire tumor volume is not the way to go. The approach 
described in chapter 8 of this thesis overcomes these issues by using PET to select patients 
for intensification of treatment and to depict the more treatment resistant subvolume of 
the primary tumor that requires a radiation boost. By decreasing the boost volume, by 
using a highly conformal SBRT technique and by applying strict dose constraints for 
organs at risk, a substantial dose escalation in a few fractions can be planned, which 
theoretically leads to an increase in local control. In three of ten patients in this planning 
study, the maximum allowed dose of 70 Gy (EQD2) to the esophagus hampered further 
dose escalation of the boost volume (chapter 8). V76 (EQD2) of the esophagus is a predictor 
for developing severe late esophageal toxicity; V76 of 7% results in a 5% risk of esophageal 
stenosis, perforation or trachea-esophagel fistulas [60]. So, a maximum allowed dose of 70 
Gy (EQD2) for the esophagus is considered quite safe. Also the RTOG 1106 protocol allows 
a maximum dose of 74-76 Gy to the esophagus. Hepel and colleagues tried to deliver a 
SBRT boost in two fractions with a total boost dose of 16-28 Gy on residual primary and 
nodal disease after 50.4 Gy concurrent chemoradiation (phase I dose escalation trial) [61]. 
Presence of residual disease was based on a CT-scan. There was no dose constraint for the 
proximal bronchial-vascular tree. One of twelve patients (8.3%) died due to fatal broncho-
pulmonary hemorrhage. Dose delivered to 4 cm3 of bronchial-vascular tree was 
substantially higher in this patient: 20.3 Gy (EQD2 53.4 Gy, BED 89 Gy, α/β-value 3 Gy) for 
SBRT boost and total dose of 73.5 Gy (EQD2 105.5 Gy, BED 175.9 Gy, α/β-value 3 Gy) [61]. In 
another phase I safety clinical trial, a SBRT boost was delivered to remaining gross disease 
(based on CT) at the primary site and involved mediastinal lymph nodes after 44 Gy (2 Gy 
per day) concurrent chemoradiotherapy to determine the maximum tolerated dose. Four 
boost dose cohorts were tested: 2 fractions of 9 Gy (n=3), 2 fractions of 10 Gy (n=6), 5 
fractions of 6 Gy (n=3), and 5 fractions of 7 Gy (n=3). In the cohorts treated with 5 fractions, 
resulting in a total BED of >100 Gy (α/β-value 10 Gy), one fatal tracheoesophageal fistula 
and one fatal hemoptysis occurred [41]. By taking this into account combined with a 
maximum tolerable dose of 70-74 Gy for the esophagus, a mediastinal SBRT boost after a 
standard schedule of 60-66 Gy chemoradiation seems not to be feasible and may increase 
the risk of fatal toxicity substantially. Also, we would not opt for de-escalating the dose to 
44-50.4 Gy for the total planning target volume (i.e. primary tumor and involved lymph 
nodes with margin) like in the trials of Hepel and Higgings, as a dose of at least 60 Gy is 
recommended for the treatment of stage III NSCLC [61-63]. In the PET boost randomized 
phase II trial, investigating dose-escalation to the entire primary tumour or redistributed 
to primary tumor regions with high pre-treatment FDG uptake >50% SUVmax, 4.9% of 
patients died due to pulmonary haemorrhage and 3.9% due to fistula. Patients with fatal 
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pulmonary haemorrhages all had centrally located tumours with encasement of large 
vessels. Normal Tissue Complication Probability (NTCP) modeling was not described in 
this study and there is currently no agreement regarding dose constraints of the airways 
and blood vessels, but caution may be warranted for boosting centrally located tumors 
with >50% encasement of large vessels [64].
Future perspectives
Resectable stage I-IIIA NSCLC
In surgically resected adenocarcinoma NSCLCs, GLUT1 and SLC1A5 expression, and 
18F-FDG uptake are associated with aggressive tumor behavior and worse survival, but not 
in squamous cell NSCLC (chapter 2-4) [2,3,25,29]. So, adenocarcinoma lung cancer patients 
with high expression of one or both markers and/or high 18F-FDG uptake might benefit 
from intensification of systemic treatment in the adjuvant setting, for example by 
inhibition of tumor metabolism. The patient cohorts described in chapter 2-5 were too 
small to perform multivariate analysis to examine whether GLUT1 expression and 18F-FDG 
uptake are independent predictors of DFS in adenocarcinoma NSCLC, or just a surrogate 
of poorly differentiated tumors and/or predominantly solid adenocarcinomas. To validate 
these results of the prognostic potential of metabolism-related markers in relation to 
histology and to define cut-off points guiding intensification of systemic treatment, a 
larger patient cohort should be investigated in a prospective observational study. Adding 
18F-(2S,4R)4-FGln-PET to this panel of markers would be of interest. As DFS was better for 
squamous cell carcinomas relative to adenocarcinomas and metabolism-related markers 
did not correlate with a worse survival in squamous cell NSCLC, intensification of systemic 
treatment by metabolic inhibition is unlikely to have added value for this histology.
 Lonidamine monotherapy at a substantial dose decreased cancer cell growth, but 
cells remained viable and treatment did not result in increased cytotoxicity in all six NSCLC 
cell lines described in chapter 7. Two cell lines survived blockage of both glucose and 
glutamine metabolism, in two cell lines treatment with 968 monotherapy (glutaminase 
inhibitor) was very cytotoxic, and in two cell lines a severe cytotoxic effect was observed 
for combination treatment but not for monotherapy with lonidamine or 968. This metabolic 
heterogeneity and flexibility may explain the contradicting results of earlier trials. Treatment 
with lonidamine as single agent at doses ranging from 450-900 mg/day resulted in a 
partial response in only 10% of NSCLC patients [36]. So, based on our in vitro data (chapter 
7) and these clinical data, lonidamine monotherapy is not sufficient. In a randomized 
clinical trial (performed in 1990-1993) comparing chemotherapy (cisplatin, epirubicin, and 
vindesine) with chemotherapy plus lonidamine 450 mg/day until tumor progression in 
metastatic NSCLC patients demonstrated an increase in overall response rate with the 
addition of lonidamine (17% versus 39%), and an improvement in median time to progression (5 
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versus 8 months) and median survival time (7.6 versus 11 months) [65]. However, another 
study could not confirm these positive effects of lonidamine [66,67]. So, metabolic 
inhibition (combined with chemotherapy) in the adjuvant setting of resectable stage I-IIIA 
NSCLC can only have an additive value by individualizing treatment and predictive 
markers are required. As suggested in chapter 7, GAC expression might predict sensitivity 
to glutaminase inhibition, and KRAS mutational status could imply that inhibition of both 
glucose and glutamine metabolism is needed. Future research has to explore the potential 
of these markers to predict sensitivity to treatment. Furthermore, the toxicity profile of 
inhibition of both glycolysis and glutamine metabolism should be thoroughly investigated.
 The PACIFIC trial showed a significantly longer 1-year progression-free survival for 
durvalumab (anti-programmed death ligand 1 antibody) after chemoradiotherapy in 
stage III NSCLC relative to no consolidation therapy (56% versus 35%), a longer median 
time to death or distant metastasis (28.3 months versus 16.2 months), and an improved 
2-year overall survival (66.3% versus 55.6%) [68,69]. Immunotherapy (durvalumab) is 
currently investigated as adjuvant therapy in completely resected primary stage IB (≥4 
cm), II and IIIA NSCLC patients (NVALT-24 study). As lactate contributes to the immunologic 
escape of tumors cells (chapter 6), glycolysis inhibition could improve the efficacy of 
immunotherapy. This would be an interesting area for future research.
Irresectable stage III NSCLC
This combination of immunotherapy with metabolic inhibition is also of interest for future 
studies as adjuvant therapy after chemoradiation in stage III NSCLC. Regarding inhibiting 
metabolism concurrent with radiotherapy, one should be cautious with this combination 
for all NSCLCs in view of the results described in chapter 7. The combination of 10 μM 968 
and 150 μM lonidamine resulted in such cytotoxic effects in H1975, SW900, H520 and H23 
tumor cells that demonstrating an additive effect of radiation to this combination was not 
possible for these cell lines. Combining 150 μM lonidamine or 10 μM 968 monotherapy 
with radiotherapy might even result in radioresistance in these cell lines. Future in vitro 
studies should examine the radiosensitizing effect of a lower compound dose of 968 and 
lonidamine. In only two of six NSCLC cell lines (H292 and HCC827), 968 and especially 
lonidamine increased sensitivity to radiotherapy. Likely, predictive biomarkers to select 
the right patients for the right treatment combination are required. These in vitro 
experiments should be repeated under hypoxic circumstances, as metabolic inhibition 
likely decreases oxygen consumption of tumor cells thereby diminishing hypoxia. As 
hypoxia causes radioresistance, metabolic inhibition could improve radiotherapy efficacy 
under hypoxic circumstances.
 Treatment for stage III NSCLC patients with a poor response to chemoradiation could 
also be optimized by radiotherapy dose escalation by using an SBRT boost directed 
towards 18F-FDG PET–based resistant primary tumor areas combined with chemoradiation. 
A randomized phase trial is required to answer this question. Local control and survival in 
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relation to histology should be assessed. It would be of interest to examine whether a 
proton boost is advantageous over a boost by using photons in terms of coverage of the 
PTVboost, and dose to organs at risk and toxicity. Currently, the NIvolumab COmbination 
with standard first-line chemotherapy and radiotherapy in Locally Advanced Stage IIIA/B 
NSCLC (NICOLAS) trial is ongoing, examining the tolerability and efficacy of this treatment 
combination (NCT02434081) [38]. However, preclinical data support that compared to 
daily fractionated low dose radiotherapy, high-dose hypofractionated radiation promotes 
anti-tumor immunity to control primary and distant tumors when combined with 
programmed cell death receptor 1 (PD-1) blockade [70]. So, immunotherapy combined 
with the proposed SBRT boost in stage III NSCLC would be an interesting treatment 
strategy to examine in the future. As lactate negatively influences the function of immune 
cells (chapter 6), adding glycolysis inhibition to this combination is of further interest.
Concluding remarks
NSCLC is a heterogeneous disease regarding biological and metabolic behavior. Expression 
of metabolism-related markers and 18F-FDG uptake differ among the major NSCLC 
histological subtypes: adenocarcinomas and squamous cell carcinomas. Although 
squamous cell carcinomas have a higher GLUT1 expression and 18F-FDG uptake than 
adeno carcinomas, regarded as a poor prognostic factor, curatively resected adeno-
carcinomas have a higher potential to metastasize and a worse DFS compared to curatively 
resected squamous cell carcinomas. 18F-FDG PET imaging and GLUT1 expression have 
stronger prognostic value if results are interpreted in relation to histology. As GLUT1 and 
SLC1A5 expression and 18F-FDG uptake correlate with aggressive behavior in adeno-
carcinomas, these metabolism-related markers may guide intensification of systemic 
treatment in curatively resected stage I-IIIA adenocarcinoma, for example by inhibition of 
tumor metabolism combined with immunotherapy.
 Squamous cell carcinomas are highly glycolytic, are less vascularized, show more 
often necrosis, and progressive localized disease is more often found for this histology. 
This anaerobic glycolytic phenotype implies radioresistant subareas requiring intensification 
of local therapy in poor-responding irresectable stage III squamous cell carcinoma, 
for example by using an SBRT boost directed towards 18F-FDG PET–based resistant primary 
tumor areas after chemoradiation, combined with metabolic inhibition and/or immuno-
therapy. Based on our in vitro results it can be concluded that only a part of NSCLC patients 
may benefit from the combination of radiation therapy and metabolic inhibition. Some 
NSCLC might even become more radioresistant when combining metabolic inhibition 
with radiotherapy. Therefore, to be able to implement metabolic inhibition in combination 
with radiotherapy into the clinic, predictive markers are required to personalize treatment.
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Summary
Lung cancer is a leading cause of cancer related death. Approximately 20% of patients 
with non-small cell lung cancr (NSCLC) are potentially curable with surgery (stage I – 
resectable stage IIIA), but about half of those die due to recurrent disease. Irresectable 
stage III NSCLC can be treated with concurrent or sequential chemoradiation. 
Immunotherapy is an important new asset in the therapeutic armamentarium of this 
disease. Despite intensive therapy, prognosis remains poor. Locoregional progression and 
certainly the occurrence of distant metastases remain a major issue. Therefore, further in-
tensification of treatment may be required in these patients. Intervention in the 
tumor-specific reprogrammed metabolism as a hallmark of cancer might be an approach 
to target NSCLC subsets. This metabolic transformation is the result of complex interactions 
between a hypoxic tumor microenvironment and oncogenic mutations. In this PhD 
thesis, the metabolic and mutational landscape of the major NSCLC histological subtypes, 
adenocarcinomas and squamous cell carcinomas, was unraveled. Furthermore, the 
prognostic value of differences in metabolism and targets for therapy were examined. 
The results can be used to further personalize treatment.
Metabolism and mutational status of NSCLC histological subtypes
Chapters 2-5 describe tumor glucose metabolism in the major NSCLC histological 
subtypes, adenocarcinomas and squamous cell carcinomas, according to expression of 
several metabolism-related markers on the mRNA and protein level, and static and 
dynamic 18-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET). Based 
on these markers and 18F-FDG PET, we showed that squamous cell carcinomas exhibit a 
much higher glycolytic rate relative to adenocarcinomas. Glycolysis in adenocarcinomas 
seems to be predominantly aerobic, while the very high glycolytic rate in squamous cell 
carcinomas is likely to be principally driven by a hypoxic tumor microenvironment 
(anaerobic glycolysis). Squamous cell NSCLCs are phenotypically characterized by a 
hypoxic tumor microenvironment: squamous cell carcinomas have a poor vascularization 
(low vascular density and low blood volume fraction on dynamic 18F-FDG PET) with often 
necrosis, and are highly glycolytic (high glucose transporter 1 (GLUT1) expression and high 
18F-FDG uptake with a high rate constant of cytoplasmic phosphorylation of 18F-FDG on 
dynamic 18F-FDG PET). Furthermore, squamous cell carcinomas express GLUT1 and mo-
nocarboxylate transporter 4 (MCT4) in a hypoxia-related pattern, and show increased 
transport and phosphorylation of glucose in areas of reduced blood volume on dynamic 
18F-FDG PET. In contrast, adenocarcinomas demonstrate lower GLUT1 expression, lower 
18F-FDG uptake and a lower phosphorylation rate of glucose under better vascularized/
perfused (and likely oxygenated) conditions (high vascular density and high blood volume 
fraction on dynamic 18F-FDG PET). GLUT1 and MCT4 are expressed in a non-hypoxia-rela-
ted pattern in this histology. 
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Chapter 4 examines the association of the expression of glucose and glutamine metabo-
lism-related markers with several oncogenic mutations in NSCLC. TP53 and PIK3CA 
mutations are more often found in squamous cell carcinomas than adenocarcinomas 
(97.4% versus 71.2% and 10.5% versus 0% respectively), while EGFR and KRAS mutations are 
more frequently observed in adenocarcinomas (10.2% versus 0% and 35.6% versus 5.3% 
respectively). Other mutations like BRAF, IDH1/2, KIT and PDGFRA are sporadically 
demonstrated. EGFR mutated tumors show a significantly lower GLUT1 protein expression, 
corresponding with the fact that predominantly lepidic and acinar adenocarcinomas are 
EGFR mutated and demonstrate low GLUT1 expression. Furthermore, EGFR mutated 
tumors have a significantly higher expression of GLS2 protein and GLS2 mRNA compared 
to EGFR wildtype tumors. KRAS mutation status correlates with a higher glutamine 
metabolism, as observed by a trend towards a higher SLC1A5 mRNA expression and a 
significantly higher GLS mRNA expression. TP53 mutation status correlates significantly 
with higher GLUT1 expression. This correlation analysis of mutational status with 
expression of metabolism-related markers and the tumor microenvironmental character-
istics described above suggest that EGFR, KRAS and TP53 mutations might drive aerobic 
tumor metabolism in adenocarcinomas. However, these associations do not necessarily 
imply that these mutations regulate metabolism of lung adenocarcinoma. In squamous 
cell carcinomas, TP53 mutations and hypoxia activating the hypoxia inducible factor 1 
(HIF-1) pathway and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling 
are associated with expression of glucose metabolism-related markers and could be the 
main drivers of metabolism in this histological subtype.
Prognostic value of metabolism-related markers and 18F-FDG PET  
in relation to histology
The differences in glucose metabolism between adeno- and squamous cell NSCLC affect 
18F-FDG PET interpretation and prognosis in the clinic. 18F-FDG PET imaging has stronger 
prognostic value if histology is incorporated in the interpretation of this imaging modality, 
which is described in chapter 3. Although squamous cell carcinomas have a higher 
18F-FDG uptake than adenocarcinomas, in general regarded as a poor prognostic factor, 
adenocarcinomas have a higher metastatic potential and a worse disease-free survival 
(DFS). In contrast, progressive localized disease is more often found for squamous cell 
histology. In curatively resected patients, high 18F-FDG uptake correlated with a worse DFS 
in adenocarcinomas, but not in squamous cell carcinomas. In line with this, high GLUT1 
expression indicates aggressive tumor behavior only in adenocarcinomas, as shown by 
the association with positive lymph nodes at diagnosis, poor differentiation grade and a 
significantly worse DFS (described in chapter 2). Chapter 4 gives further insight in tumor 
metabolism of subclassifications of adenocarcinomas (i.e. adenocarcinomas with a 
predominantly lepidic, acinar, papillary, micropapillary or solid growth pattern). GLUT1 
expression is highest in predominantly solid adenocarcinomas, which have a more 
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aggressive biological behavior with early distant metastasis and a worse survival relative 
to predominantly lepidic, acinar and papillary subtypes. This suggests that especially this 
adenocarcinoma subclassification and poorly differentiated adenocarcinomas give rise to 
the association of high GLUT1 expression and 18F-FDG uptake with worse survival. Also, 
glutamine metabolism-related markers correlate with aggressive tumor behavior only in 
adenocarcinomas. SLC1A5 protein expression is significantly higher in adenocarcinomas 
with lymph node metastases at diagnosis compared to node negative tumors and in 
adenocarcinomas with higher pTNM stage. Furthermore, SLC1A5 mRNA expression 
correlates with tumor size in this histology.  
 In conclusion, chapters 2-4 describe that GLUT1 and SLC1A5 expression, and 18F-FDG 
uptake are associated with aggressive tumor behavior and worse survival in surgically 
resected adenocarcinomas, but not in squamous cell NSCLC. So, stage I-resectable stage 
IIIA adenocarcinoma patients with high expression of one or both markers and/or high 
18F-FDG uptake might benefit from intensification of systemic treatment in the adjuvant 
setting, for example by inhibition of tumor metabolism. As lactate contributes to the 
immunologic escape of tumors cells (described in chapter 6), glycolysis inhibition could 
improve the efficacy of immunotherapy. This would be an interesting area for future 
research.
Exploiting NSCLC tumor metabolism in radiation oncology
Chapter 6 reviews how the HIF-1 pathway has a profound effect on the response 
to radiotherapy. The hypoxia-inducible factor 1 (HIF-1) pathway enables tumor cells to 
survive by changing glucose metabolism towards a glycolytic phenotype, by inducing 
angiogenesis, and by regulating pH balance and proliferation rate. Post-irradiation, 
stabilization of HIF-1α protects the vasculature, recovers blood supply and upregulates 
glycolysis and the pentose phosphate pathway. This aberrant cellular metabolism 
increases the tumor cell’s endogenous antioxidant capacity, for example through 
accumulation of pyruvate, lactate, and the redox couples glutathione/glutathione 
disulfide and NAD(P)H/NAD(P)+, and may attenuate the DNA damage that is caused by 
radiation-induced radical and oxidative stress. From the results of translational studies and 
the first clinical phase I/II trials it can be concluded that targeting tumor glucose 
metabolism at several levels reduces the antioxidant capacity of tumors, affects the tumor 
microenvironment and sensitizes various solid tumors to irradiation.
 In this PhD thesis, tumor metabolism was exploited in radiation oncology by using 
two different treatment strategies: by combining metabolic inhibition with irradiation 
(chapter 7), and by radiotherapy dose escalation directed towards 18F-FDG PET–based 
resistant primary tumor areas combined with chemoradiation (chapter 8).
 Chapter 7 is an in vitro study, examining the effect of metabolic inhibition on tumor 
cell metabolism, tumor cell growth, cytotoxicity and radiosensitivity in 6 NSCLC cell lines. 
In this in vitro study, adeno- (H23, HCC827, H1975) and squamous cell carcinoma (H520, 
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H292, SW900) NSCLC cells were treated with lonidamine (glycolysis inhibitor) and/or 968 
(glutaminase inhibitor), and also combined with irradiation. NSCLC cell lines respond 
differently to lonidamine and/or 968, largely corresponding with changes in glycolytic 
and mitochondrial metabolism upon treatment. Response patterns were not related to 
histology. Interestingly, response patterns were associated with KRAS mutation status and 
level of glutaminase C expression. The glutaminase inhibitor 968 decreases cell growth 
and is cytotoxic in cell lines with high glutaminase C expression (H1975 and H520), whereas 
combination treatment of glycolysis and glutaminase inhibition is detrimental for cell 
growth and viability in the KRAS mutated cell lines (SW900 and H23). Two of six cell lines 
(H292 and HCC827) are quite resistant to combination treatment, indicating metabolic 
flexibility. These cell lines likely depend on or switch to other fuels like phospholipids and 
lactate. So, the heterogeneity of NSCLC is reflected by the different response of cell lines 
to metabolic inhibition. Treatment with 968 and especially lonidamine resulted in radio-
sensitization of H292 and HCC827 NSCLC cell lines. For H1975, SW900, H520 and H23, no 
radiosensitizing effect could be demonstrated. In these cell lines, treatment with 
loniaminde or 968 in combination with irradiation could even result in more radioresis-
tance. Therefore, only a part of NSCLC patients may benefit from the combination of 
radiation therapy and metabolic inhibition, requiring predictive markers and making per-
sonalization necessary.
 In the planning study described in chapter 8, the maximum achievable dose 
escalation by using a stereotactic boost (SBRT) directed to radioresistant subvolumes of 
the primary tumor (PTVboost) as determined by an 18F-FDG PET/CT before start of 
chemoradiation (pre-treatment PET) and an early response monitoring 18F-FDG PET/CT 
(ERM-PET) was compared. This study demonstrates that it is possible to plan a substantial 
stereotactic radiation boost to primary tumor subvolumes with initial high or persistent 
18F-FDG uptake (i.e. poor-responding tumor areas) in addition to 60 Gy (whole tumor 
volume) concurrent chemoradiation, without exceeding the dose constraints for the 
organs at risk. The median dose (EQD2) covering 95% of the boost planning target volume 
(D95) based on ERM-PET (PTVboost;ERM) was 18 Gy (range 6-32 Gy), which in total allowed a 
median EQD2 of 78 Gy (range 66-92 Gy), compared to a standard radiotherapy schedule of 
60-66 Gy in 2 Gy fractions. Boost volume receiving a physical boost dose of ≥18 Gy (V18), 
which equals a EQD2 of ≥84 Gy/BED ≥100 Gy, was ≥80% for PTVboost;ERM in six out of ten 
patients. Median V18 of PTVboost;ERM was 88% (range 51-100). So, a stereotactic boost to 
regions with high 18F-FDG uptake is an attractive strategy to optimize therapy for 
irresectable stage III NSCLC. Differences between the planned dose before and during 
treatment were minimal due to the fact that the spatial relationship of PTVboost visualized 
on ERM-PET and organs at risk remained largely unchanged in most patients. However, in 
the minority of patients where ERM-PET demonstrates changes in tumor position, 
planning the boost on the ERM-PET should be considered.
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Concluding remarks
NSCLC is a heterogeneous disease regarding metabolic behavior and mutational status. 
As GLUT1 and SLC1A5 expression and 18F-FDG uptake correlate with aggressive tumor 
behavior only in adenocarcinomas, these metabolism-related markers may guide intensi-
fication of systemic treatment in the adjuvant setting of curatively resected stage I-IIIA 
adenocarcinoma, for example by inhibition of tumor metabolism combined with 
immunotherapy. The anaerobic glycolytic phenotype of squamous cell carcinomas 
implies radioresistant subareas requiring intensification of local therapy in poor-responding 
irresectable stage III squamous cell carcinoma, for example by using an SBRT boost 
directed towards 18F-FDG PET–based resistant primary tumor areas after chemoradiation, 
combined with metabolic inhibition and/or immunotherapy. Based on our in vitro results 
it can be concluded that only a part of NSCLC patients may benefit from the combination 
of radiation therapy and metabolic inhibition. Some NSCLC might even become more 
radioresistant when combining metabolic inhibition with radiotherapy. Therefore, to be 
able to implement metabolic inhibition in combination with radiotherapy into the clinic, 
predictive markers are required to personalize treatment.
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Longkanker is een belangrijke oorzaak van overlijden ten gevolge van een maligniteit. 
Ongeveer 20% van de patiënten met niet-kleincellig longcarcinoom (NSCLC) is in opzet te 
genezen met chirurgie (stadium I – resectabel stadium IIIA). Ongeveer de helft van deze 
patiënten komt echter toch te overlijden ten gevolge van recidief van de ziekte. Irresectabel 
stadium III NSCLC kan worden behandeld met concurrente of sequentiële chemoradiatie. 
Ondanks deze intensieve therapie blijft de prognose slecht met een 5-jaars overleving van 
36% voor stadium IIIA, 26% voor stadium IIIB en slechts 13% voor stadium IIIC. Aanvullende 
immunotherapie na chemoradiatie is een belangrijke nieuwe behandelstrategie voor 
irresectabel stadium III NSCLC, gezien het de overleving verbetert. Desondanks blijven 
locoregionale progressie en zeker het optreden van metastasen op afstand een probleem. 
Om deze reden is verdere intensivering van de behandeling noodzakelijk. Interventie in 
het tumor-specifieke metabolisme zou een benadering kunnen zijn om NSCLC aan te 
pakken. Deze metabole transformatie is het resultaat van complexe interacties tussen een 
hypoxisch tumor micromilieu en oncogene mutaties. In dit PhD project werden het 
metabolisme en mutatie landschap van de belangrijkste subtypen van NSCLC, adeno-
carcinomen en plaveiselcelcarcinomen, ontrafeld. De prognostische waarde van verschillen in 
metabolisme en targets voor therapie werden onderzocht. De resultaten kunnen mogelijk 
worden gebruikt om de behandeling verder te personaliseren.
Metabolisme en mutatie status van NSCLC histologische subtypen
Hoofdstukken 2-5 beschrijven het tumor glucose metabolisme van de voornaamste 
NSCLC histologische subtypen, adenocarcinomen en plaveiselcelcarcinomen, aan de 
hand van expressie van verschillende metabool gerelateerde markers op mRNA en eiwit 
niveau, en statische en dynamische 18-fluoro-2-deoxyglucose positron emissie tomografie 
(18F-FDG PET). Gebaseerd op deze markers en 18F-FDG PET werd geconcludeerd dat 
 plaveiselcelcarcinomen een sterker glycolytisch metabolisme vertonen ten opzichte van 
adenocarcinomen. Glycolyse in adenocarcinomen lijkt voornamelijk aëroob te zijn, terwijl 
het zeer hoge glycolytische metabolisme in plaveiselcelcarcinomen gestuurd lijkt te 
worden door een hypoxisch tumor micromilieu (anaërobe glycolyse). Plaveiselcel NSCLC 
wordt fenotypisch gekarakteriseerd door een hypoxisch tumor micromilieu: plaveiselcel-
carcinomen hebben een slechte vascularisatie (lage vaatdichtheid en een laag bloed 
volume fractie op dynamische 18F-FDG PET) met vaak necrose, en plaveiselcelcarcinomen 
zijn sterk glycolytisch (hoge expressie van glucose transporter 1 (GLUT1), en hoge opname 
van 18F-FDG met een sterke cytoplasmatische fosforylering van 18F-FDG op dynamische 
18F-FDG PET). Plaveiselcelcarcinomen brengen GLUT1 en monocarboxylaat transporter 4 
(MCT4) tot expressie in een hypoxie-gerelateerd patroon, en hebben een verhoogd transport 
en fosforylatie van glucose in tumor gebieden met een lagere bloed volume fractie op 
dynamische dynamic 18F-FDG PET. In tegenstelling, adenocarcinomen vertonen lagere 
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GLUT1 expressie, minder 18F-FDG opname en lagere fosforylering van glucose onder 
beter gevasculariseerde (en waarschijnlijk beter geoxygeneerde) omstandigheden (hoge 
vaatdichtheid en hoog bloed volume fractie op dynamische 18F-FDG PET). GLUT1 en MCT4 
worden in deze histologie tot expressie gebracht in een niet-hypoxie-gerelateerd patroon.
 Hoofdstuk 4 onderzoekt de associatie tussen de expressie van markers gerelateerd 
aan glucose en glutamine metabolisme met verschillende oncogene mutaties in NSCLC. 
TP53 en PIK3CA mutaties worden vaker gevonden in plaveiselcelcarcinomen dan adeno-
carcinomen (97.4% versus 71.2% en 10.5% versus 0% respectievelijk). EGFR en KRAS mutaties 
worden daarentegen vaker aangetoond in adenocarcinomen (10.2% versus 0% en 35.6% 
versus 5.3% respectievelijk). Andere mutaties zoals BRAF, IDH1/2, KIT en PDGFRA worden 
slechts sporadisch aangetoond. EGFR gemuteerde tumoren hebben een significant lagere 
GLUT1 eiwit expressie, wat overeenkomt met het feit dat lepidische en acinaire adenocar-
cinomen een EGFR mutatie hebben en een lage GLUT1 expressie vertonen. Verder hebben 
EGFR gemuteerde tumoren een significant hogere expressie van glutaminase 2 (GLS2) 
eiwit en mRNA in vergelijking met EGFR wildtype tumoren. KRAS mutatie status correleert 
met een hoger glutamine metabolisme, gezien de trend richting een hogere SLC1A5 
mRNA expressie en een significant hogere GLS mRNA expressie. TP53 mutatie status 
correleert significant met een hogere GLUT1 eiwit expressie. Deze correlatie van mutatie 
status met expressie van metabolisme gerelateerde markers, en de kenmerken van het 
tumor micromilieu zoals hierboven beschreven suggereren dat EGFR, KRAS en TP53 
mutaties mogelijk het aërobe tumor metabolisme in adenocarcinomen sturen. Deze 
associaties hoeven echter niet per definitie te betekenen dat deze mutaties ook werkelijk 
het metabolisme van adenocarcinomen van de long reguleren. In plaveiselcelcarcinomen 
zijn TP53 mutaties en hypoxie, wat de hypoxia-inducible factor 1 (HIF-1) route en fosfatidyl- 
inositol-3-kinase/protein kinase B (PI3K/AKT) signalering activeert, geassocieerd met 
expressie van markers gerelateerd aan glucose metabolisme. TP53 mutaties en hypoxie 
zouden dus voornamelijk de regulatoren van metabolisme kunnen zijn in dit histologische 
subtype.    
Prognostische waarde van metabool gerelateerde markers en 18F-FDG PET 
in relatie tot histologie
Het verschil in glucose metabolisme tussen adeno- en plaveiselcel NSCLC beïnvloedt de 
interpretatie van 18F-FDG PET en prognose in de klinische praktijk. 18F-FDG PET heeft een 
sterkere prognostische waarde als histologie wordt meegenomen bij de interpretatie 
van deze beeldvormende modaliteit. Dit wordt beschreven in hoofdstuk 3. Alhoewel 
plaveisel celcarcinomen een hogere 18F-FDG opname hebben ten opzichte van adeno-
carcinomen, wat in het algemeen beschouwd zou worden als een slechte prognostische 
factor, vertonen adenocarcinomen frequenter metastasen op afstand en hebben adeno-
carcinomen een slechtere ziekte-vrije overleving. In tegenstelling, lokale progressie wordt 
vaker gezien bij plaveiselcelcarcinoom histologie. Overeenkomstig geeft hoge GLUT1 
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expressie agressief tumor gedrag weer in alleen de adenocarcinomen, gezien de correlatie 
van hoge GLUT1 expressie met lymfeklier metastasen bij diagnose, slechte differentiatie 
graad en significant slechtere ziekte-vrije overleving (hoofdstuk 2). Hoofdstuk 4 geeft 
verder inzicht in het tumor metabolisme van subclassificaties van adenocarcinomen (dat 
wil zeggen adenocarcinomen met een predominant lepidisch, acinair, papillair, micro-
papillair of solide groeipatroon). GLUT1 expressie is het hoogst in solide adenocarcinomen, 
welke een meer agressief tumor gedrag vertonen met frequenter metastasen op afstand 
en een slechtere overleving ten opzichte van lepidische, acinaire en papillaire subtypen. 
Dit suggereert dat voornamelijk solide adenocarcinomen en slecht gedifferentieerde 
adenocarcinomen de correlatie van hoge GLUT1 expressie en 18F-FDG opname met 
slechtere overleving teweegbrengen. Ook metabole markers gerelateerd aan glutamine 
metabolisme correleren met agressief tumor gedrag in alleen adenocarcinomen. SLC1A5 
eiwit expressie is significant hoger in adenocarcinomen met lymfeklier metastasen bij 
diagnose en in adenocarcinomen met een hoger pTNM stadium. Verder correleert SLC1A5 
mRNA expressie met tumor grootte in deze histologie.
 Concluderend, hoofdstukken 2-4 beschrijven dat GLUT1 en SLC1A5 expressie, en 
18F-FDG opname geassocieerd zijn met agressief tumor gedrag en slechtere overleving in 
adenocarcinomen behandeld met chirurgie. Deze verbanden werden niet gevonden 
voor plaveiselcelcarcinomen. Stadium I-resectabel stadium IIIA adenocarcinomen met 
hoge expressie van 1 of beide markers en/of hoge 18F-FDG opname kunnen mogelijk 
voordeel hebben van intensivering van systemische behandeling in de adjuvante setting, 
bijvoorbeeld door remming van het tumor metabolisme. Gezien lactaat bijdraagt aan 
minder goed functionerende immuuncellen (beschreven in hoofdstuk 6), zou remming 
van glycolyse de effectiviteit van immunotherapie kunnen verbeteren. Dit is een interessant 
gebied voor onderzoek in de toekomst.
NSCLC tumor metabolisme en radiotherapie
Hoofdstuk 6 is een review dat beschrijft hoe de HIF-1 route de respons op radiotherapie 
beïnvloedt. De HIF-1 route maakt mogelijk dat tumorcellen kunnen overleven door het 
glucose metabolisme te switchen naar een glycolytisch fenotype, door het induceren van 
angiogenese, en door het reguleren van de pH balans en proliferatie. HIF-1α beschermt na 
radiotherapie de vasculatuur, herstelt de bloed aanvoer, en opreguleert glycolyse en de 
pentose fosfaat route. Dit afwijkende cellulaire metabolisme verhoogt de antioxidant 
capaciteit van tumorcellen, bijvoorbeeld door accumulatie van pyruvaat, lactaat, en de 
redox koppels glutathion/glutathion disulfide en NAD(P)H/NAD(P)+. Dit zou kunnen 
leiden tot minder DNA schade die wordt veroorzaakt door radiatie-geïnduceerde radicaal 
en oxidatieve stress. Uit de resultaten van translationele studies en de eerste klinische fase 
I/II trials kan worden geconcludeerd dat targeting van tumor metabolisme op verschillende 
niveaus de antioxidant capaciteit van tumoren vermindert, het tumor micromilieu 
beïnvloedt en verschillende solide tumoren gevoeliger maakt voor radiotherapie.
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In dit PhD project werd het tumor metabolisme op 2 verschillende manieren gebruikt om 
de effectiviteit van radiotherapie mogelijk te verbeteren: door het combineren van 
metabole remmers met radiotherapie (hoofdstuk 7), en radiotherapie dosis escalatie 
gericht op 18F-FDG PET gebaseerde radioresistente subvolume van de primaire tumor 
gecombineerd met chemoradiatie bij patiënten met irresectabel stadium III NSCLC 
(hoofdstuk 8).  
 Hoofdstuk 7 is een in vitro studie die het effect van metabole inhibitie op tumorcel 
metabolisme, tumorcelgroei, cytotoxiciteit en gevoeligheid voor radiotherapie onderzoekt 
in 6 NSCLC cellijnen. In deze in vitro studie werden adeno- (H23, HCC827, H1975) en 
plaveisel celcarcinoom (H520, H292, SW900) NSCLC cellen behandeld met lonidamine 
(glycolyse remmer) en/of 968 (glutaminase remmer), zonder en met radiotherapie. NSCLC 
cellijnen respondeerden verschillend op lonidamine en/of 968, wat grotendeels overeen 
kwam met verandering in glycolytisch en mitochondrieel metabolisme na behandeling. 
Respons patronen waren niet gerelateerd aan histologie. Respons patronen waren wel 
geassocieerd met KRAS mutatie en glutaminase C mRNA expressie. De glutaminase 
remmer 968 vermindert celgroei en is cytotoxisch in cellijnen met hoge glutaminase C 
mRNA expressie (H1975 en H520), terwijl combinatie behandeling van glycolyse en 
glutaminase remming de celgroei sterk vermindert en erg toxisch is voor de cellijnen met 
een KRAS mutatie (SW900 en H23). Twee van de 6 cellijnen (H292 en HCC827) waren vrij 
resistent voor deze combinatie behandeling, wat metabole flexibiliteit weergeeft. Deze 
cellijnen zijn waarschijnlijk afhankelijk van of kunnen switchen naar andere brandstoffen 
zoals fosfolipiden en lactaat. De verschillende responsen van cellijnen op metabole 
remming geeft de heterogeniteit van NSCLC weer. Behandeling met 968 en met name 
lonidamine resulteerde in een verbeterde gevoeligheid voor radiotherapie voor de H292 
en HCC827 NSCLC cellijnen. Voor H1975, SW900, H520 en H23 kon geen verbeterde 
gevoeligheid voor radiotherapie worden aangetoond. In deze cellijnen zou metabole 
remming in combinatie met radiotherapie juist mogelijk kunnen leiden tot een verminderde 
gevoeligheid voor radiotherapie. Dus slechts een deel van de NSCLC patiënten zou mogelijk 
een voordeel kunnen hebben van de combinatie van radiotherapie met metabole 
remming. Om deze reden zijn predictieve markers noodzakelijk om behandeling te 
kunnen personaliseren.
 In de radiotherapie planning studie (hoofdstuk 8) werd de maximaal haalbare dosis 
escalatie door middel van een stereotactische boost (SBRT) gericht op het radioresistente 
subvolume van de primaire tumor (PTVboost) onderzocht. Het radioresistente subvolume 
werd bepaald met behulp van een 18F-FDG PET/CT voor start van de chemoradiatie (60 
Gy) en een 18F-FDG PET/CT tijdens chemoradiatie (ERM-PET). De maximaal haalbare dosis 
escalatie op basis van de 18F-FDG PET/CT voor start chemoradiatie en tijdens chemoradiatie 
werd vergeleken. Deze studie toont aan dat het mogelijk is om een substantiële stereo-
tactische boost te plannen gericht op primaire tumor subvolumes met initieel hoog of 
persisterend 18F-FDG opname (dat wil zeggen slecht responderende tumor gebieden) in 
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aanvulling op 60 Gy concurrent chemoradiatie, zonder hierbij de dosis constraints voor 
organs at risk te overschrijden. De mediane dosis (EQD2) die 95% van het boost planning 
target volume (D95) gebaseerd op ERM-PET (PTVboost;ERM) omgeeft was 18 Gy (spreiding 
6-32 Gy), wat in totaal resulteerde in een mediane EQD2 van 78 Gy (spreiding 66-92 Gy). 
Boost volumes die een fysische dosis van ≥18 Gy kregen (V18), wat gelijk staat aan een 
EQD2 van ≥84 Gy/BED ≥100 Gy, was ≥80% voor PTVboost;ERM in 6 van de 10 patiënten. 
Mediane V18 van PTVboost;ERM was 88% (spreiding 51-100%). Een stereotactische boost 
gericht op primaire tumorgebieden met een hoge 18F-FDG opname is dus een 
aantrekkelijke strategie om de behandeling voor irresectabel stadium III NSCLC te 
verbeteren. Verschillen tussen de geplande dosis voor en tijdens behandeling waren 
minimaal ten gevolge van het feit dat de overlap van PTVboost gebaseerd op de ERM-PET 
met organs at risk bij de meeste patiënten grotendeels niet veranderde. Echter moet 
boost planning op de ERM-PET overwogen worden, gezien de ERM-PET ook veranderingen 
in tumor positie laat zien.
Conclusie
NSCLC is een heterogene ziekte betreffende metabolisme en mutatie status. GLUT1 en 
SLC1A5 expressie, en 18F-FDG opname correleren met agressief tumor gedrag in adeno-
carcinomen. Deze metabole markers zouden dus intensivering van de systemische 
behandeling in de adjuvante setting van gereseceerd stadium I-IIIA adenocarcinoom 
kunnen sturen, bijvoorbeeld door inhibitie van tumor metabolisme in combinatie met 
immunotherapie. Het anaërobe glycolytische fenotype van plaveiselcelcarcinomen 
suggereert radioresistente gebieden. Irresectabel stadium III plaveiselcelcarcinomen 
slecht responderend op chemoradiatie kunnen mogelijk baat hebben bij intensivering 
van lokale therapie. Hiervoor zou bijvoorbeeld een SBRT boost gericht op 18F-FDG PET 
gebaseerde radioresistente primaire tumor gebieden na chemoradiatie gebruikt kunnen 
worden, gecombineerd met metabole remming en/of immunotherapie. Gebaseerd op 
de in vitro resultaten kan geconcludeerd worden dat alleen een deel van de NSCLC 
patiënten mogelijk voordeel kan hebben van de combinatie radiotherapie met metabole 
remming. Een deel van de NSCLC tumoren zou mogelijk meer resistent voor radiotherapie 
kunnen worden bij de combinatie met metabole inhibitie. Om metabole remming in 
combinatie met radiotherapie in de kliniek te kunnen implementeren zijn predictieve 
markers dus noodzakelijk om behandeling te kunnen personaliseren.
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Fien en Ties, mijn lieve kindjes. Wat een rijkdom zijn jullie in mijn leven, jullie zijn altijd zo blij. 
Het is zo heerlijk om met jullie te knuffelen en te spelen. Het is iedere dag een feestje om 
thuis te komen. Jullie hebben me geleerd te genieten van de kleine dingen in het leven. 
Wat is het fijn om samen met jullie de wereld opnieuw te ontdekken.
Lieve Ralph, mf nrqm kilvuhxsirug pozzi rh svy rp vrmwvorqp dvvi vvmh grqw ln vvm 
kfaavo elli qv gv nzpvm. Wzmp elli zo qv orvuwv, hgvfm vm gvtvmtzh wrv qv nv svyg 
tvtvevm wv zutvolkvm qzivm. Qv yvmg nrqm nzzgqv elli svg ovevm. Dzg rh svg svviorqp 
ln hznvm nvg qlf gv dzmwvovm ozmth wv Dzzo lu rm svg ylh, gv ofmxsvm rm wv hgzw, 
hvirvh gv prqpvm vm xlmxvigvm gv yvalvpvm. Rp prqp frg mzzi lmav glvplnhg hznvm. 
Rp slf ezm qlf, pirvyvo, pmvtvm! 
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